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There are 15,000 adults and children with Sickle Cell Disease (SCD) in England. Patients 
with homozygous (HbSS) SCD are at risk of painful Vaso-Occlusive Crises (VOCs), and 
haemolysis, caused by deoxygenated, sickle shaped erythrocytes occluding the 
microcirculation. VOCs may be exacerbated by the release of procoagulant Red Cell 
Derived Particles (RCDP), including autophagic vesicles (AV) into the bloodstream. RCDP 
release occurs during erythrocyte maturation and as part of sickling and unsickling of the 
erythrocyte upon repeated deoxygenation and reoxygenation. 
Aims 
 
The primary aim is to determine if AV numbers are elevated in SCD patients who are in 
SCD crisis when compared with steady state and healthy controls. Secondary aims 
include; whether levels of microvesicles correlate with VOC; whether levels of 
microvesicles correlate with length of admission and whether levels of microvesicles 
correlate with numbers of circulating reticulocytes in SCD patients admitted in VOC. 
Methods 
Samples from 11 SCD patients, admitted to University College London Hospital (UCLH) in 
VOC were analysed using confocal microscopy and flow cytometry techniques during 
admission, to quantify RCDP and AV on the RBC and in their plasma, respectively. 
Results were compared to healthy control samples and patients in a steady state of SCD. 
Results 
In confocal microscopy studies, statistically significant (p<0.0001) numbers of PS-positive 
RCDP, and GPA-pos RCDP were identified which is concordant with previous studies. In 
flow cytometry studies, a heterogeneous population of RCDP was present in the plasma 
of both healthy controls and SCD patients in steady state and in VOC. RCDP of an inside 
out orientation, most likely AVs, were present in the plasma of SCD patients in both 
steady state and VOC but were not significantly increased in either cohort. This is a novel 
finding. No population of MV was found to be a statistically significant predictor of VOC, 
which was limited by the experimental methodology. 
Conclusion 
The study of MV in SCD provides research opportunities into the prevention of SCD 
symptoms. Future studies should utilise imaging flow cytometry, to examine potentiators 
of the symptoms of SCD. They must be used to build a complete picture of the complex 










This thesis is dedicated to my wife Kelly and to my two children Oliver and Henry. 
Without their never-ending love and support, none of my achievements would be 







This doctoral thesis completes an epic 17-year journey for me personally, from 
trainee Biomedical Scientist to Consultant Clinical Scientist; something I never 
envisaged would happen at the start of my career. Many people have helped me 
along the way, far too many to thank here, but I would like to thank the following, in 
particular, for their continued support and advice throughout my Doctoral 
programme. Dr Edwin Massey, Dr Tom Latham, Dr Mark Williams, Ruth Evans, Dr 
Shubha Allard, Dr Nay Win, and all my colleagues in the NHSBT Red Cell 
Immunohaematology (RCI) laboratories. 
I would like to thank my project supervisor Dr Tosti Mankelow and post-doctoral 
research scientist Dr Rachel Smith for all their help and support during the practical 
sections of this project and writeup / submission of this thesis. Their kind and patient 
advice has been invaluable in enabling me to complete my Doctoral research project 
and the last component of the Higher Specialist Scientific Training (HSST) 
Programme. I would also like to thank Dr Nina Dempsey-Hibbert, Programme 
Leader BSc Biomedical Science & Healthcare Science for her advice on my thesis 
revisions. 
I would like to thank colleagues at University College London Hospital (UCLH). In 
particular Dr Sara Trompeter, Ceris Tuckey and Bobby Garcia for their help and 
participation in obtaining the samples for analysis in this study. 
Special thanks go to Dr Elisa Allen, Principal Statistician, and Senior Statistician, 
Mark Jones Statistics and Clinical Studies, NHS Blood and Transplant for their help 
and advice with the statistical analysis of this thesis data. 
Most importantly, I would like to thank the patients involved in this study for 
consenting to have samples taken during their admission for what is an extremely 
painful and difficult to manage hospitalisation episode. Without this, research cannot 
begin to answer questions about disease pathophysiology, diagnosis and treatment, 
leading to improvements in care for others. 
Finally, I would like to thank my wife Kelly and my sons Oliver and Henry for their 
love and support, and my extended family and friends for patiently putting up with 
me, and for always asking “how’s the training going?” over the past 5 years. I’m 









No portion of this work referred to in the thesis has been submitted in support of 
an application for another degree or qualification of this or any other university or 



















































     
Contents 
Chapter 1: Introduction………………………………………………………………………..17 
1.1 Historical and Genetic Background .................................................................... 17 
1.2 Worldwide distribution and mortality ................................................................... 21 
1.3 Pathophysiology ................................................................................................. 23 
1.4 Clinical symptoms .............................................................................................. 29 
1.5 Treatment ........................................................................................................... 33 
1.5.1 Access to care .................................................................................................... 33 
1.5.2 Transcranial Doppler Scanning .......................................................................... 34 
1.5.3 Treatment of pain ............................................................................................... 35 





1.5.5 Treatment of anaemia ........................................................................................ 37 
1.5.6 Hydroxycarbamide (Hydroxyurea) ...................................................................... 39 
1.5.7 L-Glutamine ........................................................................................................ 40 
1.5.8 Haemopoietic Stem Cell Transplants ................................................................. 41 
1.5.9 Gene therapy ..................................................................................................... 42 
1.5.10 Inhibitors of Haemoglobin S polymerisation ....................................................... 42 
1.5.11 Inhibitors of cellular and vascular interaction ...................................................... 43 
1.6 Phosphatidylserine (PS) and thrombosis ........................................................... 45 
1.7 RBC Microparticles and Autophagic vesicles - Microparticles, Microvesicles, 
Autophagic Vesicles, Exosomes, Ectosomes & Apoptotic Blebs. ...................... 49 
1.8 Red Cell Derived Microparticles and red cell storage lesion .............................. 50 
1.9 Microparticles and Disease ................................................................................ 55 
1.10 Red Cell Derived Microparticles and SCD .......................................................... 57 
1.11 Autophagic vesicles and reticulocyte maturation in the circulation ..................... 61 
1.12 Quantification of Microvesicles ........................................................................... 67 
Chapter 2: Aims and Objectives .................................................................................... 70 
2.1 Hypothesis ......................................................................................................... 70 
2.2 Primary aim ........................................................................................................ 70 
2.3 Secondary aims ................................................................................................. 70 
2.4 Objectives .......................................................................................................... 70 
Chapter 3: Materials and Methods ................................................................................ 72 
3.1 Ethics ................................................................................................................. 72 
3.2 Participant Recruitment ...................................................................................... 72 
3.3 Patients .............................................................................................................. 73 
3.4 Controls .............................................................................................................. 73 
3.5 Sample Preparation and Transport .................................................................... 75 
3.6 Confocal Microscopy .......................................................................................... 77 
3.6.1 Live cell confocal microscopy ............................................................................. 77 
3.6.1.1 Materials .................................................................................................... 77 
3.6.1.2 Method ...................................................................................................... 77 
3.6.1.3 Live Cell Imaging ....................................................................................... 77 
3.6.2 Fixed Cell Confocal Microscopy ......................................................................... 79 





3.6.2.2 Method ...................................................................................................... 80 
3.6.2.3 Fixed Cell Imaging ..................................................................................... 82 
3.7 Flow Cytometry .................................................................................................. 83 
3.7.1 Monoclonal Antibody Labelling ........................................................................... 83 
3.7.1.1 Materials .................................................................................................... 83 
3.7.1.2 Method ...................................................................................................... 83 
3.7.2 Titration of Monoclonal Antibodies ..................................................................... 85 
3.7.2.1 Materials .................................................................................................... 85 
3.7.2.2 Method ...................................................................................................... 85 
3.7.3 Flow Cytometer Size Gating ............................................................................... 86 
3.7.3.1 Materials .................................................................................................... 86 
3.7.3.2 Method ...................................................................................................... 86 
3.7.4 Flow Cytometric Analysis ................................................................................... 87 
3.7.4.1 Materials .................................................................................................... 87 
3.7.4.2 Method ...................................................................................................... 87 
Chapter 4: Results ........................................................................................................ 90 
4.1 Confocal Microscopy .......................................................................................... 90 
4.1.1 Live Cell Confocal Microscopy ........................................................................... 90 
4.1.2 Fixed Cell Confocal Microscopy ....................................................................... 121 
4.2 Flow cytometry ................................................................................................. 127 
4.2.1 Size gating ....................................................................................................... 127 
4.2.2 Antibody Titration ............................................................................................. 128 
- BRIC256-647 0.53mg/ml .................................................................................. 128 
- BRIC256-647 0.05µg/ml ................................................................................... 128 
4.2.3 Flow Cytometric Analysis ................................................................................. 130 
4.2.4 BRIC256-647 - Right-side out RCDP ............................................................... 131 
4.2.5 BRIC163-488 – Inside-out Autophagic Vesicles ............................................... 134 
4.2.6 Annexin V FITC labelling – PS positive MVs .................................................... 136 
4.2.7 Dual-labelled BRIC256-647 / BRIC163-488 RCDP – Unsealed RBC Membrane 
Fragments ........................................................................................................ 138 
4.2.8 Dual-labelled BRIC256-647 / Annexin V FITC – PS-positive RCDP ................ 141 
4.3 Microvesicle subpopulation comparison ........................................................... 144 





Chapter 5: Discussion ................................................................................................. 148 
5.1 Confocal Microscopy ........................................................................................ 149 
5.2 Flow Cytometry ................................................................................................ 150 
5.3 Limitations ........................................................................................................ 153 
5.4 Further work ..................................................................................................... 157 
Chapter 6: Conclusion ................................................................................................ 160 
Chapter 7: References ................................................................................................ 161 
Chapter 8: Appendices ............................................................................................... 202 
Appendix 1 DClinSci C2 Module Proforma ................................................................. 202 
Appendix 2 Patient Information Sheets ....................................................................... 206 
Appendix 3 Patient Consent Forms ............................................................................ 212 
Appendix 4 Healthy Volunteer Control Information Sheets ......................................... 215 







List of figures 
Figure 1.1 Categorisation of the Haemoglobinopathies 
 
Figure 1.2 Number of Newborns with Sickle Cell Disease by Country 
(2015) 
Figure 1.3 Countries with reported indigenous cases of malaria in 2000 and 
their status by 2017 
Figure 1.4 Map of Sickle Cell Disease registrations by commissioning hub 
2016/17 
Figure 1.5. Induction of Sickling by polymerisation of 
deoxyhaemoglobin S  
Figure 1.6. HbS polymerisation and erythrocyte deformation. 
  
Figure 1.7. Photomicrograph of a blood film. Sickle cell disease (homozygosity 
for haemoglobin S) 
Figure 1.8 Complex interactions in SCD which lead to vaso-occlusion and 
tissue damage. 
Figure 1.9. Common complications from Sickle Cell Anaemia. 
Figure 1.10. Total reported serious events - Sickle Cell Disease 
Figure 1.11. Haematin-eosin-saffron stained spleen sample following 
splenectomy for acute splenic sequestration in a 5-year-old girl with 
sickle cell anaemia 
Figure 1.12 Interactions between Sickle Red Blood Cells and the sub-endothelial 
surface 
Figure 1.13 P-Selectin (in orange) interactions in vascular endothelial adhesion. 
Figure 1.14 Phosphatidylserine transport in the SCD erythrocyte 
Figure 1.15 Signals involved in interaction between macrophages and red blood 






Figure 1.16 Echinocytosis and Microvesiculation in Erythrocytes 
Figure 1.17 Normal reticulocyte maturation. 
Figure 1.18 Release of PS-exposed, inside-out autophagic vesicles is a normal 
mechanism of reticulocyte maturation 
Figure 1.19 Membrane Remodelling and Autophagy in late stage (R2) 
Reticulocytes. 
 
Figure 3.1 Confocal Microscopy - Live Cell Slide 
Figure 3.2 Confocal Microscopy – Fixed Cell Slides 
Figure 3.3 Labelling and purification of monoclonal antibodies BRIC163-488 
and BRIC256-647 
 
Figure 4.1 Quantification of Phosphatidylserine (PS) expression by live cell 
confocal microscopy. 
Figure 4.2 Serial quantification of Phosphatidylserine (PS) expression by live 
cell confocal microscopy. 
Figure 4.3 SCD Crisis Patient 3D image - Live cell confocal microscopy 
Figure 4.4 SCD Crisis Patient - Live cell confocal microscopy. 
Figure 4.5 SCD Crisis Patient - Live cell confocal microscopy 
Figure 4.6 Healthy control 1 - Live cell confocal microscopy 
Figure 4.7 Steady State SCD control – Live cell confocal microscopy 
Figure 4.8 SCD Crisis Patient - Live cell confocal microscopy 
Figure 4.9 SCD crisis Patient 8 PS positive vesicle (%) and Reticulocyte count 
(%) 
Figure 4.10 SCD crisis Patient 9; PS positive vesicle (%) and Reticulocyte count 
(%) 
Figure 4.11 Quantification of Trypsin-sensitive GPA expression by fixed cell 
confocal microscopy 
Figure 4.12 Quantification of Trypsin-sensitive GPA expression by fixed cell 
confocal microscopy 
Figure 4.13 SCD crisis Patient 9 R10 positive vesicle (%) and Reticulocyte count 
(%) 
Figure 4.14 Healthy control 2 - Fixed cell confocal microscopy 






Figure 4.16 SCD Crisis Patient - Fixed cell confocal microscopy 
Figure 4.17 Identification of RBC microparticles (MPs) based upon a fluorescent 
threshold and utilizing the mixture of absolute counting and 
calibration beads to define the light scatter parameters 
Figure 4.18 Overlaid histogram plot labelled BRIC256-647 
Figure 4.19 Gated Scatterplot for labelled BRIC256-647 
Figure 4.20 Overlaid histogram plot labelled BRIC163-488 
Figure 4.21 Gated Scatterplot for labelled BRIC163-488 
Figure 4.22 Flow cytometric analysis of BRIC256-647 labelled RCDMV at 0h in 3 
studied cohorts 
Figure 4.23 Flow cytometric analysis of BRIC256-647 labelled vesicles 
(events/µl) over time admitted (h). 
Figure 4.24 Flow cytometric anlysis of BRIC163-488 labelled vesicles at at 0h in 
3 studied cohorts 
Figure 4.25 BRIC163-488 labelled vesicles (events/µl) over time admitted (h) 
Figure 4.26 Anexin-V FITC labelled vesicles at 0h in 3 studied cohorts; 
Figure 4.27 Annexin-V FITC labelled vesicles (events/µl) over time admitted (h) 
Figure 4.28 BRIC256-647 / BRIC163-488 dual-labelled vesicles 
Figure 4.29 BRIC256-647 / BRIC163-488 dual-labelled vesicles (events/µl) over 
time admitted (h) 
Figure 4.30 BRIC256-647 / Annexin-V FITC dual-labelled vesicles at 0h in 3 
studied cohorts 
Figure 4.31 BRIC256-647 / Annexin-V FITC dual-labelled vesicles (events/µl) 
over time admitted (h) 
Figure 4.32. Average microvesicle number categorised by flow cytometric 
labelling 
 
Figure 5.1. Agglutination observed in flow cytometry testing. 
Figure 5.2 Cellular fluorescence “spot” analysis using Imaging flow cytometry to 






List of tables 
 
 
Table 1.1 Genotypic variants of SCD with genotype percentage and their 
associated severity 
Table 1.2 Genetic mutations associated with haemoglobinopathies 
Table 1.3. Acute clinical complications of Sickle Cell Anaemia, including 
common manifestations presumed pathophysiology and treatment 
options. 
Table 3.1 Titrated dilutions of BRIC163 and BRIC256 
Table 3.2 Flow cytometry test layout. 







List of Appendices 
 
 
Appendix 1 C2 Proforma – Submitted to Manchester Metropolitan University and 
the Royal College of Pathologists 
 
Appendix 2 Patient information sheets 
Appendix 3 Patient consent form 
Appendix 4 Healthy volunteer information sheets 








List of abbreviations 
 
 
ACS Acute Chest Syndrome 
AE1 Anion Exchanger 1 
APPG All Party Parliamentary Group 
ARDS Acute Respiratory Distress Syndrome 
ATP Adenosine triphosphate 
AV Autophagic vesicles 
BITS Bristol Institute of Transfusion Science 
BSH British Society for Haematology 
CPD Continuing Professional Development 
CR1 Complement Receptor 1 
EQA External Quality Assessment 
FACS Fluorescence Activated Cell Sorting 
FBC Full Blood Count 
FC Flow Cytometry 
FITC Fluorescein isothiocyanate 
FS Forward Scatter 
GPA Glycophorin A 
GvHD Graft Versus Host Disease 
Hb Haemoglobin 
Hct Haematocrit 
HbF Foetal haemoglobin 
HbSC Heterozygous Haemoglobin S / Haemoglobin C disease 
HbSS Homozygous Sickle Cell Haemoglobin 
HLA Human Leukocyte Antigen 
HPHF Hereditary Persistence of Haemoglobin F 
HS Hereditary Spherocytosis 
HSCT Haemopoietic Stem Cell Transplant 
HTA Health Technology Assessment 
IBGRL International Blood Group Reference Laboratory 
ISTH International Society of Thrombosis and Haemostasis 
mAb Monoclonal Antibody 







MSD Matched Sibling Donor 
MUD Matched Unrelated Donor 
mMUD Mismatched Unrelated Donor 
MV Microvesicle 
MVB Multivesicular Bodies 
NAD Nicotinamide Adenine Dinucleotide 
NEQAS National External Quality Assessment Scheme 
NHR National Haemoglobinopathy Registry 
NHSBT National Health Service Blood & Transplant 
NICE National Institute for Health and Care Excellence 
NIHR National Institute of Health Research 
NO Nitric Oxide 
PDPU Protein Development and Production Unit 
PE Phosphatidylethanolamine 
PHE Public Health England 
PNH Paroxysmal Nocturnal Haemoglobinuria 
PPP Platelet Poor Plasma 
PS Phosphatidylserine 
QA Quality Assurance 
RBC Red Blood Cell(s) 
RCDP Red Cell Derived Particles 
RCT Randomised Controlled Trial 
RCDV Red Cell Derived Vesicles 
RR Ribonucleotide Reductase 
SCA Sickle Cell Anaemia 
SCD Sickle Cell Disease 
SE Succinimidyl Esters 
SIRP-α Signal Regulatory Protein Alpha 
SS Side Scatter 
STOP Stroke Prevention Trial in Sickle cell disease 
TCD Transcranial Doppler 
TFP Tetrafluorophenyl 






TSP1 Thrombospondin 1 
TTP Thrombotic Thrombocytopenic Purpura 
UCH University College Hospital 
UKAS United Kingdom Accreditation Service 
VOC Vaso-Occlusive Crises 
vWF von Willebrand’s Factor 







CHAPTER 1. INTRODUCTION 
 
 
1.1 Historical and Genetic Background 
 
 
Sickle cell disease (SCD) was first described by Dr James Herrick in 1910 in a 
West Indian patient named Walter Clement Noel. Following this discovery, further 
cases of SCD were subsequently reported (Washburn, 1911; Cook & Myer, 1915). 
The molecular association of the disease was first described by Pauling & Itano et 
al. in 1949; and in 1956, Ingram described the Glutamic acid (Glu) to Valine (Val) 
point mutation at codon 6 in the β-globin gene (βS). This single point mutation is 
responsible for formation of the sickle haemoglobin tetramer (α2β2s). Inheritance of 
SCD follows an autosomal recessive pattern. Inheritance of two βS genes (HbSS) 
leads to symptomatic homozygous SCD, while heterozygous inheritance of 
HbA/HbS results in sickle cell trait. Sickle cell trait typically does not manifest any 
symptoms (Ware et al. 2017) and affords limited protection to heterozygous 
carriers from endemic Plasmodium falciparum malaria infection at a population 
level. (Nagal, 1990; Killian et al. 2015). 
SCD can also be inherited in a compound heterozygous form with other 
haemoglobinopathies which are prevalent within distinct populations, such as 
haemoglobin C (HbC) with HbS (HbSC), HbS with β-thalassaemia (HbS/β0- 
thalassaemia or HbS/β+-thalassaemia), and HbS with other beta-globin variants 
such as HbSD or HbSOArab, all of which express sufficient HbS to cause 
intracellular sickling. The genotypic variants of SCD and their clinical severity 
are shown in Table 1.1. The different mutations responsible for the 
haemoglobinopathies are shown in Table 1.2. 
Table 1.1 Genotypic variants of SCD with genotype percentage and their associated severity 
(adapted from Rees, 2013). 
 
 
Types of SCD and genotype percentage 
Very mild SCD Mild SCD Severe SCD 
HbSE (1-2%) HbSC (25-30%) HbSS (Sickle cell 
anaemia) (50-60%) 
HbS/Hereditary 
Persistence of foetal 
haemoglobin (1-2%) 
HbS / β+-thalassaemia 
(5-10%) 
HbS / β-thalassaemia 
(1-3%) 
HbS / Lepore (1-2%) HbS / OArab (1-2%) 





Table 1.2. Genetic mutations associated with haemoglobinopathies 
(adapted from Bain, 2008). 
 
Types of mutation responsible for haemoglobinopathies 




Same sense or neutral mutation 
Mutant codon codes for the same 
amino acid as normal codon – no 
consequences. 
Many mutations are this type. 
One third of point mutations 
result in no amino acid change. 
 
Missense mutations 
Mutant codon codes for a different 
amino acid to the normal codon. 
 
Nonsense mutations 
Mutant codon does not code for 
an amino acid but functions as a 
premature stop codon. 
 
New-sense mutations 
HbS; HbC; HbE disease. 
 
 
Haemoglobin McKees Rocks. 





Haemoglobin Constant Spring. 
Haemoglobin F-Port Royal 
 
Some β- thalassaemias 
 
 
Some β- thalassaemias 




Most α-thalassaemias, some β- 
thalassaemias. 
 



























Deletion or duplication 















Conversion of a stop codon to a 
coding sequence. 
 
Gene conversion +/- point 
mutation 
 
New splice site leading to 
structurally abnormal DNA 
 
Mutation of an enhancer 




Loss of expression or function 
of gene 
 
Loss of function of one gene 




Loss of one α gene but normal 
α-chain is encoded 
 
Reduced rate of synthesis of 




Synthesis of a variant 
haemoglobin in addition to 
increased production of 
haemoglobin F 







The genetic association of SCD was first described by Pauling & Itano et al. in 
1949. It was subsequently isolated to a defect in the β-globin gene in 1956 by 
Ingram. There are two globin genes, HBA located on chromosome 16, which 
codes for α-globin, and HBB, located on chromosome 11, which codes for β- 
globin. Normal adult haemoglobin consists of two alpha (α) subunits and two beta 
(β) subunits (Hagar & Vichinsky, 2008). Defects in the HBB gene give rise to the 
various haemoglobinopathies. Mutations causing quantitative defects in globin 
chain synthesis result in thalassaemia, whereas qualitative defects result in 







Figure 1.1. Categorisation of the Haemoglobinopathies. 
Haemoglobinopathies can be subdivided into two categories; where mutations cause qualitative 
variants in expression of the haemoglobin molecule, leading to SCD among other structurally 
abnormal haemoglobinopathies, Alternatively, quantitative variants of haemoglobin expression are 
referred to as the thalassaemia’s. (Adapted from PHE, 2013). 
Unusual genes that 




as α or β 
thalassaemia 
Haemoglobin 
variants such as 
HbS, HbO and HbE. 
Unusual genes that 









SCD is an autosomal recessive disease caused by a point mutation in the β-globin 
gene (HBB), found on chromosome 11p15.5. The point mutation, at codon 6 
causes a substitution of Glutamic acid (Glu) to Valine (Val) and results in the 
formation of the sickle haemoglobin tetramer (α2β2s), if inherited from both parents 
in a homozygous form. Homozygous (HbSS) SCD is now the commonest inherited 
single gene disorder in the UK (Streetly & Clark et al. 2008) affecting 50-60% of 
SCD sufferers and it is clinically the most severe. The heterozygous form, with 
inheritance of one normal HBB allele and one abnormal HbS HBB allele is termed 
sickle cell trait. 
Other forms of sickle cell disease include compound heterozygous conditions 
such as HbSC disease, where inheritance of a haemoglobin C (HbC) allele along 
with a HbS allele results in the compound expression of both HbS and HbC. HbC 
inheritance is governed by a point mutation in codon 6 of the β-globin gene (HBB), 
at the same position as that of the HbS mutation, but on the alternative HBB allele, 
but in HbC disease the point mutation is a substitution of Glutamic acid (Glu) to 
Lysine (Lys). HbSC heterozygotes have clinical symptoms similar to those with 
homozygous HbSS disease, and is characterized by erythrocyte dehydration, 
intracellular sickling and increased blood viscosity (Pecker et al. 2017). Although 
considered a milder sickle cell disease (SCD) variant, HbSC is associated with 
potentially severe morbidities and therefore requires surveillance and intervention 
(Pecker et al. 2017; Nagel et al. 2003). Other compound heterozygote 
haemoglobinopathies include HbS / β-thalassaemia, which results in severe 
clinical symptoms akin to those in homozygous HbSS disease. 
 
A diagnosis of SCD is established by identification of significant quantities of HbS 
with or without an additional abnormal β-globin chain variant identified by a 
haemoglobin assay in screening tests, as described previously, or by identification 
of a bi-allelic compound HBB pathogenic variant where at least one allele is the 
variant HBB gene (e.g., heterozygous HBB.Glu6Val; Glu6Lys in HbSC disease) 










1.2 Worldwide distribution and mortality 
 
 
Homozygous SCD prevalence rates have been reported to be as high as 3% of 
births in Sub-Saharan Africa, whilst heterozygous SCD (trait) has been detected in 
up to 45% of populations within this region. SCD is also found in considerable 
numbers in those of Indian, Arabic and Greek decent. (Figure 1.2). Mortality rates 
in Sub-Saharan Africa are reported to be in the range of 50-90%, however 
significant studies in this area are scarce due to a severe lack of funding and 
associated healthcare resources in this region (Grosse & Odame et al., 2011). 
One population study estimates that by 2050 the number of affected infants 
worldwide could increase by 30%, especially within Africa. (Piel et al. 2013). 
 
Globally, SCD is more common in areas where malaria is endemic (Figure 1.3) as 
it provides limited protection against infection with some forms of malaria. The 
protective effect of sickle cell trait (HbAS) over those affected by sickle cell 
disease (HbSS) was first described by A. Allison in 1954. Allison showed that not 
only was the HbS gene frequently detected in areas with high malarial 
transmission, but also that HbAS (sickle trait) individuals seemed to have less 
symptomatic episodes of severe malarial infection. Subsequent studies (Garlick, 
J.P. 1960 & Thompson, G.R. 1962) and epidemiological data have shown that 
sickle trait individuals do get malaria, but their blood contains lower numbers of 
parasitized red cells. 
 
The 2015 Global Burden of Disease report (GBD, 2015) states SCD as “causing 
more than 100,000 deaths, a 6% p.a. increase in prevalence since 2005”. 
At present, it is estimated there are more than 15,000 adults and children with 
SCD in Britain, with most patients living in or near in the larger cities such as 
London, Birmingham and Manchester (Figure 1.4). Every year about 350 babies 
are born in the UK with SCD (Sickle Cell Society, 2017). As the population of the 
United Kingdom becomes more diverse it is becoming increasingly difficult to 
manage these patients. They require blood transfusion support from a largely 
Caucasian donor pool that have differences in expressed antigens on the red 
blood cell (RBC) surface, particularly those in the Rh, Kell, MNSs, and Duffy blood 





production, making subsequent transfusions more challenging and increasing the 
risk of acute and delayed haemolytic transfusion reactions, and episodes of 
hyperhaemolysis (Win, N. 2009). 
  
Despite NHS Blood & Transplant (NHSBT) marketing campaigns (NHSBT, 
2014), recruitment of Black, Asian and Minority Ethnic (BAME) donors remains 
a challenge and they are under-represented in the UK donor population, where 
less than 5% of blood donors who gave blood in the last year were from black, 
Asian and minority ethnic communities. (NHSBT, 2019). 
 
Figure 1.2 Number of Newborns with Sickle Cell Disease by Country (2015). 






Figure 1.3 Countries with reported indigenous cases of malaria in 2000 and their status by 








Figure 1.4. Map of Sickle Cell Disease registrations by commissioning hub 2016/17. 






In SCD, the erythrocytes undergo rapid but reversible shape change upon 
deoxygenation and reoxygenation. Repeated deoxygenation and reoxygenation 
causes haemoglobin S to align, forming long parallel rods of HbS polymers, 
resulting in the cell becoming sickle-shaped (figure 1.5). The HbS polymers 
dissolve upon reoxygenation, restoring the original biconcave disc shape. 
Eventually, these HbS polymers form into a helical fibre structure with 14 HbS 
molecules in each section which reduces, and eventually prevents the erythrocyte 
membrane from being flexible and deformable (Serjeant & Serjeant, 1992). The 
role of the HbS single point mutation from glutamic acid to valine in the formation 
of long HbS polymers is that, once formed, the helical fibres enable hydrophobic 
contacts to form between the valine of one HbS molecule and alanine, 
phenylalanine and leucine from an adjacent HbS molecule, reducing deformability 
through the aggregation of the helical fibres (Vekilov, 2007). The decreased 
erythrocyte deformability leads to erythrocyte membrane damage, vaso-occlusion 







































Figure 1.5. Induction of Sickling by polymerisation of deoxyhaemoglobin S. 
Normal haemoglobin A (HbA) is formed by two α-globin subunits and two β-globin subunits, which 
are encoded by HBA and HBB respectively. The sickle Hb (HbS) HBB allele occurs when an 
adenine-to-thymine substitution results in the replacement of glutamic acid with valine at position 6 
in the mature β-globin chain. SCD occurs when both HBB alleles are mutated and at least one of 
them is the βS allele. Sickle haemoglobin (HbS) polymerises upon repeated oxygenation and 
deoxygenation. HbS polymers stiffen the erythrocyte membrane, leading to reduced deformability. 
Individuals with one βS allele have the sickle cell trait (HbAS) but not SCD; individuals with sickle 








Eventually the HbS erythrocyte becomes irreversibly damaged, leading to 
increased cation permeability and dehydration (Hannemann et al. 2015; Kato et al. 
2018). Normally, RBC cation homeostasis is maintained by an ATP-driven 
Na+/K+-pump in addition to passive permeability through various additional 
transport pathways (figure 1.6). High cation permeability causes RBC to lose 
intracellular solutes, become dehydrated and shrink, which increases intracellular 
concentrations of HbS (Lew and Brookchin, 2005) and results in the characteristic 
sickling seen (figure 1.7). Polymers of HbS affect structural membrane proteins 
including the band 3 anion transport protein, Anion Exchanger 1 (AE1) 
(Westerman et al. 2008). These changes cause membrane microvesiculation, the 
release of erythrocyte microparticles and exposure of prothrombotic 
phosphatidylserine (PS) on the erythrocyte surface. (De Jong et al. 2001; Yasin et 
al. 2003; Piccin et al. 2007). 
 
SCD erythrocytes have a reduced lifespan in the circulation (10 - 20 days) when 
compared to erythrocytes in a healthy individual (90 – 120 days) (Piel et al. 2017). 
Reduced erythrocyte lifespan results in increased levels of haemolysis and release 
of haemolytic by-products such as haem, which aggravates pro-inflammatory 
mediators, and scavenges the vasodilator, Nitric Oxide (NO) causing 
vasoconstriction, activation of endothelial cells and platelets (Kato et al. 2018). 
Premature RBC degradation and destruction leads to increased erythropoiesis and 
reticulocytosis as the bone marrow is stimulated to produce more RBC due to the 
underlying anaemia, which in turn leads to an increased number of vesicles, 
including Autophagic Vesicles (AV’s) released as part of reticulocyte maturation in 
the peripheral circulation. (Platt, 2000; Sharma et al. 2007; Griffiths et al. 2012; 









Figure 1.6. HbS polymerisation and erythrocyte deformation. Long polymers of sickle 
haemoglobin (HbS) eventually align into parallel rods within the erythrocyte. The polymerization of 
HbS depends on a number of contributing factors, including concentration of HbS, partial pressure 
of oxygen (pO2), temperature, pH, 2,3-diphosphoglycerate (2,3-DPG) concentration and the 
presence of different Hb molecules. 
Cation homeostasis is abnormal in sickle erythrocytes, leading to the dehydration of cells. 
Potassium loss occurs via a calcium-activated potassium channel, protein 4 (also known as the 
Gardos channel) and K–Cl cotransporter. (Adapted from Kato et al. 2018). 
 
Figure 1.7. Photomicrograph of a blood film. Sickle cell disease (homozygosity for 









Although the primary pathophysiology of SCD is reduced deformability leading to 
aggregation, vaso-occlusion and episodes of acute pain (termed crises), combined 
with a haemolytic anaemia; the complex interactions between blood cells, plasma 
factors and the vascular endothelium lead to many of the symptoms associated 
with the disease (figure 1.8). These include vascular–endothelial dysfunction, 
functional nitric oxide deficiency, inflammation, oxidative stress and reperfusion 
injury, hypercoagulability, increased erythrocyte adhesion, increased neutrophil 
adhesiveness, and platelet activation (Piel et al. 2017) 
 
Existing research into the causative agents of vaso-occlusive crises has focussed 
upon many of the different physiological and non-physiological aspects of the 
condition, from abnormalities in structure of erythrocytes (Kaul et al. 1996), 
adhesiveness of erythrocytes (Kaul et al 2006; Joneckis et al. 1993; Brittain et al. 
2004; Manodori et al. 2000) the pro-inflammatory state caused by elevated 
haemolysis (Hoppe, 2014; Owusu-Ansah et al. 2016), pro-thrombotic markers 
(Westerman et al. 1999; Ataga & Orringer, 2003), elevated reticulocytosis 
(Joneckis et al. 1993), to microparticle / microvesicle release by platelets, 
monocytes, endothelial cells and erythrocytes and their precursors (Hebbel & 







Additional modifiers of disease severity include inherited genotype, as discussed, 
with less severe clinical manifestations observed in compound heterozygotes who 
inherit another globin gene mutation such as Hereditary Persistence of 
Haemoglobin F (HPHF) or α- thalassaemia, in addition to HbS (Thein, 2017). 
 
 
Figure 1.8 Complex interactions in SCD which lead to vaso-occlusion and tissue damage. 
These include interactions between Blood cells, Plasma factors and Vascular endothelium which 
contribute towards a cumulative effect of VOC and tissue damage due to deoxygenation. The 
absence of a predictive test for VOC means that clinicians are unable to predict when a patient 
experiences VOC and cannot proactively manage the condition. Microparticle associated factors, 
both in the vascular endothelium and from the blood cells, are associated with this triad of VOC 
interaction. (Adapted from Ware & De Montalembert, et al. 2017) 
 
Non-physiological modifiers attributable to disease severity include wind speed, 
temperature, altitude, air quality and poverty (Jones et al. 2005; Tewari et al. 
2015). An association has been made between higher wind speed and low 
humidity causing rapid changes in skin temperature due to direct cooling and rapid 
evaporation of sweat (Jones et al. 2005). This has been linked to vaso-occlusion 






Resar & Oski, 1991). The subsequent complex interaction between these 
physiological and non-physiological processes plays a role in the disease 
pathophysiology, and requires a multimodal, multidisciplinary therapeutic 
approach, or emerging gene therapy to provide either amelioration of symptoms, 
or a cure in the best-case scenario. 
 
1.4 Clinical symptoms 
 
A wide range of clinical symptoms are experienced in SCD patients, making them 
extremely complex to manage (table 1.3). SCD can affect the cardiothoracic, 
nervous, reticuloendothelial, musculoskeletal, urogenital and gastrointestinal 
systems (figure 1.9). Many of the symptoms result from vaso-occlusion and 
impairment of oxygen supply to tissues and organs, due to rigid sickle cells 
occluding the microcirculation, as previously discussed. In addition, there are also 
associated changes in vascular endothelial cells due to excess levels of plasma 
free haem, released upon intravascular haemolysis and extravascular removal by 
the reticuloendothelial system. (Ware & De Montalembert et al. 2017) 
Table 1.3. Acute clinical complications of Sickle Cell Anaemia, including common 
manifestations, presumed pathophysiology and treatment options. 
(Adapted from Ware & De Montalembert et al. 2017) 
 
 Manifestation Pathophysiology Treatment 
Painful event Dactylitis; pain in 
the sternum/ribs; 









































Figure 1.9. Common complications from Sickle Cell Anaemia. 
Acute complications are shown in bold (adapted from Piel et al. 2017). 
 
Clinical symptoms can vary in severity and frequency between individuals with the 
same inherited HbSS phenotype, which can make the condition extremely difficult 
to manage and treat, as prediction of clinical severity is often not possible, with a 
previous clinical history (if available) often an important predictor of likely ongoing 
clinical support. 
Data on reported serious events from the national haemoglobinopathy registry 






different age groups. The most common single clinical symptom encountered is 





Figure 1.10. Total reported serious events - Sickle Cell Disease (All Years by age group - 
Figure from National Haemoglobinopathy Registry annual report 2016/17. 
 
ACS is an acute illness characterized by fever and/or respiratory symptoms, 
accompanied by a pulmonary infiltrate on chest X‐ray (Charache et al. 1979; 
Ballas et al. 2010). 
ACS is a leading cause of morbidity and mortality in SCD patients (Howard et al. 
2015) and is the third most common cause of death reported in adults with the 
disease (Lucas et al. 2008). ACS in adults tends to be a severe illness marked by 
hypoxia, which further exacerbates sickling of RBC, leads to a higher requirement 
for transfusion and higher mortality. The process of ACS is described as acute 
lung injury that can progress to acute respiratory distress syndrome (ARDS) 
progressing, albeit infrequently, to acute multi-organ failure. Half of patients 
present initially with a painful vaso-occlusive crisis and then develop this 
complication whilst in hospital. ACS will often develop 24–72 h after the onset of 






and/or pulmonary infarction. Transfusions, either a simple top up, or exchange 
(manual or automated) are recommended, based upon the clinical severity of the 
ACS (Howard et al. 2015; Davis et al. 2017b). ACS can also develop post- 
operatively, if patients are not given pre-operative blood transfusion before 
surgery, such as abdominal surgery. The Transfusion Alternatives Preoperatively 
in Sickle Cell Disease (TAPS) study (Howard et al. 2013) found that preoperative 
transfusion was associated with decreased perioperative complications in patients 
with sickle-cell disease who underwent low-risk to medium-risk surgery. 
 
An additional significant clinical complication includes increased risk of stroke, 
particularly in childhood where prior to the implementation of routine trans-cranial 
doppler (TCD) screening, childhood stroke occurred in 5-10% of cases (Ohene- 
Frempong et al. 1998; Balkaran et al. 1992; Mazzucco et al. 2017). The 
consequences of stroke include permanent motor, cognitive, and psychological 
damage. TCD screening measures the maximum time-averaged mean velocity 
(TAMV) of blood flow in the intracranial arteries, enabling the identification and 
treatment of children, with abnormal velocities (≥200 cm/s) who are at highest risk 
of developing stroke (Belisário et al. 2018; Adams et al. 1992). 
 
Patients are also particularly susceptible to bacterial infections, due to damage to 
the spleen in infancy. Repeated splenic vaso-occlusion causes fibrosis and 
progressive atrophy of the spleen (autosplenectomy) and are generally asplenic by 
5 years of age (Brousse et al. 2014). This leaves patients at risk of life-threatening 
pneumonia, sepsis and meningitis. Patients are managed with ongoing penicillin 
prophylaxis and immunization from an early age with routine vaccinations in 
accordance with the child immunization programme. Additional vaccinations are 
required, and include Pneumococcal polysaccharide vaccine, Hepatitis B, 
seasonal Haemophilus influenzae and meningitis if they are travelling to areas of 













Treatment for SCD is limited when compared to other conditions of a similar 
prevalence, despite increasing knowledge of the pathophysiology of the disease. 
Therapies are multimodal, and require a multidisciplinary approach, with the aim to 
improve survival, reduce acute and chronic complications, and improve overall 
quality of life. Patients with SCD are advised to take proactive measures to 
prevent symptoms occurring or the worsening of existing symptoms. These 
measures include drinking plenty of fluids to avoid dehydration, wearing 
appropriate clothing to keep warm and avoiding sudden drops in temperature, 
such as swimming in cold water (NHS, 2016). Whether these measures are wholly 
effective in preventing the development of recurrence of symptoms is debatable. 
Research suggests that self-management strategies do not always transfer from 
one disease to another (Greenhalgh, 2009), and that the onus of prevention 
should not rest with the patient, and should engage the patient, family members 
and professionals alike, to ensure understanding of the individuals physical, 
psychological and socioeconomical factors, which can all contribute to the 
effective management of the condition. 
 
1.5.1 Access to care 
 
 
In the NHS there is a recognised inequality in access to consistent, good quality 
treatment and care for sufferers of SCD and Thalassaemia (All Party 
Parliamentary Group on Sickle Cell and Thalassaemia 2009). As the most 
common genetic condition in England, SCD is more prevalent than cystic fibrosis, 
yet awareness of the health, social and educational impact its symptoms and 
treatment have upon sufferers is not widely known. The publication of standards 
for the clinical care of adults with sickle cell disease in the UK (Olujohungbe et al. 
2008; 2018) provides a suggested framework with a wide range of 
recommendations for treating adults with the condition, with the aim of reducing 
levels of morbidity and mortality and improving the experience of 
haemoglobinopathy patients by reducing inequities in treatment, inequality of 
care and providing timely access to high quality expert care. Implementation of 





screening programme, national haemoglobinopathy registry, haemoglobinopathy 
coordinating centre networks and routine transcranial doppler screening to 
reduce the risk of childhood and adult stroke have improved the identification and 
treatment of patients dramatically, but there is still a lot of progress to be made. 
 
1.5.2 Transcranial Doppler Scanning 
 
 
The use of transcranial Doppler (TCD) ultrasonography identifies children with 
SCD who are at high risk for stroke, which is a serious complication of SCD. The 
risk is particularly increased during childhood due to smaller lumens in the 
microcirculation, with an estimated incidence of 11% of patients with homozygous 
SCD having a stroke by the age of 20 years (Ohene-Frempong et al.1998). The 
publication of the Stroke Prevention Trial in Sickle cell disease (STOP) trial 
(Adams et al. 1998; Lee et al. 2006), led to the publication, of standards for TCD 
screening in children in the UK (UK Forum for haemoglobin disorders, 2016). The 
standards recommend annual monitoring of arterial blood velocities by TCD to 
determine the relative risk of stroke in patients from the age of 2 years until at least 
the age of 16 years. With low (velocities <170cm/s) borderline (170-199cm/s) and 
high (≥200cm/s) risk categories defined, with subsequent recommended follow up 
actions, including chronic transfusion regimens in those at risk. 
In response to the identification of a paucity of data on European screening practices or 
on adherence to the STOP TCD screening protocol (Mazzucco et al. 2017). A European 
multi-centre study was undertaken to promote the standardisation and delivery of 
effective screening. It found that gaining competency in stroke screening using 
transcranial Doppler scanning (TCD) in SCD is easier for professionals with an 
ultrasound imaging background. It identified the need for a quality assurance (QA) 
system and suggested that further work was in progress to develop an achievable and 







1.5.3 Treatment of pain 
 
 
Episodes of pain experienced by SCD patients are managed with the aims of 
improving quality of life and helping patients understand the different types of pain 
that they are experiencing, whether it be acute or chronic “every day” pain. 
Management includes medical and psychological intervention, with personalised 
care the optimal approach. (NICE, 2012) Medication can include strong opioid 
painkillers, which have a number of side effects, including addiction. One survey 
of hospital staff showed that over half of emergency department doctors and 
nearly a quarter of haematologists believed that one in five of SCD patients were 
‘addicted’ to analgesics (Shapiro et al. 1997; Elander et al. 2004). This may lead 
to an unintended consequence of the patient being treated as an addict, with 
effective pain relief denied inappropriately by less experienced clinicians. As pain 
can be hard to manage in SCD, it is important that patients and staff use all 
available resources including psychological coping mechanisms such as cognitive 
behavioural therapy in addition to conventional pharmacological treatment (Smith 
et al. 2008). 
 
1.5.4 Prevention of infection 
 
 
The spleen is the first organ to be injured in sickle cell disease (Brousse et al. 
2014), with patients rapidly becoming functionally asplenic due to sequestration 
and infarction (figure 1.11). This leads to increased susceptibility to infection, due 
to the spleen’s role in immune defence. The spleen eliminates blood-borne 
bacteria through direct recognition and phagocytosis by red pulp macrophages, 
and the generation and maintenance of IgM memory B cells which produce 
natural IgM antibodies, allowing an efficient T-cell dependent immune response 
which produces high affinity antibodies. (William and Corazza, 2007) Splenic 
injury reduces the trapping of blood-borne bacteria, which can impair the 
generation or maintenance of IgM memory B cells, in addition to increasing the 
risk of life- threatening infections with encapsulated bacteria such as 
Streptococcus pneumoniae, Nesseiria meningitidis and Salmonella – all of which 





(PROPS) Group study (Gaston et al. 1986), children with SCD now receive 
ongoing penicillin prophylaxis and immunization with routine vaccinations in 
accordance with the child immunization programme. Additional vaccinations 
include Pneumococcal polysaccharide vaccine, Hepatitis B, seasonal 
Haemophilus influenzae and meningitis if they are travelling to areas of high risk 
for meningitis (NICE, 2016). 
 
 
Figure 1.11. Haematin-eosin-saffron stained spleen sample following splenectomy for acute 
splenic sequestration in a 5-year-old girl with sickle cell anaemia, showing sickled red cells 
(arrows) retained upstream of the sinus inter endothelial slits. Original magnification 91000. 













1.5.5 Treatment of anaemia 
 
 
The resulting anaemia and associated symptoms experienced by SCD patients 
are treated by RBC transfusion, normally initiated by monitoring of HbS% levels or 
as a result of symptoms experienced when a patient is admitted in acute chest 
crisis (ACS), a complication which cannot be predicted. Indications for RBC 
transfusion in SCD are either acute or elective, with elective subdivided into one- 
off transfusions prior to surgery (Howard et al. 2013) or ongoing transfusion as 
part of a longer-term programme. SCD patients often continue to live a normal 
quality of life at considerably lower Hb levels than the acceptable normal range for 
healthy individuals (130-170g/l males / 120-150g/l females Dacie et al. 1975), and 
as a consequence should be managed according to symptoms experienced, 
rather than an arbitrarily defined transfusion trigger. Historically, some indications 
for transfusion remain questionable, with little evidence behind the efficacy of the 
treatment, although the publication of recent BSH guidelines should standardise 
treatment and improve outcomes (Davis et al. 2017a, 2017b). Transfusion should 
be initiated on a case‐by‐case basis, after analysis of the associated risks and 
benefits, especially for unproven or controversial indications such as 
hyperhaemolysis syndrome (Win, 2009) and severe sepsis. SCD patients should 
therefore receive ABO, Rh (CcDEe) and K compatible, HbS negative units 
(<7days old for exchange / <10 days old for top up) as routine. In addition, blood 
should also be antigen negative for clinically significant antibodies that are 
currently or have previously been detected. (Davis et al. 2017a). 
 
Emergency transfusion for acute anaemia, defined as a rapid fall in haemoglobin 
≥20 g/l below the steady state value, or if the Hb <50g/l, is usually indicated for 
conditions such as aplastic crises, splenic or hepatic sequestration, 
haemodynamic compromise or when there is concern about multiple organ failure 
(Davis et al. 2017). Transfusion in SCD is performed by two transfusion 
approaches, simple transfusion (sometimes referred to as top up), which is the 
transfusion of one unit of blood at a time to correct a mild anaemia, or exchange 
transfusion, a whole-body volume exchange of patient RBC with donor RBC, 
undertaken either manually, by removing a volume of whole blood before replacing 





machine as part of an automated exchange procedure The choice of transfusion 
method, i.e. simple (top up) or exchange, should be based on clinical judgement of 
individual cases, taking into account the indication for transfusion, the need to 
avoid hyperviscosity and minimise alloimmunisation, maintenance of iron balance, 
venous access issues and available resources (Davies et al. 2017). 
Automated exchange transfusion is usually indicated for conditions such as 
aplastic crises, splenic or hepatic sequestration, haemodynamic compromise or 
when there is concern about multiple organ failure (Schwartz et al. 2016) and 
should be available in the UK at all specialist centres, with manual RBC exchange 
training available in addition. The target of exchange being to reduce the HbS% to 
<30 and increase the haematocrit (Hct) to >30% to alleviate ACS or stroke 
(Padmanabhan et al. 2019). Risks of regular transfusion include iron overload, and 
consideration must be given to the need for iron chelation. While rare, iron 
cardiomyopathy is detectable in about 2.5% of chronically transfused SCD patients 
(Meloni et al. 2014). Automated exchange transfusion is preferable to manual 
exchange transfusion, as there is anecdotal evidence that it reduces 
alloimmunisation in addition to the greater benefit of lowering the need for iron 
chelation (Porter & Huehns, 1987; Kim et al, 1994; Michot et al. 2015; Dedekan et 
al. 2018). 
 
However regular exchange transfusion and top up transfusions still result in 
alloimmunisation in many patients. and can increase the risk of alloimmunisation 
to erythrocyte antigens to 20%-50%, through exposure to multiple blood donors 
with different red cell phenotypes due to the ethnic background of the donor 
population (Yazdanbakhsh et al. 2012). The most common alloantibodies 
developed in SCD patients are to those in the Rh blood group system (Rosse et al. 
1990, Chou et al. 2013) as the number of RHD and RHCE gene variants are 
greater within patients of black African or black Afro Caribbean ancestry and 
therefore immunisation to donor units which may also carry variant RH genes is 
more common. Recent studies have shown RH gene variants in 29% of RHD and 
53% of RHCE alleles in black African and Afro Caribbean patient and donor 
cohorts (Chou et al. 2018), making alloimmunisation effectively unavoidable, 
unless genotype matched blood is provided, but this is currently unsustainable due 





which is able to identify the most common Rh variants found in populations where 
SCD is more prevalent should also be performed. This can make compatibility 
testing and blood provision easier should a multi-transfused patient make multiple 
alloantibodies. However, many of these tests are currently performed in batches 
due to the cost of the reagents and therefore are subject to long turn-around times 
which render them ineffective in an urgent scenario where genotype matched 
blood is required imminently. 
 
1.5.6 Hydroxycarbamide (Hydroxyurea) 
 
 
Pharmacological treatment with hydroxycarbamide (also known as 
hydroxyurea), is the only drug that has been shown to modify the symptoms of 
Sickle Cell Anaemia. Hydroxyurea was first licenced for use by the United 
States Food and Drug Administration (FDA) in 1967 (McGann & Ware, 2015), 
and is currently the only medication licensed in the UK for the prevention of 
recurrent painful crisis in patients with SCD (Qureshi et al. 2018). No alternative 
pharmacological therapy has been introduced since that time. A large 
collaborative placebo controlled, randomised Multicentre Study of Hydroxyurea 
(MSH study) was undertaken by Charache et al., in 1995. It comprised 299 
adult patients, and found lower annual rates of pain crises, longer time between 
episodes of crisis, in addition to a lower overall incidence of ACS, a reduced 
need for blood transfusion and increased total Hb and haemoglobin F levels. 
The study was so beneficial that it was terminated early and all patient cohorts 
were given hydroxycarbamide. The Baby HUG study, performed in children, 
found that hydroxyurea was associated with statistically significantly lower rates 
of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and 
hospitalization. (Thornburg et al. 2012) 
 
The exact mechanism of action of hydroxycarbamide is unknown, and responses 
to therapy are variable. The most important effect appears to be blocking of the 
ribonucleotide reductase system resulting in inhibition of DNA synthesis (eMC, 
2018). This inhibition raises the amount of foetal haemoglobin in red blood cells 
(Maier-Redelsperger et al. 1998; Kinney et al. 1999; Zimmerman et al. 2004) and 





globin found in HbSS, in addition to reducing intracellular adhesion through 
integrin downregulation and increasing vasodilation by increasing Nitric Oxide 
(NO) levels, thereby reducing sickling. The dose is usually 15mg/kg/day (adults) or 
20mg/kg/day (children) with a therapeutic target of an increase on HbF, in addition 
to maintaining WBC and RBC indices. (Charache et al.,1995). Current evidence 
shows that hydroxycarbamide is effective at decreasing the frequency of acute 
painful episodes and raising fetal haemoglobin levels in the blood of people with 
SCD (Qureshi et al. 2018; Sheehan et al. 2014). Hydroxycarbamide is also 
effective at preventing strokes in patients who are at an increased risk of stroke 
(Kratovil et al. 2006). Side effects include bone marrow suppression, with 
leucopenia as the first and most commonly occurring sign, in addition to painful 
leg ulcers which are usually difficult to treat and require cessation of therapy. 
Other risks include teratogenicity and reduced spermatogenesis, which means 
some SCD patients, for example pregnant women, are not able to take it, 
exposing them to a higher level of risk. As a consequence, strict adherence to the 
hydroxycarbamide regimen remains an ongoing challenge (Candrilli et al. 2011; 





More recently, phase III trials of the amino acid L-Glutamine have shown 
promising results (Niihara et al. 2018). L-Glutamine plays a physiological role in 
the production of Nicotinamide Adenine Dinucleotide (NAD). NAD is a co-factor 
involved in redox reactions in the erythrocyte, enabling oxidation and ATP 
production as part of the Embden-Meyerhof pathway (Brown, 1996). The uptake of 
L-glutamine by HbS erythrocytes is greater than that of normal red cells as they 
seek to increase the total intracellular NAD level due to increased oxidative stress 
and cellular damage (Niihara et al. 1997). By reducing oxidative stress through 
administration of L-Glutamine, the red cells of SCD patients treated for 4 weeks 
showed reduced endothelial adherence when compared to an untreated SCD 
control (Niihara et al. 2005 & 2018). Updated guidance now states that L-glutamine 
can be considered in patients aged 5 years and older who are intolerant to 
hydroxycarbamide or who continue to have painful events while on 






1.5.8 Haemopoietic Stem Cell Transplants 
 
 
Currently, curative hematopoietic stem-cell transplantation (HSCT) is only 
available to a limited cohort of patients, with the NHS funding HSCT only in those 
up to 19 years of age with severe SCD and a suitable sibling donor. Even then, its 
use is restricted by the high cost, toxicity, and limited availability of suitable donors 
(Hsieh & Fitzhugh et al. 2011). Indications for HSCT in adults have historically 
been limited, due to the increased risk of mortality from aggressive conditioning 
regimens. Most published studies on adults with SCD report positive outcomes of 
HSCT, but they are studies involving small numbers of patients, who have been 
transplanted with different types of conditioning regimens and most frequently from 
Human Leukocyte Antigen (HLA) identical siblings. HLA matched sibling donor 
(MSD) transplants offer the best outcomes for SCD, but less than 14% of patients 
with SCD have a sibling that is HLA matched (Shenoy, 2013; Gluckman et al. 
2017). Other sources of HSCT include matched unrelated donors (MUD) or 
mismatched unrelated donor (mMUD), an umbilical cord blood (UCB) product or a 
haplo-identical (half-matched) donor from the family. Each of these transplant 
approaches are associated with complications innate to the graft source and 
transplant approach used and include Graft Versus Host Disease (GVHD) and 
delayed immune reconstitution, each of which can result in unacceptable 
outcomes. However, emerging therapies such as gene therapy may offer a 






1.5.9 Gene therapy 
 
 
Gene therapy treatment has shown early promise and is in the very early stages 
of clinical trials. In a recent study by Ribeil et al. (2017), the researchers treated a 
patient with lentiviral vector–mediated addition of an anti-sickling β-globin gene 
into autologous hematopoietic stem cells. This showed encouraging results, with 
15-month post-transplant outcomes suggesting engraftment of transduced stem 
cells that were capable of long-term repopulation. The patient experienced no 
recurrence of sickle crises and had correction of the biological hallmarks of the 
disease. Further clinical trials are underway, evaluating the efficacy and safety of 
LentiGlobin drug product in Beta-Thalassemia Major and SCD, and looking at the 
long-term follow -up of subjects with haemoglobinopathies treated with ex-vivo 
gene therapy (NCT02151526 & NCT02633943 respectively). The cost is currently 
prohibitive for routine treatment, with estimated costs in the region of £380,000-
£540,000. Full calculations of a cost benefit ratio, particularly for using the therapy 
in young patients, are yet to be done, and the benefits of gene therapy may 
outweigh the long-term costs of treatment and care. In addition, the consequences 
of genome editing, including the effects of the semi- random nature of lentivirus 
integration leading to off-target mutations, and the sustainability of any therapeutic 
effects all await additional long-term study (Steinberg, 2020). 
 
1.5.10 Inhibitors of Haemoglobin S polymerisation 
 
 
One emerging therapy, Voxelotor, is designed to specifically target the sickle 
haemoglobin (HbS) molecule. Voxelotor is an HbS polymerisation inhibitor that 
reversibly binds to haemoglobin to stabilise the molecule in its oxygenated state, 
therefore inhibiting HbS polymerisation and subsequent sickling of the erythrocyte 
(Vichinsky et al. 2019). A phase III double-blind trial of Voxelotor (HOPE trial) 
found that it significantly increased haemoglobin levels and reduced markers of 
haemolysis. Concerns remain regarding the increase in haemoglobin causing an 
increased risk of vaso-occlusive events. Additionally, the increase in blood flow to 
the brain of young patients on Voxelotor may result in an increased chance of 
white matter injury, where current treatment with hydroxyurea has shown some 







1.5.11 Inhibitors of cellular and vascular interaction 
 
 
The complex interaction between physiological processes and abnormal 
expression of cellular adhesion molecules in SCD has been previously described 
(Zennadi & De Castro et al. 2008; Koehl & Nivoit et al. 2017; Cartron & Elion 2008; 
Canalli & Proença et al. 2011; Conran & Costa, 2009; Manwani & Frenette, 2013). 
An increased propensity for interaction between cellular surface molecules and 
activation of vascular endothelium through inflammatory processes are thought to 
be the underlying cause for VOC, in addition to anaemia-induced reticulocytosis 
and inefficient maturation to erythrocytes in SCD. A number of adhesion molecules 
are present on reticulocytes but are lost or reduced on maturation to erythrocytes, 
and this is a common theme throughout the research literature. Cell surface 
proteins thought to be responsible for HbS erythrocyte / vascular endothelium 
interaction and adhesion include Lu/BCAM (B Cell Adhesion Molecule), P-selectin, 
E-selectin, CD44 and ICAM-4 (Inter-Cellular Adhesion Molecule) among others. 
 
The number of cellular and vascular endothelial interactions however are complex, 
(figure 1.12) and the exact cause of a hypercoagulable state and of the increased 
tendency of thrombosis and VOC in SCD has not been fully elucidated, 
suggesting a number of biological interactions are responsible for the vaso-
occlusive pathophysiology. Ongoing research aims to identify and affect the 
interaction(s) of most significance in the pathophysiology of VOC. 
 
Novel, anti-adhesive therapies are therefore developed with the aims of either 
blocking or reducing these interactions between HbS erythrocytes and the 
vascular endothelium. Of particular interest are the selectins, adhesion molecules 
which are present on RBCs and on the vascular endothelial surfaces. Increased 
expression of selectins (P-selectin and E-selectin) are associated with severity of 
SCD and are known to contribute to vaso-occlusion (Johnson and Telen, 2008). 
Novel therapies include panselectin inhibitors, such as Rivipansel (RESET trial; 
NCT02187003), which did not meet its primary or secondary endpoints and was 
unfortunately not effective (Clinicaltrials.gov, 2020) or specific selectin inhibitors, 










Figure 1.12 Interactions between Sickle Red Blood Cells and the sub-endothelial surface. 
(Adapted from Cartron & Elion, 2008) 
 
In the SUSTAIN study, Crizanlizumab, a monoclonal antibody directed toward P-
selectin, was found to block cell to cell interaction (figure 1.13). It was therefore 
proposed that it may reduce the risk or incidence of sickle cell pain crises. P-
selectin is found in endothelial cells and platelets and is transported to the cell 
membrane on activation of the cell during processes such as inflammation. 
Studies in P-selectin-deficient transgenic mice with sickle cell disease have shown 
that they have defective leucocyte recruitment to the vessel wall and are protected 
from vaso-occlusion (Turhan et al. 2002). It is thought that increased expression of 
P-selectin in endothelial cells and platelets contributes to the pathogenesis of 
SCD. In the SUSTAIN study, high-dose Crizanlizumab therapy significantly 
reduced the frequency of sickle cell-related pain crises when compared with the 
placebo cohort. When compared with patients who were on hydroxyurea, where 
the annual rate of crisis was 32.1%, sickle cell-related crisis events were 50% 
lower with high-dose Crizanlizumab compared to those patients not taking any 
hydroxyurea therapy (Ataga et al. 2016; Ataga et al. 2017). 
However, there was no reduction in haemolysis, and the Crizanlizumab did not 
prevent all episodes of vasoocclusive crises, indicating that P-selectin is not solely 
responsible for episodes of vasoocclusive crises and haemolysis, and that these 









Figure 1.13 P-Selectin (in orange) interactions in vascular endothelial adhesion. (Adapted 
from Ataga & Kutlar et al. 2016). 
 
1.6 Phosphatidylserine (PS) and thrombosis 
 
 
One of the key cell surface proteins known to be contributory to VOC and a 
potentiator of thrombosis in SCD is Phosphatidylserine (PS) (Setty et al. 2002; Tait 
& Gibson,1994; Kuypers et al. 1996). PS is located on the inner leaflet of the 
membrane bilayer and it plays a role in thrombosis via enhanced interactions with 
receptors on endothelial cells and platelets, thereby contributing to micro-vascular 
occlusion (Lentz, 2003). A deficiency in PS, known as Scott syndrome, is 
associated with increased bleeding (Zwaal et al. 2004). In Scott syndrome, the 
mechanism for translocating PS to the platelet membrane is defective, resulting in 
impaired thrombin generation (Toti et al. 1996). 
 
There are two main mechanisms by which PS is transported in the erythrocyte. 
Both are aided by the actions of two translocase enzymes, Flippase and 
Scramblase. Flippase-mediated transport of PS is an ATP-driven process, which 
maintains PS expression in the inner membrane leaflet, whilst the calcium ion 
(Ca2+) dependent scramblase moves PS quickly in a bidirectional process which 
causes disruption of phospholipid asymmetry (Williamson et al. 1992; Weiss et al. 
2010). In normal RBCs, PS is largely confined to inner leaflet, through the 
dominant action of the flippase whilst the scramblase remains quiescent. 
 
In SCD, repeated deoxygenation and reoxygenation of the erythrocyte results in 
damage and dehydration, which causes Ca2+ influx which results in abnormally 






ATP-driven flippase and activation of scramblase (figure 1.14) (Wagner et al. 
1985; Lubin et al. 1981; Dekkers et al. 1998; Yasin et al. 2003). Additionally, PS 
exposure and generation of procoagulant erythrocyte microvesicles can be caused 
by alternative mechanisms such as protein kinase C (PKC) activation (De Jong et 
al. 2002). 
 
The increased PS exposure on SCD erythrocytes contributes to a shortened 
erythrocyte life span due to increased complement recognition and cell destruction 
via eryptosis (Wang et al. 1993; Lim et al. 2013; Bogdanova and Lutz, 2013). PS is 
well documented as present in greater numbers in circulating RBCs in 
splenectomised SCD patients (Kuypers et al. 1996; Tait & Gibson,1994; Setty et 
al. 2002), and subpopulations of PS positive erythrocytes have been implicated as 
the cause of stroke in SCD patients and they are thought to be one of the major 
contributors to VOC (Styles et al. 1997). 
 
 
Figure 1.14 Phosphatidylserine transport in the SCD erythrocyte 
Actions of the ATP-dependent Flippase enzyme and subsequent inhibition of ATP by Ca2+ influx, 
causing translocation of PS to the external erythrocyte surface by scramblase. This externalisation 







An early study by Wood et al. in 1996 examined the association of PS in patients 
with SCD. They measured exposed levels of PS on the outer surface of the 
erythrocyte membrane based on addition of fluorescein-labelled Annexin V to 
whole-blood specimens and subsequent flow cytometric (FC) analysis. The 
physiological role of annexins within the body is not completely understood. 
Annexins are mainly cytosolic but can also be found as extracellular proteins. They 
are involved in a wide range of intra- and extracellular biological processes, most 
of them directly related with the ability to bind to phospholipid bilayers: membrane 
trafficking, membrane-cytoskeleton anchorage, ion channel activity and regulation, 
as well as anti-inflammatory and anticoagulant activities. (Lizarbe et al. 2013). 
Annexin is able to bind in the presence of Calcium ions (Ca2+) to 
phosphatidylserine to form a membrane-bound two-dimensional crystal lattice. 
(van Genderen et al. 2008). The PS affinity is such that labelled annexin 
molecules are used in both the lab and clinically for PS identification. In vivo, 
annexin’s anticoagulant role is dependent on its ability to block the adhesion of 
clotting factors V and VIII to PS displayed on endothelial surfaces (Thiagarajan et 
al. 1991; Ahmad et al. 2000). It is the binding capacity of labelled annexins and 
their anti-inflammatory and anticoagulant activities that have made analysis of PS 
and annexin targeted therapy a focus of study among researchers of SCD. 
 
Wood et al. (1996) looked at 17 SCD patients and 2 β-Thalassaemia patients and 
found that when compared to normal controls, levels of PS were elevated in 96% 
of patients studied. The percentage of annexin-positive cells always decreased 
after transfusion and levels of PS were higher in those patients who had recently 
been in SCD crisis. The observed decrease could not have arisen through the 
dilutional effect of transfusion alone and it was suggested that it may be due in 
part to suppression of erythropoiesis and to faster clearance of abnormal 
erythrocytes. Wood et al. (1996) concluded that because of the thrombogenic 
nature of exposed PS, and the dependence of coagulation reactions on the 
percentage of PS in the membrane, small numbers of HbS erythrocytes could 
have a substantial thrombogenic effect, especially if they are concentrated at a site 






In experiments to characterise the subpopulations of PS-exposed sickle RBCs, De 
Jong et al. (2001) described populations of PS-exposed cells that are present in 
both high and the very low-density fractions of sickle RBCs, in the very young, 
transferrin receptor–exposing reticulocytes and also in more mature RBCs. These 
findings correlate with PS exposure at the reticulocyte cell maturation stage, as 
described by Mankelow et al. (2015) and the effect of cell membrane damage on 
older, mature erythrocytes due to calcium ion influx caused by repeated sickling in 
vivo, leading to induction of membrane phospholipid scrambling, as described 
(Williamson et al. 1992; Weiss et al. 2010). 
 
One later paper by Kennedy (2015) hypothesises the use of annexin V to 
terminate ongoing sickle cell crises. Kennedy describes how approximately 1/3 of 
sickle erythrocytes are prematurely senescent, causing them to display PS 
molecules on their surface and that the adhesive and procoagulant character of 
PS is responsible for a haemolysis and VOC in SCD. Kennedy proposed that 
annexin V dosing may aid biological levels of annexin V in the blocking of 
endothelial PS receptor, thrombospondin, therefore reducing the tendency towards 
coagulation. However, examples given by Kennedy et al. were in animal models 
only, and currently in-human trials have not been performed to date. 
 
A more recent, in-human study by Whelihan et al. (2016) showed RBC PS levels 
were significantly elevated in SCD patients when compared with controls, and that 
there was a correlation between increased RBC PS exposure when compared to 
reticulocyte count. The authors state that this could be due to localisation of 
phosphatidylserine to a few discrete areas of the membrane in normal 
reticulocytes, as well as on red cells from SCD patients. The localised patches of 
PS shown in Whelihan et al. (2016) are very similar to that shown as the site of AV 
extraction in SCD and splenectomised individuals as described by Mankelow et al. 
(2015). Whelihan et al. proposed that the large population of PS+ RBCs and 
reticulocytes with a significantly shortened half‐life accelerates protein S clearance 
from the circulation and results in the low levels of protein S and subsequent pro- 







Other studies in this area which examine cell surface adhesion in the study design 
have demonstrated that PS is a major determinant of RBC–endothelial adhesion 
when compared to other cell surface adhesion molecules, such as erythrocyte 
adhesion receptor, CD36. (Setty et al. 2002). Further investigations into the 
mechanisms by which PS positive erythrocytes interact with the vessel wall need 
to be performed, and the full implications of erythrocyte PS exposure in relation to 
the vascular pathology of SCD require further research. (Setty et al. 2002). Better 
predictors of the severity of SCD could lead to more precise treatment and 
management (Piel et al 2016). Correlation between levels of circulating PS 
positive microvesicles and sickle cell crises could be a possible method of 
predicting severity and frequency of crises. When combined with apheresis 
methodologies that can remove the causative cells or cellular microparticles of 
interest, this could offer a novel treatment for patients with SCD who are at 
increased risk of VOC. 
 
1.7 RBC Microparticles and Autophagic vesicles - Microparticles, 
Microvesicles, Autophagic Vesicles, Exosomes, Ectosomes & Apoptotic 
Blebs. 
 
There are varying accounts in the literature as to what constitutes a microparticle 
(MP), and the nomenclature surrounding the topic is confusing. The stated size 
range of MPs varies from 100–3000nm and does not exclude other small 
particulates. At the top end of the scale, particulate matter could include apoptotic 
blebs from end-stage cells (500– 3000nm), and at the bottom end are exosomes 
(70–120nm), immune complexes, lipoprotein particles and viral particles. In the 
literature, the term ‘extracellular vesicles’ can include exosomes, ectosomes and 
apoptotic blebs, despite their distinct generative origins and detection 
methodologies (Pol et al, 2016). Red cell microparticles are generally smaller in 
size than those described for other cell types above. They are approximately 
150nm in diameter and are accompanied by a smaller type of vesicle of 
approximately 60nm, termed nanovesicles (Allan et al. 1980; Piccin et al. 2007). 
All cells release particulate matter as they mature or degrade as part of cell 
development or apoptosis. When referring to microparticle release in blood, 






endothelial cells, and all may contribute to the complex processes involved in SCD 
crises. The focus of this review will be on RBC-derived Microparticles (RCDP), 
Autophagic Vesicles (AVs), and their potential effect on SCD crises. 
 
1.8 Red Cell Derived Microparticles and red cell storage lesion 
 
 
Red blood cell microparticle (RCDP) formation occurs throughout normal 
erythrocyte maturation, and the phenomena in vivo was first described by 
Dumaswala and Greenwalt in 1984. During early maturation, RBCs lose 
approximately 20% of their volume, increasing intraerythrocytic haemoglobin (Hb) 
concentration by approximately 14% (Said and Doctor, 2017) through the release 
of RCDP into the circulation. Once mature, and under normal circumstances, while 
in the circulation, RBCs accumulate damage as they move throughout the 
vasculature (Crosby and Benjamin, 1957). In the final stage of the erythrocyte 
lifecycle, after approximately 120 days, senescent RBCs are removed from the 
circulation. This gradual RBC maturation and final senescence is associated with a 
decrease in deformability, with the eventual removal of the aged RBC from the 
circulation by splenic macrophages through the process of erythrophagocytosis 
(Kaestner and Bogdanova, 2014). 
 
The effects of RBC vesiculation include loss of haemoglobin and RBC surface 
area, and as a result the RBC becomes smaller and denser (Allan et al, 1982; 
Piomelli and Seaman, 1993; Willekens et al. 2003). Vesiculation and the 
mechanism of selective removal of both the released RCDP and the mature, 
senescent RBC by splenic macrophages, located in the red pulp of the spleen, 
explains the efficient removal of damaged content while leaving the RBC intact but 
reduced in size. However, the exact molecular mechanism by which macrophages 
in the spleen facilitate specific RCDP removal is still unknown. 
 
The deterioration of the RBC as it ages is a gradual process, and there is no 
accumulation of signalling molecules which leads to the removal of senescent 
RBCs. In fact, these RBC surface signalling molecules appear as a rapid and non- 
linear cascade of events at the terminal stage of the aging process shortly before 






changes in the conformation of the following membrane-bound proteins, Anion 
Exchanger-1 (AE-1), PS, CD47 and Complement Receptor 1 (CR1) lead to the 
appearance of a senescent cell-specific antigen phenotype which is recognized by 
specific, naturally occurring autologous immunoglobulin G (IgG) antibody. This 
marks senescent erythrocytes for removal by macrophages, such as Kupffer cells 
in the liver and spleen (Kay et al. 2005). See figure 1.15. 
 
AE-1 (also referred to as Band 3) is a transmembrane protein that is ubiquitously 
found throughout the RBC membrane. It has been found to be a major target of 
IgG antibodies and is implicated in macrophage-mediated clearance of senescent 
and damaged RBC. It is thought that oxidative damage to haemoglobin occurs 
during the RBCs lifecycle. This results in the formation of hemichromes which bind 
to AE-1, and in time lead to AE-1 clustering which results in the IgG antibody- 
mediated clearance of the RBC (Pantaleo et al. 2008; Arashiki et al. 2013). 
 
As previously described, the loss of phospholipid asymmetry and exposure of PS 
on the RBC surface in apoptotic cells may be a general trigger for RBC removal. 
Phosphatidylserine (PS) exposed on the RBC membrane can directly bind 
Stabilin-2, Tim-1, Tim-4, or CD300 on the macrophages and is presumed to give a 
pro-phagocytic signal. Throughout their lifecycle, red blood cells spontaneously 
shed PS-positive MVs. It is estimated that each RBC generates approximately 230 
vesicles during its lifespan (Bosch et al. 1994). It is estimated that if there was a 
total erythrocyte mass of 25 x 1012 in a healthy male, this would produce 580 x 106 
vesicles per second. These would have to be removed at the same time, 
assuming homeostasis. In their study, the total amount of erythrocyte-derived 
vesicles measured in the blood was 850 x 106, indicating that it takes only 0.7secs 
to clear half of all the vesicles from the circulation (Willekins et al. 2008). Vesicles 
have been observed in erythrocytes of all ages, and have been shown to 
accumulate after splenectomy (Reinhart and Chien, 1988) 
 
CD47 is a signal regulatory protein alpha (SIRP-α) acts as a strong “don’t eat me” 
signal for phagocytosis and functions as a marker of “self” on RBC. Reduced 
expression of CD47 may contribute to the uptake of these RBC by macrophages. 






murine models showing a >20% reduction in CD47 expression in older RBC 
(Fossati-Jimack et al. 2002; Burger et al. 2012). 
 
Complement Receptor 1 (CR1) on human RBC binds opsonised complement 
particles bearing C3b/C4b in the circulation. A recent study has shown that signal 
transduction downstream of CR1 following binding of complement resulted in 
alterations in RBC membrane deformability and CR1 clustering on the surface of 
the RBC. This enhanced binding of more complement and more importantly, it 
leads to ATP secretion, which has a direct stimulatory effect on particle uptake and 
removal by phagocytes (Melhorn et al. 2013) 
 
A study by Willekens et al. (2008) concluded that vesiculation provides a 
mechanism for the removal of erythrocyte membrane patches associated with 
removal molecules, thereby delaying the premature elimination of otherwise 
healthy erythrocytes. Research continues into which stages of erythrocyte 
production and maturation the most vesiculation occurs, with some studies 
concluding that vesiculation peaks in the latter third of erythrocyte life cycle and 
some studies finding increased vesicle release during the later stages of 
maturation of the reticulocyte into the erythrocyte within the circulation (Willekens 







Figure 1.15 Signals involved in interaction between macrophages and red blood cells (RBC) 
regulating clearance. RBCs and macrophages interact with each other through ligand–ligand 
interactions. Phosphatidylserine (PS) exposed on the RBC membrane binds to macrophage 
receptors Stabilin-2, Tim-1, Tim-4, or CD300 on the macrophages to stimulate phagocytosis. AE-1 
clusters form and promote opsonization with naturally occurring IgG antibodies (nAb) and 
complement on the RBC. This enables binding to the macrophage via Fc receptors and CR-1 and 
facilitates phagocytosis. As a counterbalance, CD47–SIRPα interactions inhibit phagocytosis of 
RBCs by the macrophage (adapted from Klei et al. 2017). 
 
RBC microparticle formation is increased during storage of red cells for transfusion 
in a process termed storage lesion (Kim-Shapiro et al. 2011). Storage lesion can 
be further defined as a variety of changes identified within the RBC 
and storage media during RBC preservation that are correlated with reduced 
tissue oxygenation and the potential concern of transfusion-associated adverse 
effects (Tzounakas et al. 2017; Steiner et al. 2015; Lacroix et al. 2011).The effects 
of storage lesion include the loss of Adenosine triphosphate (ATP), 2,3- 






biomechanical changes to the erythrocyte, for example, the modification of the 
RBC shape. Decreased ATP deregulates cation homeostasis and disorders 
membrane symmetry through inhibition of flippase activity and activation of 
scramblase, exposing the phospholipids phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) which, as described earlier are normally in the 
inner membrane bilayer. This combination of accumulated damage and 
expression of leads to microparticle formation (Yoshida et al. 2019). 
 
Over time, stored RBCs become more rigid, which limits their ability to pass 
through capillaries. This reduces tissue oxygenation efficiency (Hovav et al. 1999; 
Blasi et al. 2012). The normal discoid RBC changes shape, and becomes a 
spherical cell, and in doing so, passes through intermediate echinocyte and 
sphero-echinocyte shapes. (Delobel et al. 2016). During this shape change, RBCs 
release increasing amounts of Microvesicles (MVs) (figure 1.16). Numerous 
studies have examined red cell storage lesion, and there have been a number of 
large Randomised Controlled Trials (RCT) in various clinical settings which have 
compared fresh (6-12 days on average) to standard-issue or moderately aged 
RBC units (~3 weeks on average) which found no differences in mortality or 
morbidity, indicating that there is no inferiority in transfusing RBCs using standard 
practice (oldest units available) when compared to transfusing fresher RBCs 
(freshest available) (Lacroix et al. 2011; Garraud, 2017; Chai‐Adisaksopha et al. 
2017). 
Figure 1.16 Echinocytosis and Microvesiculation in Erythrocytes 
Left image: Stored blood first undergoes echinocytosis. It then begins to fragment by budding and 
microvesiculation from the surface of the RBC. (Right image) Buds and microspherules seen with a 






1.9 Microparticles and Disease 
 
 
The ability for various cell types to form microparticles is integral to physiological 
coagulation pathways. Aminophospholipids, such as PS and PE on the surface of 
platelet and endothelial cell microparticles provide binding sites for factors IXa, 
VIII, Va and IIa in addition to tissue factor (del Conde et al. 2005). Microparticles 
have long been considered as cell fragments or debris without any biological 
function. Although their true biological function is still unknown, there are more and 
more indirect evidence that MPs are involved in a broad spectrum of biological 
activities. (Rubin et al. 2008) An increase in MP formation is observed under 
conditions of stress and injury and so MPs have been investigated as potential 
disease biomarkers. MPs have been the focus of research due to their potential 
involvement in inflammatory and autoimmune diseases, as well as in 
cardiovascular disorders and diabetes (Leroyer et al. 2008a, 2008b).  For 
example, circulating monocyte, platelet and endothelial cell-derived microparticles 
are found in septic patients (Raeven et al. 2018) with one study concluding that 
the presence of microparticles may predict a more favourable outcome in severe 
sepsis (Soriano et al. 2005). The extent to which they contribute to the disease 
process in other conditions is not fully known, although numerous papers describe 
their contribution to disease pathophysiology. 
 
Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic haemolytic 
anaemia (MAHA) characterised by failure to cleave very large multimers of von 
Willebrand’s Factor (vWf) in the circulation. TTP causes extensive clots 
(microscopic thrombi) to form in small blood vessels throughout the body and if not 
treated quickly can be fatal. Normally, these large multimers of vWF are cleaved 
by the enzyme ADAMTS13, however in TTP ADAMTS13 stops working because 
of autoimmune anti-ADAMTS13 production (Tsai & Lian, 1998). Increased levels 
of platelet microparticles circulate during the acute and chronic phases of TTP and 
express the proteolytic enzyme calpain on their surface. Expression of calpain is 
associated with the early generation of microparticles which contain functional 
adhesive receptors with procoagulant activity on their surface. The activation of 
calpain leads to degradation of actin filaments and breaking of bonds between the 






the cytoskeleton initiates the budding and shedding of MVs (Dekkers et al.1998; 
Kalra et al. 2016). These MVs function to disseminate procoagulant activity and 
stabilize the formation of platelet clots, contributing to the formation of thrombi in 
the microcirculation in TTP (Kelton et al. 1992). 
 
Microparticles are increased in the circulation of patients with paroxysmal 
nocturnal haemoglobinuria (PNH), and are derived from platelets, monocytes and 
endothelial cells (Hugel et al.1999). PNH is an acquired disorder of the blood 
characterised by intravascular haemolysis and thrombophilia due to the absence 
of glycosylphosphatidylinositol-anchored proteins (CD55 and CD59) on the 
membrane surface of blood cells (Rosse, 1997). These microparticle 
subpopulations have been shown to carry prothrombotic activity, offering an 
explanation for the increased incidence of thrombosis in PNH. In addition, 
microparticles caused by complement activation (C5b-9) have high expression of 
binding sites for factors Va and VIIIa, further contributing to the prothrombotic 
state. 
 
RCDPs have been more specifically associated with disease states including 
hereditary spherocytosis (HS) and SCD (Piccin et al. 2007; van Beers et al. 2009). 
Rubin et al. (2013) describe how RCDPs increased thrombin generation, even in 
the absence of tissue factor, suggesting that tissue factor may be expressed on 







1.10 Red Cell Derived Microparticles and SCD 
 
 
As discussed, most SCD patients do not have a functional spleen as a result of 
splenic infarction and autosplenectomy at an early age (Brousse et al. 2014). The 
consequences of this are multifactorial, and lead to aggravation of the patient’s 
symptoms. Studies have shown that circulating RCDP are 8-10 times higher in 
SCD patients than in normal controls (Mahfoudhi et al. 2012) as the SCD patient is 
unable to remove RCDPs from the circulation via splenic macrophage activation. 
This results in elevated numbers of pro-coagulant PS positive RCDP and RBCs in 
the circulation (van Beers et al.2009) increasing the tendency to clot and the 
associated risk of VOC and stroke. 
 
Generation of RCDP is also enhanced by inflammatory conditions, such as those 
experienced in SCD. When engulfed by circulating phagocytic cells, RCDP have 
been found to significantly enhance the production and secretion of pro- 
inflammatory cytokines IL-6, TNF-α, and IL-1β from macrophages, markers of 
systemic inflammation and promoters of endothelial cell adhesion (Pathare et al. 
2003; Awojoodu et al. 2014). Up to one-third of cell-free heme in SCD may be 
carried by circulating RCDP. Such heme-laden RCDP transfer haem directly to 
vascular endothelium, causing oxidative stress and endothelial apoptosis. Such 
linkage of haemolysis to endothelial injury has been proposed as a trigger for SCD 
vaso-occlusive crises. (Camus et al. 2015). Heme-laden microparticles react with 
Nitric Oxide (NO) about 1000 times faster than with intact erythrocytes. In in vivo 
studies by Donadee et al. (2011) they showed that haemoglobin, even at 
concentrations below 10μmol/L (in heme), produces potent vasoconstriction. 
 
However in the published literature, there is some disagreement about the origin of 
the causative MVs in SCD, with some attributing RBC-derived MVs as greater in 
number (Shet et al. 2003; van Beers et al. 2009; Mahfoudi et al. 2012; Camus et 
al. 2012), and some studies finding endothelial, monocyte or platelet-derived MVs 
as the larger subpopulation (Nebor et al. 2014). 
Shet et al. (2003) found that RCDP always constitute the majority of blood MPs in 
patients with SCD. They found that RBC and monocyte-derived MPs were 






control subjects, with RCDP the largest population detected. The monocyte- 
derived MPs were triple-labelled with Cy5-labeled annexin V, a cell type–specific 
PE-labelled MoAb against either CD14 (macrophage-specific lipopolysaccharide 
ligand) or CD144 (endothelial-bound calcium-dependent cell–cell adhesion ligand) 
and a FITC-labelled MoAb against Tissue Factor (TF). TF is a transmembrane 
receptor for Factor VII/VIIa (FVII/VIIa). It is constitutively expressed by cells 
surrounding blood vessels. Breakage of the endothelial barrier leads to exposure 
of extravascular TF and rapid activation of the clotting cascade (Mackman, 2009). 
Shet et al. (2003) found that patients in crisis had significantly higher total TF 
positive MPs compared with those in steady state or healthy subjects, and 
subjects in steady state had significantly higher numbers than healthy subjects. 
They concluded that markers of coagulation were elevated in patients with sickle 
cell disease versus control subjects and correlated with total MPs and TF-positive 
MPs, and that their findings support the concept that SCD is an inflammatory state 
with monocyte activation and abnormal TF activity. They did not, however, 
consider the PS content and procoagulant activity of the RCDP which were the 
most abundant type of MV detected in both steady state and crisis SCD patients in 
the study. 
 
A study by van Beers et al. (2009) found that the majority of microparticles 
originated from both platelets and erythrocytes. There was no significant difference 
in MP number between SCD patients in crisis and those in steady state. They 
observed that numbers of all types of microparticles were lower in healthy controls 
than in patients during baseline conditions. This difference, was, however, clearer 
for erythrocyte-derived microparticles. This is concordant with the findings of other 
studies (Setty et al. 2002; Shet et al. 2003). Importantly, they identified a 
distinctive population of microparticles exposing CD71, the transferrin receptor, but 
lacking glycophorin A. This correlated to the percentage of reticulocytes found in 
the SCD patients studied. Van Beers et al. postulated that the CD71+ 
microparticles were selectively shed from reticulocytes during erythrocyte 
maturation. An observation that had been reported previously in animal studies 
(Chitambar et al. 1991). They authors state that the large difference in the number 
of circulating CD71+ microparticles between patients and controls reflects the 






This finding regarding large numbers of RBCMV shed by reticulocytes was echoed 
in the findings of other studies (Johnstone et al. 1986; Hillery et al. 1996 and 
Mankelow et al. 2015) 
Nebor et al. (2014) looked at 3 cohorts of Jamaican SCD patients. A severe group 
(n=12), a non-severe group (n=17) and a negative control group (n=20). They 
found that the plasma concentration of MPs shed by platelets was greater in 
number in both the severe and non-severe groups, when compared to RBC- 
derived MPs. They concluded that PS-positive MPs from platelets was a 
biomarker of vaso-occlusive phenotype-related severity. However, due to the small 
size of the study, they concluded that larger studies focusing on the relationship 
between plasma concentrations of these sub-cellular elements and the other SCD 
clinical manifestation should be undertaken. 
 
A study by van Tits et al. in 2009 examined annexin V, an intracellular protein 
present in endothelial cells and platelets and is released upon tissue injury. 
Annexin V has high affinity for PS and has been shown to inhibit several PS- 
mediated pathophysiological processes (Kennedy, 2015). They could show that 
HbSS sickle cell patients have elevated plasma concentrations of annexin V 
compared to healthy controls. Increments were seen in both HbSS and HbSC 
patients at presentation with a painful crisis. However, they found no significant 
differences in the annexin A5/MP–PS ratios at presentation with a painful crisis as 
compared to the steady state. This would, in theory be expected to increase if 
annexin calcium-dependent cell–cell adhesion levels were associated with 
increased PS levels in crisis. 
 
A more recent study in 2012 by Mahfoudhi et al. used a triple Annexin 
V/CD41/GPA staining method enabling them to detect and quantify both platelets- 
derived and erythrocyte-derived MPs in the same sample. These findings agreed 
with the previous findings of other studies in that erythrocyte-derived MPs were 
increased in their cohort of SCD patients. Patient MPs were monitored before and 
after exchange transfusion therapy. They observed a selective reduction in the 
number of erythrocytes-derived MPs after treatment, while the number of platelets- 






Camus et al. (2012) looked at vasoocclusion in kidneys using murine models. 
They induced erythrocyte MPs using Thrombospondin-1 (TSP1). They found that 
TSP1 triggered rapid erythrocyte conversion into spicule-covered echinocytes, 
followed by MP shedding. The shed MPs were then administered back into the 
mice, where they triggered immediate renal vasoocclusion. The effects were 
inhibited by saturating MP phosphatidylserine with annexin-V. The increased 
number of MVs released by the unstable sickle erythrocytes as they undergo 
sickling and unsickling upon deoxygenation and reoxygenation respectively, levels 
of circulating MVs in sickle cell patients are increased when compared to normal 
healthy controls. 
 
Gerotziafas et al. (2012) Examined changes in thrombin generation (TG) to see if 
there was a link with the concentration(s) of erythrocyte- or platelet-derived 
microparticles (Ed-MPs and Pd-MPs) in a cohort of patients with steady-state 
SCD. They compared steady-state SCD patients, of whom some (19) were 
receiving treatment with hydroxyurea, with healthy age- and sex-matched controls. 
They found that the steady-state SCD patients who were not taking hydroxyurea 
had a significantly accelerated propagation phase of TG which correlated with the 
dual labelled Ed-MP PS+ subpopulation. This led them to postulate that the 
acceleration of the propagation phase of TG is driven by Ed-MP/PS+. They 
suggested that the presence of these MP may contribute to blood coagulation in 
patients with steady-state SCD. 
 
There remains a lack of clarity with regard to the RBC sub-population most 
responsible for RCDMV production. Some suggest that senescent RBCs are 
responsible for the majority of RCDMV production in vivo, while others have 
shown that during storage younger RBC populations produce the majority of 
RMPs. In all previous studies examining RCDMV, the authors utilise antibodies to 
extracellular epitopes, predominantly on GPA, which won’t detect inside out AV. In 
addition, those that dual stain with anti-GPA and annexin V will detect a PS 
positive vesicle that isn’t attributed as derived from a red cell as it will be GPA 
negative AVs very little is known about the very early stages of erythrocyte 






stage of erythropoiesis, and no previous studies have accounted for Autophagic 
Vesicle (AV) numbers, especially for SCD in VOC. 
 
1.11 Autophagic vesicles and reticulocyte maturation in the circulation 
 
 
Vesicle Formation during reticulocyte maturation was first described by Johnstone 
et al. in 1996. During the process of erythropoiesis, the premature enucleated 
erythrocyte (reticulocyte) must undergo a series of physiological processes to 
transform into a mature erythrocyte. The term reticulocytes normally refers to 
erythroid cells that have undergone enucleation and are not yet fully biconcave, 
whereas in reality, reticulocytes are a heterogeneous population of erythroid 
lineage cells at all stages in between enucleated reticulocytes and erythrocytes. 
 
Heilmeyer and Westhauser first described diversity within the reticulocyte 
population in the early 1930’s (Heilmeyer and Westhauser, 1932). With further 
work performed by Mel et al. (1977) subdividing reticulocytes into class 1 (R1) 
and class 2 (R2) reticulocytes based upon a two-stage living cell cytological 
classification in animal studies on rats. Since then, a number of methodologies 
have been used to differentiate reticulocyte maturation based upon staining with 
the RNA stain, Thiazole Orange (TO), but these methods have been found to be 
unreliable in the presence of parasitaemia or erythrocyte inclusions found in 
certain haematological malignancies (Choi and Pai, 2001; Wollman et al. 2014). 
 
The transferrin receptor (TfR or CD71) has now become a standard marker for 
reticulocyte maturation. Levels of TfR decrease throughout reticulocyte maturation. 
Once haemoglobin synthesis is complete, reticulocyte Tfr1 is rapidly 
downregulated to prevent continued iron importation, and iron-mediated toxicity 
(Ney, 2011). Studies have found that when dual stained with CD71/TO, it is now 
possible to differentiate four stages of reticulocyte maturation from early 
reticulocytes (R1 stage) to late reticulocytes (R4 stage) (Malleret et al. 2013; 
Ovchynnikova et al. 2017). 
To adopt a bi-concave erythrocyte shape, membrane stability and deformability, 
reticulocytes undergo a maturation process within the circulation. Membrane- 






unstructured reticulocyte to a morphologically biconcave and functional 
erythrocyte. Reticulocytes are released from the bone marrow into the circulation, 
and at the point of release contain nuclear material and cytosolic organelles which 
must be exuded from the cell by through enucleation, endosomal, exosomal 
pathways and autophagy. The reticulocyte loses up to 20% of its cell surface area 
and volume during this enucleation step, as well as the nuclear material and 
cytosolic organelles which are not required in the mature erythrocyte (figure 1.17). 
Reticulocyte maturation is accompanied not only by a loss of cytosolic organelles, 
but also by an intense membrane remodelling. It takes 1–2 days in the circulation 
for the reticulocyte to obtain bi-concaveness and mature into fully functional 
erythrocyte. Unfortunately, not much is known about how this process of volume 
loss and membrane reorganisation occur during differentiation. 
 
Figure 1.17 Normal reticulocyte maturation. 
There are four main steps in reticulocyte maturation. 1) Iron bound to transferrin is internalized via 
endocytosis into an endosomal compartment. After acidification of the endosomal compartment 
and release of transferrin-bound iron, transferrin is recycled to the cell surface. 2) Vesicles 
congregate at the nuclear cytoplasmic junction, creating a new membrane. The sides are pinched 
inwards by the combined action of vesicle trafficking and microfilaments. 3) Vesicles are recruited 
and surround cellular organelles in an autophagic process. Organelles are subsequently degraded 
and eliminated by exocytosis. 4) Membrane is lost, and transferrin receptor and other membrane 






The role of splenic and hepatic macrophages in the development of reticulocytes 
has been 
extensively studied (Klei et al. 2017), however the influence of the shear stress 
forces, and capillary interactions involved in reticulocyte development remains 
unclear. It is known that reticulocytes and erythrocytes of SCD patients share 
many ligands. Levels of surface expressed adhesion proteins facilitate adhesion 
with the vascular endothelium in both reticulocytes and erythrocytes in SCD 
leading to VOC in the latter instance. Proteins such as α4β1 integrin, which is 
widely expressed on reticulocytes interacts with VCAM-1, and CD47 which binds 
to thrombospondin, and Lu/BCAM which interacts with laminin, a major constituent 
of the vascular basement membrane (Rasmussen and Karsdal, 2016). These 
interactions with the endothelium serve no known biological purpose, whether 
shear stress forces combined with enhanced endothelial adhesion result in 
removal via physical forces of membrane bound constituents or MVs is yet to be 
seen. 
 
The dogma regarding MV formation during reticulocyte maturation has followed 
the theory that loss of plasma membrane and organelles was facilitated by 2 
separate mechanisms. The first mechanism, involving plasma membrane loss via 
an endosome-exosome pathway, describes a process where small plasma 
membrane vesicles are endocytosed and incorporated into multivesicular 
endosomal bodies which then fuse with the plasma membrane, releasing 
unwanted material as exosomes. This is mediated by endosomal sorting 
complexes required for transport (ESCRT) machinery (Saksena et al. 2007). The 
ESCRT machinery comprises four complexes (ESCRT 0, I, II, III) that are involved 
in MV formation. It is generally believed that ESCRT complexes recognize 
membrane proteins that need to be sorted into MV to be excluded from the 
maturing reticulocyte as a discrete MV (Odorizzi et al.1998; Hislop and von 
Zaslow, 2011). 
 
The second mechanism is an autophagic pathway, where unwanted cellular 
material is enclosed in a double membrane to form an autophagosome. First 
described by Kent et al. (1966) autophagy, or “self-digestion”, is an intracellular 






and organelles such as mitochondria (Ney, 2011). These are delivered to 
lysosomes and expelled from the cell (Johnstone et al.1987; Ney, 2011). As 
described, these two processes are considered to be distinct from each other, with 
each serving a separate biological purpose. A further study by Fader et al. (2008) 
suggested that there may be overlap at the cellular and molecular levels. Fader et 
al. used K562 cells from an erythroleukemic cell line that generates multivesicular 
bodies to demonstrate that autophagosomes fuse with endosomes, forming so 
called amphisomes, a pre-lysosomal hybrid organelle. Fader et al. described how 
amphisome formation is driven by intracellular Ca2+ influx, indicating that fusion of 
multivesicular bodies (MVBs) with the autophagosome compartment is a calcium- 
dependent event. 
 
At the cellular level, both pathways are able to terminate with exocytosis of 
vesicles of intracellular components, suggesting a common mechanism. However, 
the mechanisms and pathways involved in the formation and fusion of the vesicles 
with the membrane and their subsequent secretion are still not yet fully 
understood. Earlier work on erythropoiesis and reticulocyte maturation had been 
performed using animal-derived bone marrow cells and reticulocytes from animals 
forced (by stimulation with erythropoietic agents or phlebotomy) to undergo stress 
erythropoiesis. (Mel et al. 1977; Chasis et al. 1989). 
 
Recently an ex vivo culture system has been developed that allows for the 
relatively easy study of human erythropoiesis and reticulocyte maturation. Using 
this culture system, Griffiths et al. (2012) were able to replicate human 
erythropoiesis using peripheral blood CD34+ stem cells which had been isolated 
from the mononuclear cell fraction discarded from blood donations during routine 
processing. Their work provided more detail regarding the interaction of the 
endosome-exosome and autophagic pathways. Using their ex vivo culture system, 
they also concluded that reticulocyte maturation occurs in two stages. 
 
The first stage occurring in the bone marrow, when plasma membrane 
components not required in the mature erythrocyte such as CD71, CD98, and 
α4β1 are eliminated via the endosomal-exosome pathway. The second stage 






fuse with autophagosomes, and the contents are mechanically expelled, during 
passage through the spleen. They described how this process may also result in 
the loss of plasma membrane by “blebbing” of large GPA positive vesicles, termed 
autophagic vesicles (AV) from the reticulocyte membrane (see figure 1.18). It is 
this continuous process that defines the reticulocyte’s final maturation step to an 
erythrocyte, which then gives the erythrocyte stability and deformability 
characteristics that sustain it through multiple passages through the peripheral 
circulation. 
 
Figure 1.18 Release of PS-exposed, inside-out autophagic vesicles is a normal mechanism 
of reticulocyte maturation. Reticulocytes produced by the method as described by Griffiths et al. 
2012. Cultured reticulocytes were treated with the proteolytic enzyme trypsin and then fixed and 
stained with an anti–GPA antibody (red). Following permeabilization, they were then stained with 
an anti–trypsin-sensitive GPA antibody (green). Inside-out GPA positive Autophagic Vesicle (AV) 
release shown (green). Image from Mankelow et al. 2015. Scale bars 7µm. 
 
Mankelow et al. (2015) then utilised the findings by Griffiths et al. (2012) to study 
autophagic vesicles and their secretion from R2 stage reticulocytes in more detail. 
The R2 reticulocytes are less motile, more mechanically stable and comprise ~2% 
of circulating RBCs. Mankelow et al. used two monoclonal antibodies (mAb) to 
Glycophorin A (GPA), R10 and BRIC 256, to label two different epitopes on the 
glycoprotein extracellular domain of R2 stage reticulocytes. The R10 epitope was 
sensitive to trypsin but the BRIC256 was not. The mAbs when incorporated into 
immunofluorescence and confocal microscopy experiments confirmed that the 
endocytosed plasma membrane, which fuses with the autophagosome is 
subsequently expelled from the reticulocyte in an intact state and that there was 
interaction between the membrane removal and autophagic pathways as 
previously described, resulting in the release of a GPA positive AV (figure 1.19). 
The group looked at the orientation of these extruded vesicles, by staining cultured 






epitopes BRIC163 (GPA) and BRIC155 (AE1). Using these intracellular-specific 
epitope markers, they were able to confirm that the large GPA-positive AVs 
described by Griffiths et al. (2012) were inside-out at the point of expulsion from 
the maturing R2 stage reticulocyte. There found no evidence to suggest that the 
vesicle membrane fuses with the plasma membrane, which would be expected if 
residual organelle material were expelled by exocytosis prior to blebbing, as 
previously described. 
Figure 1.19. Membrane Remodelling and Autophagy in late stage (R2) Reticulocytes. 
A GPA positive endosome is formed which then fuses with an autophagosome to create an 
autophagosome / GPA positive endosome hybrid. The contents of this are then expelled from the 
reticulocyte as a discrete PS-decorated RCDP, termed an autophagic vesicle. Note the inside-out 
conformation of the autophagic vesicles. (adapted from Mankelow et al. 2016). 
 
The observation that these AV were inside-out when expelled from the reticulocyte 
led the researchers to postulate whether the expression of intracellular proteins, 
which would now be expressed extracellularly could be contributory to the adverse 
effects observed in some haematological disease states, with SCD a particular 
area of focus. As these AV are inside-out they express PS, a procoagulant 
phospholipid that, due to the action of a phospholipid translocase, is normally 
located on the intramembrane side of the plasma membrane (Mankelow et al 
2015). If the AVs have an inside-out orientation, they would not be detected using 
existing monoclonal antibodies used in previous studies which have examined 
extracellular red cell epitopes on MVs and erythrocytes. There remains a 
possibility that this particular subset of RBC-derived PS-decorated AV exists in 






The association between PS and prothrombotic states has been studied 
extensively (Setty et al. 2002; Tait & Gibson,1994; Kuypers et al. 1996). Levels of 
PS are known to be up to 8 times higher in SCD patients (Kuypers et al. 1996, 
Wood & Gibson et al.1996). Most SCD patients have hyposplenism before 12 
months of age (Brousse et al. 2014) and therefore have no functioning spleen, 
where the elimination of vesicles occurs. It had previously been presumed that PS 
expression was uniform over the cell surface, but the studies by Mankelow et al. 
(2015) showed, through confocal microscopy, that PS was isolated in discrete 
regions on cultured reticulocytes, corresponding to AVs. To confirm the PS- 
positive cells observed by microscopy correlated with those detected by flow 
cytometry, PS-positive SCD cells were sorted using a cell sorter and subsequently 
imaged. All cells positively sorted for PS showed fluorescence exclusively in large 
vesicles. Negatively sorted cells did not show any PS fluorescence. The study 
showed increased levels of PS-decorated AV in steady state SCD patients, when 
compared with healthy controls and highlighted that previous flow cytometric 
studies, which label extracellular PS on erythrocytes, may have detected 
erythrocytes carrying an AV and assumed as they were positive for PS that it 
decorated the whole cell rather than just a small patch. It is likely in these studies 
that the PS positive red cell population detected was in fact two sub populations, 
reticulocytes and young erythrocytes with an attached AV and older senescent red 
cells with PS expressed across the entire plasma membrane. Mankelow et al. 
(2015) hypothesized that in the absence of a functional spleen (as is the case in 
SCD) that the AV produced as part of reticulocyte maturation would eventually be 
released into circulation, this, however, has never been tested (Discher & Ney, 
2015). 
 
1.12 Quantification of Microvesicles 
 
Flow cytometry (FC) is the standard method to detect, quantify and characterize 
MVs in physiological and in pathological conditions. However, current literature is 
based on limited sampling, because MV have been defined by flow cytometry 
characteristics that were technically achievable at the time. RBC-derived vesicles 
are generally smaller in size than those of other cell types. They are approximately 






approximately 0.06µm in size, termed a microparticle (Allen et al. 1980). This 
presents a problem when trying to enumerate vesicles using flow cytometric 
techniques, as some flow cytometers are not able to distinguish particles of such a 
small size. Flow cytometers are primarily designed to characterise intact cells 
rather than MPs. Until very recently, this meant particles that ranged from 500– 
1000 nm in size and expressed PS, as detected by annexin V binding (Freyssinet 
& Toti, 2010; Lacroix et al, 2010) were classed as MVs. This specific criteria meant 
there was the potential to miss the greater proportion of extracellular vesicles that 
are smaller and/or PS negative (Hebel & Key, 2016). 
Other techniques including atomic force microscopy, dynamic light scattering, 
confocal microscopy and nanoparticle tracking analysis can be used for smaller 
particle enumeration (van der Pol et al. 2016). However, they lack the ability to 
differentiate the phenotypic origin of MVs. Using flow cytometry, two main 
approaches have been employed in analysing RBC-derived MVs. 
• Selection of microvesicles based on a size, followed by analysis of the 
fluorescent signals of events limited to this preselected size. 
• Initial selection based on the fluorescent signals then limiting the analysis 
by scatter gating to these signals 
However, several variables must be considered when performing MV quantitation 
and classification by flow cytometry. Pre-analytical variables in sample preparation 
can lead to falsely elevated numbers of MVs. Centrifugation of the sample before 
freezing is a crucial step, to avoid residual RBCs and platelets falsely elevating MV 
counts. Lacroix et al. (2013) recommended dual centrifugation of blood samples at 
2500 g for 15 min at room temperature to ensure that the plasma is truly cell free 
before freezing prior to analysis. 
 
Analytical variables associated with FC analysis are generally related to issues 
with particle size. These issues are generally encountered with older FC 
technologies and are corrected in modern FC by utilisation of latex bead size 
calibrators and careful set up of the FC software to ensure the correct populations 
are gated and subsequently captured. 
The choice of reagent used in FC can affect study outcomes. In many studies, 
Annexin V has been used to label PS-Positive MVs. Whether this is specific 






IBGRL PDPU department in Bristol also produce a large number of antibodies to 
intracellular epitopes on the cytoplasmic portions of RBC antigens. These include 
BRIC163 (GPA), BRIC155 (AE-1), BRIC132 (AE-1), BGRL100 (glycophorin C) 
and BRAC67 (glucose transporter-1). They all have been used to detect AVs on 
RBCs (Mankelow et al. 2015) in SCD patients in both flow cytometric tests and 
confocal microscopic analysis. 
 
Additionally, newer technologies for analysing small cellular particles and debris 
are being employed including imaging flow cytometry. Imaging flow cytometry is a 
benchtop, multispectral, imaging flow cytometer which is able to acquire up to 12 
channels of cellular imagery. By collecting large numbers of digital images per 
sample and providing a numerical representation of image-based features, 
imaging flow cytometers are able to combines the per cell information content 
provided by standard microscopy with the statistical significance afforded by large 
sample sizes common to standard flow cytometry (Litwin and Marder, 2011). They 
are, in effect a combination between an advanced flow cytometer and a confocal 
microscope. However, they are currently not used in clinical diagnostic settings, 
but are becoming increasingly utilised in research. 
 
Taking the described pre-analytical variables into account, using effective control 
measures including sample preparation methodologies to minimise microvesicle 
formation in vitro, cell particle size gating bead technology and specific mAbs that 
target intracellular reticulocyte epitopes such as those described by Mankelow et 
al. (2015) on a more modern flow cytometer platform, would it be feasible to 
enumerate the numbers of PS-decorated AVs, attached to erythrocytes and/or free 
in circulation to see if these were significantly raised in SCD patients who were 
admitted in VOC? Additionally, from the results of this testing, would it then be 
feasible to develop a prognostic test to predict when SCD patients are likely to 
experience VOC and to administer an interventional therapeutic measure such as 
apheresis, chemotherapy or transfusion? This feasibility study aims to seek 












The overarching aim of this study is to explore the feasibility of a prognostic test, 
which could be used to predict the likelihood of VOC in SCD patients, to aid earlier 
intervention and improve the clinical management of this condition. 
 
The null hypothesis is that there are no significant differences in numbers of 
AVs between SCD patients in VOC and steady state / healthy controls. 
 
The alternative hypothesis, therefore, is that there are significant differences in 
numbers of AVs between SCD patients in VOC and steady state /healthy controls. 
 
2.2 Primary aim 
 
 
To determine if AV numbers are elevated in SCD patients who are in SCD crisis 
when compared with steady state and healthy controls. 
 
2.3 Secondary aims 
 
 
To determine whether levels of microvesicles correlate with VOC? 
To determine whether levels of microvesicles correlate with length of admission? 
To determine whether levels of microvesicles correlate with numbers of circulating 





This feasibility study is performed in collaboration with the Microvesicles and 
coagulation in sickle cell disease (MACS) study at University College London 
Hospital (UCLH). This is an observational case control study involving SCD 
patients from the UCLH. All samples from SCD patients and healthy controls will 






Haematologist and Paediatric Haematologist Joint Red Cell Unit who is also a 
Consultant Haematologist at NHSBT. 
In order to achieve the above aims the following objectives were addressed: 
- To identify the RBC-derived AV content of three distinct populations using 
flow cytometry and confocal microscopy and monoclonal antibodies, 
specific for intracellular AV proteins. 
- To determine if microvesicles, in particular RBC-derived autophagic 
vesicles (AV), are elevated in SCD in patients admitted in crises. 
- To establish whether there is a correlation between AV number and disease 
severity or likelihood of VOC. 
- To establish whether these then decrease once treatment has commenced. 
- To deduce whether the aims indicate the feasibility of the development of a 












Ethical approval for this study was granted by the Health Research Authority, 
NRES committee London – Harrow, including the use of Human blood samples, 
kindly provided by Dr Sara Trompeter, Consultant Haematologist and Paediatric 
Haematologist, Joint Red Cell Unit, University College London NHS Foundation 
Trust. (REC Reference: 10/H0715/61; IRAS Project ID: 59193) 
 
3.2 Participant Recruitment 
 
 
Participants were recruited to the study at UCLH. Participant number was 
determined by projected number of admissions and likelihood of participant 
consent over the duration of the study period. Participants were identified and 
recruited to the study by a team of National Institute of Health Research (NIHR) 
funded research nurses, working in the emergency department, using the following 
set of inclusion and exclusion criteria. 
Patient inclusion criteria: 
- Adult SCD patient presently stable. 
- Patient able to give informed consent 
- Compound heterozygote or homozygote for a sickling disorder 
- Having a blood test in any case 
Patient exclusion criteria: 
- Unable to meet all inclusion criteria 
Control inclusion criteria: 
- Adult able to give informed consent 
- Must know their sickle cell status or be highly unlikely to be HbSS through 
ethnicity. 
Control exclusion criteria: 









A total of 11 (homozygous HbSS) SCD patients in VOC were recruited to the 
study. None of the patients were on hydroxyurea therapy. In crisis was defined as 
presenting in the Emergency Department at UCLH in pain. They were identified by 
the investigators from the inpatient setting as meeting the inclusion criteria. The 
study was explained to them verbally in addition to the provision of a patient 
information sheet (see appendix 2). Patient participants were consented using a 
written patient consent form (see appendix 5). Patient participants were consented 
to have samples drawn at regular intervals throughout the course of their 
admission, at the following intervals: 
 
- 0 hours (day of admission after VOC stabilised) 
- 24 hours (day 1) 
- 48 hours (day 2) 
- 72 hours (day 3) 
- 120 hours (day 5) 
 
 
Samples were taken only during the length of a patient’s hospitalisation and so 
could be prematurely stopped by discharge. There was no payment for 





Six SCD (homozygous HbSS) steady state controls were recruited to the study. 
None of the steady state controls were on hydroxyurea therapy. Steady state was 
defined as attending the outpatient haemoglobinopathy clinic at UCLH for a routine 
red cell exchange transfusion and not having had a transfusion in the previous 4 
weeks. They were identified by the investigators from the outpatient setting as 
meeting the inclusion criteria. The study was explained to them verbally in addition 
to the provision of a patient information sheet (see appendix 2). Patient 






Samples were taken only during the length of a patient’s hospital visit for 
monitoring / treatment and so one sample only was obtained for steady control 
SCD patients. There was no payment for participation in the study. 
 
Four healthy control participants were recruited to the study. They were identified 
by the investigators as meeting the inclusion criteria. The study was explained to 
them verbally in addition to the provision of a healthy control information sheet 
(see appendix 3). Participants were consented using a written healthy control 
consent form (see appendix 4). 
Healthy control participants were consented to have samples drawn at regular 
intervals throughout the course of the study to duplicate those taken from the SCD 
crisis patients. Samples were collected at the following intervals: 
 
- 0 hours (day of admission after VOC stabilised) 
- 24 hours (day 1) 
- 48 hours (day 2) 
- 72 hours (day 3) 
- ≥120 hours (day 5) 
 
 
There was no payment for participation in the study. 
 
 
Serial samples were not obtained for SCD steady state controls, as they were day 
case patients, and some SCD VOC patients were not admitted for long enough in 
order to obtain serial samples. Longitudinal data throughout the study reflects 







3.5 Sample Preparation and Transport 
 
 
On arrival at the Emergency Department (ED) at UCLH, and once stabilised and 
consented, a 5ml whole blood sample was taken from the participant, into a 
sodium citrate vacutainer® (Becton Dickinson, Oxford). The whole blood was then 
centrifuged (Sorvall Legend T, Thermo Fisher, UK) at 2000 x g for 10 minutes at 
room temperature with no brake. 
The plasma was separated from the cells (buffy coat and red cells) in a sterile 
laminar flow hood, using sterile tips and sterile tubes, leaving a small layer of 
plasma behind to ensure no cells were transferred into the plasma. Tubes were 
labelled with anonymised participant numbers and the date and time of sampling. 
Tubes containing the separated plasma and cells were stored at 4°C until 
collection, to minimise in vitro vesicle release. All samples were processed and 
stored within 2 hours of collection. Samples were collected by courier and 
transported to NHSBT, Filton, Bristol for analysis by flow cytometry and confocal 
microscopy. Upon arrival in Bristol, the platelet poor plasma was centrifuged 
(Sorvall Legend RT, Thermo Fisher, UK) at 2500 x g for 15 minutes at room 
temperature with no brake, to ensure full removal of cells and that only vesicles 
were present before analysis. Plasma samples were separated into 150µl aliquots 
in a sterile laminar flow hood, using sterile tips and were frozen at -80°C in 
polypropylene cryo-tubes (2 ml cryo-tubes (Sarstedt Ltd. Leicester, UK) until flow 






UK) was added to the packed RBC in a sterile laminar flow hood, using sterile tips, 
and was thoroughly mixed to ensure adequate suspension of cells. 
Steady state control samples were drawn from SCD patients attending routine 
haemoglobinopathy clinic appointments at UCLH. Single samples, at 0h only, were 
obtained from this cohort due to the period of their admittance as day case 
patients. Healthy controls samples were taken from healthy volunteers at NHSBT 
Filton, samples were taken at the different time points; 0, 24, 48 72 and ≥120 hrs 
to mimic that of the crisis samples. All control samples were processed identically 







3.6 Confocal Microscopy 
 
 
3.6.1 Live cell confocal microscopy 
 
 
Live cell imaging was used to determine the number of erythrocytes with a PS 
positive vesicle attached in SCD patients undergoing episodes of sickle cell crises, 
steady state SCD patients and healthy volunteer participants. PS was detected 
using Annexin-V fluorescein isothiocyanate (FITC) conjugated mAb (Annexin V- 





Human blood sample, RBC only. 
Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Indianapolis, USA) 
4% w/v BSA / Phosphate Buffered Saline 
- Albumin Bovine Fraction V (Parks Scientific, Northampton, UK) 
- Dulbecco’s Phosphate Buffered Saline (Sigma-Aldrich, Gillingham, UK) 





A 100µl volume of packed RBC added to 500µl of 4% w/v BSA / Phosphate 
Buffered Saline and left to incubate for 20 mins at room temperature. The cells 
were then washed once in BSA / Phosphate Buffered Saline and resuspended in 
400µl incubation buffer from the Annexin-V-FLUOS staining kit (Roche 
Diagnostics, Indianapolis, USA). Resuspended cells (50µl) were aliquoted into an 
8-well u-chamber slide (Ibidi, Martinsried, Germany) for analysis (see figure 3.1). 
 
3.6.1.3 Live Cell Imaging 
 
 
Morphological analysis of slides was undertaken. Samples were imaged at 19°C 
with the use of 40x oil-immersion lenses on a Leica DMI6000 B inverted 






scanning microscope (Leica) using an Argon laser set at 5% to read fluorescence 
at 488nm. Images were obtained using Leica LAS software (LAS AF 1.6.3 build 
1163) (Nuβloch, Germany) confocal microscope, with installed accompanying LAS 
software. 5 random stacks were taken. AV number and total RBC number were 
counted at 3x magnification to give a total number of AVs present, as described in 
Mankelow et al. 2015. 
 
Figure 3.1. Confocal Microscopy - Live Cell Slide – Healthy control 3, 48h and 168h samples 






3.6.2 Fixed Cell Confocal Microscopy 
 
 
Fixed cell imaging was used to determine the AV number within the erythrocytes in 
participants undergoing episodes of sickle cell crises, steady state controls and 
healthy volunteer participants. R10, a mouse monoclonal antibody to a trypsin 
sensitive epitope of extracellular Glycophorin A (GPA) was used to stain fixed, 
permeabilised erythrocytes, in particular GPA-decorated intracellular AV. These 






Human blood sample, RBC only. 
Phosphate Buffered Serological Saline (PBS) pH7.0 (Source Bioscience, 
Nottingham, UK). 
Bovine Trypsin 2.5mg/ml (Sigma Aldrich, Gillingham, UK). 
Poly-L-Lysine solution 0.1% w/v in H2O (Sigma Aldrich, Gillingham, UK). 
Hank’s Balanced Salt Solution (Sigma Aldrich, Gillingham, UK). 
Superfrost Microscope slides (VWR International, Leighton Buzzard, UK). 
Coverslips (VWR International, Leighton Buzzard, UK). 
Vectashield™ mounting medium for fluorescence (Vector Laboratories, 
Peterborough, UK). 
Monoclonal antibodies: 
- R10 intracellular anti-GPA (IBGRL PDPU, Bristol, UK) 
- Goat anti-Mouse 488 (IBGRL PDPU, Bristol, UK) 
Rinse Buffer: 
- PBS pH7.0 (Source Bioscience, Nottingham, UK) 
- Albumin Bovine Fraction V (Parks Scientific, UK) 
- D - Glucose (BDH Laboratory supplies, Poole, UK) 
1% w/v formaldehyde / 0.01% w/v in PBS: 
- PBS pH7.0 (Source Bioscience, Nottingham, UK) 
- 36% w/v Formaldehyde (TAAB Laboratories, Reading, UK) 






Glycine Rinse Buffer: 
- Rinse buffer (as above) 
- 1M Glycine, pH8.0 (Sigma Aldrich, Gillingham, UK) 
 
 
0.1 % w/v Triton-X in Rinse Buffer: 
- Rinse buffer (as above) 






40µl of whole blood was washed 4 times with 1ml PBS and centrifuged at 
4000rpm for 1min. 10µl of packed RBC were added to 40µl of Bovine Trypsin 
2.5mg/ml solution and incubated at 37ºC for 30 minutes. After trypsin treatment, 
the packed RBC were washed a further 4 times, as before. The packed, washed 
RBC were resuspended in rinse buffer at a ratio of 1:400. (2 µl packed cells and 
798µl of rinse buffer). 
 
An appropriate number of glass coverslips were covered with Poly-L-Lysine 
solution and left to incubate at room temperature for 30 minutes in preparation for 
the seeding of the trypsin-treated erythrocytes. Excess Poly-L-Lysine solution was 
aspirated off and the coverslips were washed twice by flooding the coverslip with a 
solution of Hank’s Balanced Saline. 
 
300µl of trypsin-treated erythrocytes were seeded onto the coverslips and left at 
room temperature for 60 minutes to allow attachment to occur. Excess rinse buffer 
was aspirated, and cells were fixed with 1% w/v formaldehyde / 0.01% w/v in PBS 
at room temperature for 20 minutes. The coverslips with the fixed erythrocytes 
were then washed once in rinse buffer, once in glycine rinse buffer, to reduce 
autofluorescence when viewed on the confocal microscope, and once again with 
rinse buffer before the permeabilization step. 
 
Fixed, washed cells were permeabilised with 0.1% w/v Triton-X in Rinse Buffer at 








Fixed, permeabilised cells, seeded onto coverslips were labelled with 80µl of a 
1:100 dilution of the primary R10 mAb at room temperature for 60 minutes. They 
were then washed twice in rinse buffer before being labelled with a secondary 4% 
Alexa Fluor 488-conjugated goat anti-mouse mAb and left to incubate at room 
temperature for 60 minutes. After incubation the coverslips were washed twice in 
rinse buffer and mounted onto microscope slides. One set of coverslips was 
retained as a negative control and had been labelled with 4% Alexa Fluor 488- 
conjugated goat anti-mouse mAb only. 
 
The coverslips were mounted onto microscope slides using Vectashield™ 
mounting medium and were sealed with clear lacquer to prevent the coverslips 
from moving during confocal microscopy (see Figure 3.2). 
 
 
Figure 3.2 Confocal Microscopy – Fixed Cell Slides – Healthy control 3, 48h and 168h samples 
dual stained with primary R10 and secondary Alexa Fluor 488 goat anti-mouse mAb and negative 






3.6.2.3 Fixed Cell Imaging 
 
 
Morphological analysis of slides was undertaken. Samples were imaged at 19°C 
with the use of 40x oil-immersion lenses on a Leica DMI6000 B inverted 
microscope with phase contrast connected to a Leica TCS-SP8 confocal laser 
Scanning microscope (Leica) using an Argon laser set at 5% to read fluorescence 
at 488nm. Images were obtained using Leica LAS software (LAS AF 1.6.3 build 
1163) (Nuβloch, Germany) confocal microscope, with installed accompanying LAS 
software. 5 random stacks were taken. AV number and total RBC number were 







3.7 Flow Cytometry 
 




BRIC163, 1mg/ml (IBGRL PDPU Bristol, UK). 
BRIC256, 1mg/ml (IBGRL PDPU Bristol, UK). 
Molecular probes kit - Alexa Fluor 647 (Red) / Alexa Fluor 488 (Green) (Life 
technologies, Carlsbad, Ca) 




Two murine monoclonal antibodies (BRIC163 and BRIC256) were supplied for the 
study. 
BRIC163 is a mAb to intracellular glycophorin A (GPA) epitopes found in the 
cytoplasm (Okubo et al. 1988). BRIC256 is a mAb to an extracellular trypsin- 
resistant epitope on GPA (Reid et al. 1997). Monoclonal antibodies were supplied 
as unconjugated supernatants of concentration 1mg/ml and required labelling and 
titration / dilution to a functional concentration before use. 
BRIC163 and BRIC256 mAbs were conjugated to fluorescent dyes Alexa Fluor 
647 and Alexa Fluor 488, respectively, using a molecular probes kit. (Life 
technologies, Carlsbad, Ca). A full methodology can be found at 
https://www.thermofisher.com/uk/en/home/life-science/antibodies/secondary- 
antibodies/fluorescent-secondary-antibodies/alexa-fluor-secondary-antibodies.html 
Briefly, a 1M solution of sodium bicarbonate was prepared by adding 1ml of 
deionised water (dH2O) to a vial of sodium bicarbonate (kit component B). The 
sodium bicarbonate solution (pH8-9) was thoroughly mixed by pipette before use. 
100µl of the sodium bicarbonate solution was added to 900µl of each mAb to be 
labelled. 100µl of this solution was transferred to the vial of reactive dye and then 
gently mixed and left to incubate at room temperature for 1hr, with gentle agitation 
every 10-15 minutes. 
Purification was undertaken to remove unconjugated dye from the dye-conjugated 






1.5 ml of purification resin (kit component C) was added to the column. The 
column was centrifuged (Sorvall Legend RT, Thermo Fisher, UK) at 1100 x g for 3 
minutes to enable the column buffer to permeate throughout the column. 
100µl of labelled mAb was added, dropwise onto the centre of the spin column, 
and was allowed to absorb into the resin bed. 
Figure 3.3 Labelling and purification of monoclonal antibodies BRIC163-488 and BRIC256- 
647. (Source: Life Technologies, 2017: online) 
 
The spin column was placed into an empty collection tube and centrifuged (Sorvall 
Legend RT, Thermo Fisher, UK) at 1100 x g for 5 minutes. 
After centrifugation, the column contained 100µl of the labelled mAb, pH 7.2, with 
2mM sodium azide. The spin column was then discarded, and the procedure 
repeated for the other mAb. 
 
Following purification, the concentration of the labelled mAbs was determined 
using the NanoDrop® 2000 spectrophotometer (Thermo Fisher, UK). A 0.5µl 
volume of labelled, purified sample was pipetted directly onto the optical 






of purified labelled/conjugated protein was determined by the NanoDrop® 2000 
operating software (version 1.6). 
 
3.7.2 Titration of Monoclonal Antibodies 
 
 
Conjugated antibodies BRIC163-488 and BRIC256-647 were titrated to determine 
a working dilution for the assay. Starting points for serial dilutions were determined 
from previous studies performed using the mAbs. (Mankelow et al. 2015). 
 
3.7.2.1 Materials 
Human Blood sample – Platelet Poor Plasma. (PPP) 
BRIC163-488, 1.6µg/ml (IBGRL PDPU, Bristol, UK). 
BRIC256-647, 0.4µg/ml (IBGRL PDPU, Bristol, UK). 
Sterile Filtered Binding Buffer (Roche, Welwyn Garden City, UK) 





All buffers were sterile and filtered using a 0.2-µm filter. Binding buffer (Roche, 
UK) was used mAbs BRIC163 and BRIC256 were diluted in serial dilutions to the 




1.6µg/ml 0.4 µg/ml 
0.8 µg/ml 0.2 µg/ml 
0.4 µg/ml 0.1 µg/ml 
0.2 µg/ml 0.05 µg/ml 
0.1 µg/ml 0.025 µg/ml 
 
Table 3.1 Titrated dilutions of BRIC163 and BRIC256 mABs that were used in flow cytometric 






A 20µl volume of Human PPP was added to 80µl of each concentration of diluted 
antibody. A ‘blank’ control, consisting of 20µl of Human plasma and 80µl of binding 
buffer was included. 
Samples were incubated on ice, in the dark for 30 minutes before the addition of 
300µl of binding buffer (Roche, Welwyn Garden City UK). Samples were run at low 
flow speed on a Navios flow cytometer (Beckman Coulter, Wycombe, UK) with 
Kaluza Version 1.2. 50,000 events were measured before analysis was 
undertaken. 
 
3.7.3 Flow Cytometer Size Gating 
 
 
Flow cytometric size gating was undertaken using Megamix™ beads, a blend of 
monodisperse fluorescent beads of four diameters (0.1 µm, 0.3 µm, 0.5 µm and 
0.9 µm). Gating was set to capture RBC-Derived microparticles, which have an 












A full methodology can be found at 
https://www.biocytex.com/fileadmin/user_upload/80- 
Biocytex/kits/EN_package%23insert%23Megamix_7801_20161001.pdf 
Briefly, following agitation, 500µL of Megamix™ reagent was pipetted into a flow 
cytometry tube and analysed at low flow speed on a Navios flow cytometer 
(Beckman Coulter, Wycombe, UK) with Kaluza Version 1.2. Events were 
measured for 1 minute before analysis was undertaken. Regions of interest were 












Human Blood sample – Platelet Poor Plasma. 
BRIC163-488, 0.8µg/ml (IBGRL PDPU, Bristol, UK). 
BRIC256-647, 0.05µg/ml (IBGRL PDPU, Bristol, UK). 
Annexin-V FITC, Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Indianapolis, 
USA). 
Flow Buffer pH7.4: 
- PBS (Source Bioscience, Nottingham, UK) 
- 1% BSA (Parks Scientific, UK) 
- 0.05% sodium azide (Sigma Aldrich, Gillingham, UK) 
Binding Buffer pH7.4 (Roche Diagnostics, Indianapolis, USA): 
- 50mM HEPES 
- 700mM NaCl 
- 12.5nM CaCl2 
AccuCount® Counting beads [1x106 particles/ml = 49655 particles / 50µl] 
(Spherotech, Chicago, IL, USA) 






Two murine monoclonal antibodies (BRIC163-488 and BRIC256-647) and one 
commercially supplied recombinant marker (Annexin-V FITC) were used in the 
study. BRIC163 is a mAb to intracellular glycophorin A (GPA) epitopes found in 
the cytoplasm (Okubo et al. 1988). BRIC256 is an extracellular trypsin-resistant 
epitope on GPA (Reid et al. 1997). Annexin V is a Ca2+-dependent phospholipid- 
binding protein with high affinity for phosphatidylserine. Recombinant Annexin-V is 
produced in E.Coli (strain NB42) and is purified by standard purification protocols 
and conjugated with a FITC marker. 
Working dilutions of fluorescein-conjugated BRIC163-488, BRIC256-647 and 






found to be optimal from previous experiments, or from the recommended 
concentration from the supplied instructions for use (Roche Diagnostics, 2018). 
All MAbs were centrifuged at 13,000 rpm prior to use. All buffers were sterile and 
filtered using a 0.2-µm filter. 
A 20µl volume of Human platelet poor plasma was added to 80µl of each 
concentration of diluted MAb. A negative control, consisting of 20µl of Human 
plasma and 80µl of binding buffer was included in addition to three blank controls, 
consisting of 20µl of each mAb and 80µl of binding buffer (see table 3.2). 
 
Table 3.2 Flow cytometry test layout. Tubes include negative control, Single specificity, dual 
stain and blank controls for each single stain. 
 
 
Tube number Sample Antibody 
1 Plasma Buffer (Negative Control) 
2 Plasma BRIC256-647 
3 Plasma BRIC163-488 
4 Plasma Annexin-V FITC 
5 Plasma BRIC256-647 / BRIC163-488 (Dual Stain) 
6 Plasma BRIC256-647 / Annexin V FITC (Dual Stain) 
7 Buffer BRIC256-647 (Blank Control) 
8 Buffer BRIC163-488 (Blank Control) 
9 Buffer Annexin-V FITC (Blank Control) 
 
Samples were incubated on ice, in the dark for 30 minutes. 20µl of well vortexed 
AccuCount® counting beads were added to tubes 2-7. 300µl of binding buffer was 
added to each tube immediately before testing. 
Samples were tested at low flow speed on a Navios flow cytometer (Beckman 
Coulter, Wycombe, UK) with Kaluza Version 1.2. Forward Scatter (FS) and Side 
Scatter (SS) were set in a log scale, detecting MPs of interest based upon size 
and granularity respectively. Threshold parameters were set using the FS 
parameter. MP gating was accomplished by preliminary standardization 
experiments using fluorescent microbeads of different sizes as described earlier. 
Events in the MP gate were further assessed for labelling with BRIC163-488; 






and thereby increase the specificity of MP detection as described by Shet et al. 
2003. Flow cytometry protocols were stopped once either 50,000 events were 
measured or after 300 seconds before final analysis was undertaken. 
For MP quantification, a known quantity of 7.2µm AccuCount® counting beads 
were added to tubes 2 to 7. The diameter of these beads allowed discrimination 
from the MP population on light scatter and could be counted using a separate 
gate. Counting bead quantities / ml were supplied by the manufacturer 
(Spherotech, Chicago, IL, USA) and the following formula (as described in Nielsen 
et al. 2014) was applied to calculate MP quantity µl-1, where N is the number of 
positive events recorded. 
(N x Beadsadded) / (Beadscounted x test volume) 
 
The number of beads per µl was provided by the manufacturer and the test 
volume was 400µL. 
 
 
3.8 Statistical analysis 
 
Statistical analysis of the results was performed by Microsoft Excel using unpaired 
t-test to determine the statistical significance between the means of all groups 
tested with +/- SD included, where appropriate. The values were taken as a 
significant difference when p ≤ 0.05. A Binomial Generalised Linear Model (GLM) 
with logit link was used to describe the likelihood of occurrence of VOC in sickle 
cell patients when compared to the measured variables in this study. All statistical 
analyses were performed using SAS Enterprise Guide v7.1 software (SAS 
Institute Inc., Cary, NC, USA). Assistance in the statistical analysis was provided 






Chapter 4: Results 
 
4.1 Confocal Microscopy 
 
4.1.1 Live Cell Confocal Microscopy 
 
 
Previous studies have shown that localised PS expression is increased in SCD 
patients in steady state when compared to healthy controls (Wood et al. 1996; 
Kuypers et al. 1998; Setty et al. 2001). This localised PS expression has been 
demonstrated on mature R2 human reticulocytes which have not been removed by 
splenic macrophages due to functional asplenia in SCD patients. (Mankelow et al. 
2015). 
Analysis of erythrocyte-bound PS in our three cohorts at 0h using annexin-V-FITC 
and live cell confocal microscopy showed accordance with these previous studies. 
The live cell imaging of PS positive RBCs in adult healthy control, steady state 
control and SCD crisis patient RBC samples stained with Annexin-V-FITC PS 
marker showed significant differences between the percentage of PS-positive 
vesicle number in the studied cohorts. A 60-fold, statistically significant (t-test, 
p<0.0001) difference in (live cell) vesicle percentage between the healthy controls 
(mean 0.09%; SD +/- 0.12%) and the SCD crisis cohort (mean 5.47%; SD +/- 
3.45%) was observed. A 30-fold statistically significant (t-test p<0.0001) increase 
in PS-positive vesicles was observed between healthy controls (mean 0.09%; SD 
+/- 0.12%), and steady state controls (mean 2.77%; SD +/- 1.55%) and a 2-fold 
statistically significant (t-test, p<0.05) increase was observed between steady state 
controls (mean 2.77%; SD +/- 1.55%) and the SCD crisis cohort (mean 5.47%; SD 








Figure 4.1 Quantification of Phosphatidylserine (PS) expression by live cell confocal 
microscopy. Localised PS positive vesicles were stained with Annexin-V fluorescein 
isothiocyanate (FITC) conjugated mAb following incubation with 4% w/v BSA / Phosphate Buffered 
Saline. % of PS positive vesicles was quantified. Random stacks, n=5 were counted and a mean 
average % of PS positive vesicles calculated. Solid bars indicate mean average of each cohort 
with error bars showing +/- 2SD  A 60-fold increase in PS positive vesicles was observed between 
healthy controls and the SCD crisis cohort. 
 
Over the period of admission, PS positive vesicles were quantified in SCD crisis 
patients where serial samples were received (Crisis patients 1, 2, 3, 4, 5, 8 and 9), 
and compared to serial samples in the healthy control cohort (Healthy controls 1- 
4). Significantly higher levels of PS positive vesicles were observed in the SCD 
crisis cohort than the healthy control cohort, where serial samples were tested. An 
overall decreasing trend in PS positive vesicle number was observed throughout 









Figure 4.2 Serial quantification of Phosphatidylserine (PS) expression by live cell confocal 
microscopy. Localised PS positive vesicles were stained with Annexin-V fluorescein 
isothiocyanate (FITC) conjugated mAb following incubation with 4% w/v BSA / Phosphate Buffered 
Saline. Random stacks, n=5 were counted and a mean average % of PS positive vesicles for each 
timepoint calculated. % of PS positive vesicles was quantified over serial time points for SCD crisis 
patients 1, 2, 3, 4, 5, 8 and 9. These were compared to healthy controls 1-4. PS positive vesicle 
number was up to 7-fold higher in SCD patients with serial samples upon admission than those in 
healthy control cohorts (range 0.7%-7.75%) Overall, a decreasing trend was observed in PS 
positive vesicle number during the course of admission. SCD crisis patients 4 and 9 showed a rise 
in PS positive vesicle number near the end of their admission period, which correlated with the 
extended time of their admission. 
 
It is of interest to note that two of the SCD crisis patients (crisis patient 4 and crisis 
patient 9) were admitted for >72h before they were discharged. In both patients, 
the PS positive vesicle at admission was similar to that seen in patients with a 
shorter period of admission. It was observed that PS positive vesicle number rose 
slightly before they were discharged from hospital following the episode of VOC. It 
may be that this rise in PS positive vesicle number may be associated with VOC 
severity, and hence length of admission, due to the contribution of PS to 
thrombosis in SCD patients. These findings are in line with previous studies that 
have described the externalization of PS on sickle erythrocytes and their potential 






Images from the live cell confocal microscopy experiments clearly showed PS 
positive stained vesicles (figures 4.3, 4.4 and figure 4.5), measuring approximately 
0.8µm in diameter. This is in accordance with published findings which report 
RBC-derived vesicle size to be in the range of 0.1-1.0µm in diameter (Rubin et al. 
2008; Nielsen et al. 2017). The AV’s observed by live cell imaging in this study are 





Figure 4.3 SCD Crisis Patient 3D image - Live cell confocal microscopy. Sample taken from 
SCD crisis patient at 0h time interval and stained using Annexin-V fluorescein isothiocyanate 
(FITC) conjugated mAb. The presence of green FITC-conjugated Annexin-V Phosphatidyl Serine / 








Figure 4.4 SCD Crisis Patient - Live cell confocal microscopy. Sample taken from SCD patient 
at 0h time interval and stained using Annexin-V fluorescein isothiocyanate (FITC) conjugated mAb. 
The presence of a FITC-conjugated Annexin-V Phosphatidyl Serine / Autophagic Vesicle can be 
seen (stained green). 
 
 
Figure 4.5 SCD Crisis Patient - Live cell confocal microscopy. Sample taken from SCD 
patient at 0h time interval and stained using Annexin-V fluorescein isothiocyanate (FITC) 
conjugated mAb Live cell confocal microscopy. Measurements performed using a RBC 
measuring 9.56µm in diameter shown, in addition to 0.8µm diameter, FITC-conjugated 







Live cell confocal images taken from serial SCD crisis samples and healthy control 
samples clearly showed the difference in PS positive vesicle number. Significantly 
more (p<0.0001) PS positive vesicles could be seen in the SCD crisis cohort both 
at 0h and throughout the period of admission when compared to the serial 
samples from the healthy controls. Steady state samples (taken at 0h only) 
showed a visually noticeable, smaller number of PS positive vesicles when 
compared to the SCD crisis cohort, and more PS positive vesicles when compared 







Live cell confocal microscopy 




Figure 4.6 Healthy control 1 - Live cell confocal microscopy. Serial images from samples taken at 0h, 24h, 48h, 72h and 120h intervals. Note the normal 





































Figure 4.7 Steady State SCD control – Live cell confocal microscopy. Images from samples taken at 0h. Note the presence of FITC-conjugated Annexin 









Figure 4.8 SCD Crisis Patient - Live cell confocal microscopy. Serial images from samples taken at 0h, 24h, 48h, 72h and >120h intervals. Note the 
presence of green FITC-conjugated Annexin V Phosphatidyl Serine / Autophagic Vesicle marker (red arrows) at 0h showing a decreasing trend throughout 





Where reticulocyte count was measured in the SCD patient cohort, a loose 
correlation between PS positive vesicle number (%) and reticulocyte count 
(%) was seen (see figures 4.9 and 4.10). In the SCD crisis patients with serial 
samples available, PS-positive vesicle percentage decreased with length of 
admission, as did reticulocytopenia (reticulocyte NR: 0.5-2.5% (50-100 x 
109/l), Dacie and Lewis, 2001) but not in absolute amounts. The reticulocyte 
count only decreased by approximately 0.5%, but the percentage of PS 
positive vesicles decreased by 5%. 
 
This discrepancy could suggest that red cells with an AV get caught up in the 
occluded vessel to a greater degree than those without an AV present, which 
would result in circulating reticulocytes captured in RETIC counts on 
automated haematology analysers being AV negative. However, the limited 
amount of data available made a strong association between reticulocyte 
count and PS positive vesicle percentage impossible, but PS positive vesicles 
would be expected in increased numbers in patients who have increased 














Figure 4.9 SCD crisis Patient 8 PS positive vesicle (%) and Reticulocyte count (%). 
Measurement of PS positive vesicles (%) in serial samples received over the course of 
admission by live cell confocal microscopy compared with reticulcyte count (%), measured 
using the RETIC function on the FBC analyser at UCLH. Random stacks, n=5 were counted 
and a mean average % of PS positive vesicles for each timepoint calculated is shown with 
error bars showing +/- 2SD. A decrease in PS positive vesicle number and a corresponding 





In SCD crisis patient 9, where serial samples had been received during the 
course of admission, an increasing trend in reticulocyte count towards the end 
of admission correlated with an increasing PS positive vesicle number. (See 
figure 4.10). The inverse relationship between PS positive cells and number of 
reticulocytes seen at 0h correlates with the prothrombotic action of PS during 
a VOC potentiated by a free circulating haem following haemolysis, and the 
following reticulocytosis to correct the anaemia (Manwani et al.2013). The 
number of these PS positive vesicles would make them likely candidates for 
involvement in the pathology of SCD due to their involvement in prothrombotic 
biological pathways (van Tits et al. 2009; Noubouossie et al. 2016). Therefore, 
an increasing number of PS-decorated vesicles would be anticipated in a 
patient who has a longer admission due to the severity and subsequent 
treatment of VOC. 
 
 
Figure 4.10 SCD crisis Patient 9; PS positive vesicle (%) and Reticulocyte count (%). 
Measurement of PS positive vesicles (%) in serial samples received over the course of 
admission by live cell confocal microscopy compared with reticulcyte count (%), measured 
using the RETIC function on the FBC analyser at UCLH. Random stacks, n=5 were 
counted and a mean average % of PS positive vesicles for each timepoint calculated is 
shown with error bars showing +/- 2SD. PS positive vesicle number and reticulocyte count 
was variable throughout admission, but showed a rising trend at 72h, correlating with PS 





4.1.2 Fixed Cell Confocal Microscopy 
 
 
Fixed cell confocal microscopy analysis of an extracellular trypsin-sensitive 
GPA epitope using a mAb to trypsin-sensitive GPA (R10) showed significantly 
increased levels of trypsin-sensitive GPA-decorated vesicles when compared 
to a healthy control (see figure 4.11). This difference is in accordance with 
previous work (Mankelow et al. 2015). However, a greater difference in 
trypsin-sensitive GPA-decorated vesicles, when compared to healthy controls 
was observed in this study than had previously been reported. 
 
A significant 23-fold increase in R10-positive vesicles was observed between 
healthy controls (mean 0.54%; SD +/- 0.52), steady state controls (mean 
12.4%; SD +/- 12.3%) and SCD crisis cohort (mean 13%; SD +/- 13.3%). 
These differences were statistically significant between the healthy controls 
and crisis patients (p<0.0001), with the mean vesicle percentage being 
significantly larger in the latter than in the former group. There was no 
significant difference in R10-positive vesicle expression between the steady 
state and SCD crisis cohorts. 
 
Although the findings show no significant difference between steady state and 
SCD crisis patients, this may be explicable due to a variation in the 
repeatability of the manual experimental procedure. It was noted that during 
the course of the permeabilization stage of the experiment, cell lysis occurred 
with some of the patients studied, leading to a lower overall cell count, and a 
subsequent variation in R10-positive percentage value. This variation in 
quality of fixation and staining, and of the subsequent result is reflected in the 
wide standard deviation observed in this part of the study. 
 
The poor quality of staining in fixed cell confocal microscopy experiments may 
also be due to the damage to the plasma membrane and/or cytoskeleton in 
SCD, due to repeated sickling and unsickling during de-oxygenation and re- 
oxygenation. The SCD RBC are therefore more fragile, and more susceptible 





method used was initially established using healthy erythrocytes in healthy 
controls and may need further optimising for future use on more fragile cells 




Figure 4.11 Quantification of Trypsin-sensitive GPA expression by fixed cell confocal 
microscopy internal R10 positive vesicles were stained with R10 conjugated mAb following 
incubation with 4% w/v BSA / Phosphate Buffered Saline and the % of R10 positive vesicles 
were quantified. Random stacks, n=5 were counted and a mean average % of R10 positive 
vesicles calculated and a mean average % of R10 positive vesicles for each timepoint 
calculated is shown with error bars showing +/- 2SD. An average 13-fold increase in R10 
positive vesicles was observed between healthy controls and the steady state control and 







Figure 4.12 Quantification of Trypsin-sensitive GPA expression by fixed cell confocal 
microscopy SCD red cells were trypsin treated then fixed, permeabilized, and stained with 
trypsin-sensitive GPA mAb R10 to detect intracellular GPA. Random stacks, n=5 were 
counted and a mean average % of R10 positive vesicles calculated. An average 13-fold 
increase in R10 positive vesicle number at the point of admission, in addition to a decreasing 
trend of R10 positive vesicle number was observed when comparing SCD crisis patients with 
healthy controls. 
 
Overall the percentage of R10-positive vesicles fell over time during the period 
of admission but did not fall to levels seen in healthy controls (see figure 
4.12). This may be due to the increased reticulocytosis in these patients 
compared to healthy individuals, even in a steady state where the effects of 
an underlying anaemia are manifested in an increased reticulocyte count as 
the body seeks to replace erythrocytes lost to the haemolytic process (See 
Figure 4.13). 
 
In two SCD patients, (SCD patients 3 and 8) high levels of R10-positve 
vesicles were observed throughout the course of their admission. Higher 
levels of R10 positive vesicles did not have any correlation to length of stay, 
with both patients discharged at 48h following admission. It was noted that 
patients with lower levels of R10 positive vesicles were hospitalised for longer 







Figure 4.13 SCD crisis Patient 9 R10 positive vesicle (%) and Reticulocyte count (%). 
Measurement of R10 positive vesicles (%) in serial samples received over the course of 
admission by fixed cell confocal microscopy compared with reticulcyte count (%), measured 
using the RETIC function on the FBC analyser at UCLH. Random stacks, n=5 were counted 
and a mean average % of R10 positive vesicles for each timepoint calculated is shown with 
error bars showing +/- 2SD. R10 positive vesicle number and reticulocyte count was variable 
throughout admission, but showed a rising trend at 72h. 
 
 
Images of fixed cell R10 positive staining are also provided (see figures 4.14, 
4.15, and 4.16). Increased numbers of R10 positive vesicles in steady state 









Figure 4.14 Healthy control 2 - Fixed cell confocal microscopy Serial images from samples taken at 0h, 24h, 48h, 72h and 120h intervals. Note the 












Figure 4.15 Steady state control - Fixed cell confocal microscopy Images from samples taken at 0h. Note the presence of anti-trypsin sensitive GPA 











Figure 4.16 SCD Crisis Patient - Fixed cell confocal microscopy. Serial images from samples taken at 0h, 24h, 48h, 72h and >120h intervals. Note the presence 






4.2 Flow cytometry 
 
 








Figure 4.17 Identification of RBC microparticles (MPs) based upon a fluorescent 
threshold and utilizing the mixture of absolute counting and calibration beads to define 
the light scatter parameters. (a) Side Scatter (SSC) and forward Scatter (FSC) parameters 
of RBC MPs (b). Side Scatter (SSC) and forward Scatter (FSC) parameters of RBC MPs in 
relation to the 0.1, 0.3, 0.5 and 0.9µm beads mixture being analysed (c). Representative 
histogram of the mixture of absolute counting standard microbead and calibration beads (0.3, 
0.5 and 0.9µm) 
 
Results of flow cytometric size gating undertaken using Megamix™ beads, as 
described in methods, showed discrete populations of reagent microparticle 
beads (see figure 4.17). Some studies define MPs as events by flow 





Therefore, we defined MPs as vesicles that are 1µm or less in size following a 
prior ultracentrifugation step. Gating was set to capture these RBC-Derived 
microparticles, which have an average size range of 0.15µm- 0.9 µm (Piccin 
et al. 2007; Xiong et al. 2013). Positive events were defined as those that 
were detected in the gate in (a) figure 4.17 which subsequently exceeded 
threshold fluorescence values defined in the methods. 
 
4.2.2 Antibody Titration 
 
 
The two mAbs used in this study, BRIC256 and BRIC163 were used because 
they stain for right-side out Red Cell Derived Microparticles (RCDP) and 
inside-out RCDP respectively. Following fluorescent labelling with fluorescent 
dyes Alexa Fluor 647 and Alexa Fluor 488 respectively, and subsequent 
purification they had the following concentrations (mg/ml) when assayed at 
A280 on the NanoDrop® 2000 spectrophotometer (Thermo Fisher, UK). 
 
- BRIC256-647 0.53mg/ml 
- BRIC163-488 0.91mg/ml 
 
 
From these starting concentrations, working dilutions were determined by 
serial dilution and titration of the mAbs. Working concentrations were chosen 
from gated scatterplots (figures 4.18, 4.19, 4.20 and 4.21), which showed 
clear separation of positive and negative events in the respective FL6 and FL1 
channels. Following titration, the following working concentrations were 
chosen: 
 
- BRIC256-647 0.05µg/ml 








Figure 4.18 Overlaid histogram plot labelled BRIC256-647 Flow cytometric titration 
analysis of labelled GPA positive vesicles from 0.4µg/ml to 0.025 µg/ml dilutions colour 
labelled in the legend above and negative (flow buffer) control shown in red. 
 
Figure 4.19 Gated Scatterplot for labelled BRIC256-647 Flow cytometric titration analysis 
at the chosen dilution of 0.05 µg/ml, showing separation of BRIC256-647 (extracellular GPA) 
postive (orange) and BRIC256-647 negative (red) populations in the FL6 channel on the 
Navios flow cytometer 
 
Figure 4.20 Overlaid histogram plot labelled BRIC163-488 Flow cytometric titration 
analysis of labelled GPA positive vesicles from 1.6µg/ml to 0.1 µg/ml dilutions colour labelled 
in the legend above and negative (flow buffer) control shown in red.and negative (flow buffer) 








Figure 4.21 Gated Scatterplot for labelled BRIC163-488 Flow cytometric titration analysis 
at the chosen dilution of 0.8 µg/ml, showing separation of BRIC163-488 (Intracellular GPA) 
postive (green) and BRIC163-488 negative (red) populations on the Navios flow cytometer. 
 
4.2.3 Flow Cytometric Analysis 
 
To mitigate against the amount of in vitro vesicle release the following 
measures were taken. 
All samples were collected in Sodium citrate vacutainer® tubes as described 
by Xiong et al. (2012). The whole blood was then centrifuged (Sorvall Legend 
T, Thermo Fisher, UK) at 2000 x g for 10 minutes at room temperature with no 
brake. This ensured separation of any cells from the plasma. Samples were 
processed under sterile conditions, to prevent microbial growth which may 
affect any vesicles present and can also show up as false positives in flow 
cytometric analysis. Within 2 hours of collection all samples were processed, 
and the tubes containing the separated plasma and cells were stored at 4°C 
until collection. Upon arrival in Bristol, the platelet poor plasma was 
centrifuged (Sorvall Legend RT, Thermo Fisher, UK) at 2500 x g for 15 
minutes at room temperature with no brake, to remove any remaining cells 
and large extracellular debris, and to ensure only small vesicles or 





In order to detect all Red Cell Derived Microparticles (RCDP) in SCD plasma 
we stained with BRIC256, an antibody recognising an extracellular epitope on 
GPA, and BRIC163, an antibody recognising an intracellular epitope on GPA, 
so we could distinguish between right-side out vesicles (BRIC256 positive) 
and inside-out AVs (BRIC163 positive) respectively. To detect PS positive 
vesicles, we stained with FITC-conjugated Annexin V. Dual stain tubes were 
also included to establish whether the different populations of RCDMV 
observed were extracellular GPA / PS positive, or extracellular GPA / 
intracellular GPA positive which would therefore mean that they were likely to 
be unsealed membrane fragments from lysed red cells rather than discrete 
RCDP. 
Serial samples for 0h, 24h, 48, 72h and ≥120h were received for all healthy 
controls in the study. For steady state SCD patients, only 0h samples were 
received, as these were obtained at routine day haemoglobinopathy day unit 
appointments. Serial samples were received for SCD crisis patients 1, 2, 3 , 4, 
5, 8 and 9. This is reflected in the graphs displaying monitoring of RCDP over 
time which omit the data for steady state controls and those SCD crisis 
patients for whom serial samples were not obtained (SCD crisis patients 1, 6, 
7, 10 and 11). 
 
4.2.4 BRIC256-647 - Right-side out RCDP 
 
 
At 0h, when comparing the SCD crisis patients (mean: 2210 events/µl; SD: +/- 
1852 events/µl) with healthy controls (median: 572 events/µl; SD:+/- 234 
events/µl), there was a 4-fold increase in right-side out RCDP. There was a 
larger 6-fold increase in steady state SCD patients (median: 3612 events/µl; 
SD: +/- 2695 events/µl) when compared to healthy controls (see figure 4.22). 
The differences in right-side out RCDP between healthy controls and SCD 
crisis patients was not statistically significant (p=0.10), neither was the 
difference between healthy controls or steady state SCD patients (p=0.11). 
 
There were outliers in the data, most notably steady state controls 3 and 4, 





calculation by use of a median average. However even when this was taken 
into account, the average RCDP number for each cohort do not alter. Figure 
4.22 appears to show a slight trend towards increased BRIC256-647 
extracellular GPA-positive vesicles in SCD crisis patients which may have 
been more pronounced given a larger dataset. The fact that more data may 
have informed a more accurate outcome is one of the recognised limitations 
of the study. 
 
Comparison of the levels of extracellular GPA-positive RCDMV over the 
course of admission did not show any signficant difference between healthy 
controls and SCD patients in crisis, with levels of BRIC256-647 extracellular 
GPA-positive RCDMV generally stable throughout the period monitored (see 
figure 4.23). SCD crisis patient 1 showed an increase in extracellular GPA-pos 
RCDMV over the course of their admission before they were discharged at 
24h. SCD crisis patient 5 also showed an increase, which then fell at 48h 
before discharge. 
 
The elevated levels of MVs in patients 1 and 5 are consistently high in flow 
cytometry studies throughout the study, but these findings of increased levels 
of MV in their plasma were not associated with an increased length of 







Figure 4.22 Flow cytometric analysis of BRIC256-647 labelled RCDMV at 0h in 3 studied 
cohorts; Healthy controls, Steady State SCD patients and Crisis Cohort SCD patients. There 
was a 4-fold increase in extracellular-GPA pos RCDMV between healthy controls and SCD 
crisis patients. There was a larger 6-fold increase between steady state SCD patients and 
healthy controls. The differences between the cohort means were not statistically significant. 
 
Figure 4.23 flow cytometric analysis of BRIC256-647 labelled vesicles (events/µl) over 
time admitted (h). Studied cohorts where serial samples obtained only; Healthy controls (red 





4.2.5 BRIC163-488 – Inside-out Autophagic Vesicles 
 
 
When quantifying AVs using BRIC163-488 at 0h, there were approximately 
equal numbers of AVs observed in the healthy control cohort (median: 1367 
events/µl; SD +/- 1013 events/µl) compared to the SCD crisis patients (Mean: 
1068 events/µl; SD +/-1307 events/µl). The steady state SCD patients had on 
average, twice as many AVs in their plasma (median: 2654 events/µl; SD +/- 
events/µl as the SCD crisis cohort (median: 1068 events/µl; SD +/- 1307 
events/µl) and healthy controls (median: 1367 events/µl; SD +/- 1013 
events/µl) (see figure 4.24). The differences between the averages of the 
cohorts studied were not statistically significant when comparing healthy 
controls to SCD patients in crisis (p=0.42) or healthy controls to steady state 




Figure 4.24 Flow cytometric anlysis of BRIC163-488 labelled vesicles at at 0h in 3 
studied cohorts; Healthy controls, Steady State SCD patients and Crisis Cohort SCD 
patients. There was a no real observed increase in intracellular GPA-pos RCDMV between 
healthy controls and SCD crisis patients. The steady state SCD patients had on average, 
twice as many AVs in their plasma as the SCD crisis cohort and healthy control, although the 






Over the period of admission, AV levels declined for SCD crisis patients 1 and 
5, but AV number remained stable for the other SCD crisis patients studied, 
except for patient 2, whose AV numer rose before discharge (see figure 4.25). 
For healthy control 4, AV number was higher at admission, but fell after 24h. 
However the numbers of AVs for healthy control 4 were higher throughout the 
study period than any of the SCD crisis patients. These results suggest that 




Figure 4.25 BRIC163-488 labelled vesicles (events/µl) over time admitted (h). Studied 
cohorts where serial samples obtained only. Healthy controls (red line, small markers) and 





4.2.6 Annexin V FITC labelling – PS positive MVs 
 
Annexin V FITC staining for PS positive MV showed that these were the most 
numerous population out of all subpopulations of MVs studied (see figure 4.26 
and 4.32). These results reflect the observations in live cell confocal 
microscopy analysis and are in line with other studies (de Jong et al. 2001; 
Westerman et al. 2008; van Tits et al. 2009). PS positive vesicle number was 
approximately equal between SCD crisis patients (mean:13630 events/µl; SD 
+/- 7741 events/µl) and SCD steady state controls (mean:13334 events/µl; SD 
+/- 9562 events/µl). PS positive MV number in SCD crisis patients was 30% 
higher than healthy controls (median: 9939 events/µl; SD +/- 7025 events/µl). 
however there were no statistically significant differences between the 3 
cohorts with the differences in p values not <0.05, where SCD crisis patients 
Vs healthy controls (p=0.97). 
 
Figure 4.26 Anexin-V FITC labelled vesicles at 0h in 3 studied cohorts; Healthy controls, 
Steady State SCD patients and Crisis Cohort SCD patients. There was a 50% increase in PS 
pos RCDMV between healthy controls and SCD crisis patients, but this was not significant. 






Throughout the course of the study, PS positive MVs did not remain stable in 
either the healthy controls or the SCD crisis patients studied (see figure 4.27). 
There was no observable difference in the levels of PS pos MVs between 
healthy controls and SCD crisis patients studied, and no decreases in PS 
positive MV number were noted over the time period observed. Variation in 
PS expression may be accounted for by the ongoing inflammatory state 
present in SCD. Alternatively, limitations in the methodology particularly in the 
use of annexin V, rather than an alternative PS-specific label, such as 
lactahedrin, may have led to the variation seen, and are further explored in the 
discussion. 
 
Figure 4.27 Annexin-V FITC labelled vesicles (events/µl) over time admitted (h). Studied 
cohorts where serial samples obtained only. Healthy controls (red line, small markers) and 





4.2.7 Dual-labelled BRIC256-647 / BRIC163-488 RCDP – Unsealed RBC 
Membrane Fragments 
 
There was no significant difference observed between in cohorts dual-labelled 
with BRIC256-647 / BRIC163-488 RCDP (see figure 4.28). These MVs, which 
most likely represent unsealed membrane fragments from lysed red cells were 
the smallest subpopulation of MVs detected, although it is known that they 
vary greatly in size and therefore would not all be captured by our size gating 
protocol. There was an approximate two-fold increase in dual-labelled events 
detected in SCD steady state patients (mean:1893 events/µl; SD +/- 1800 
events/µl) compared to SCD crisis patients (mean:765 events/µl; SD +/- 790 
events/µl), and healthy controls (median: 923 events/µl; SD +/- 341 events/µl). 
However, no statistically significant differences were observed between any 
cohort. The increase observed in steady state controls was not significantly 
higher when compared to healthy cohorts or SCD crisis patients (p=0.31 and 
p=0.69 respectively). In addition, SCD crisis patients did not differ significantly 









Figure 4.28 BRIC256-647 / BRIC163-488 dual-labelled vesicles at 0h in 3 studied cohorts; 
Healthy controls, Steady State SCD patients and Crisis Cohort SCD patients. There was a 2- 
fold increase in dual labelled extracellular-GPA pos RCDP between SCD steady state 
patients compared to SCD crisis patients and healthy controls. However, the differences 








Figure 4.29 BRIC256-647 / BRIC163-488 dual-labelled vesicles (events/µl) over time 
admitted (h). Studied cohorts where serial samples obtained only; Healthy controls and 
Crisis Cohort SCD patients 
 
During the course of admission, crisis patients 1 and 5, and healthy control 3 
had higher levels of dual-labelled membrane fragments in their plasma which 
decreased at, or shortly after 24 hours following treatment (see figure 4.29). 
The levels of fragments in the plasma did not have effect on the period of 
admission, and therefore the severity of crisis as other patients (patient 9) 
were admitted for longer. However, this could have been due to other co- 
morbidities or contributing social factors, rather than the severity of the VOC 
event. The majority of patients and healthy controls had stable levels of dual- 
labelled red cell fragments in their plasma throughout the study period, 





4.2.8 Dual-labelled BRIC256-647 / Annexin V FITC – PS-positive RCDP 
 
 
Dual-labelled extracellular GPA-pos RCDP, which express procoagulant PS 
were 6-fold higher on average in SCD crisis patients (mean:5402 events/µl; 
SD +/- 3612 events/µl) when compared to healthy controls (mean:811 
events/µl; SD +/- 650 events/µl), and 50% higher than steady state SCD 
patients (mean:3520 events/µl; SD +/- 2837 events/µl) (see figure 4.30). 
These findings were not significant however, with no statistically significant 
differences observed between the averages of the SCD crisis patients and 
healthy controls (p=0.19), or SCD crisis patients and SCD steady state 
patients (p=0.42) 
The presence of increased RCDP which express PS in SCD patients, whether 
in steady state or in VOC is not surprising. These findings are in concordance 
with the exisiting literature and are in line with the results of the confocal 







Figure 4.30 BRIC256-647 / Annexin-V FITC dual-labelled vesicles at 0h in 3 studied 
cohorts; Healthy controls, Steady State SCD patients and Crisis Cohort SCD patients. Dual- 
labelled extracellular GPA-pos RCDP, which express procoagulant PS were 6-fold higher on 
average in SCD crisis patients when compared to healthy controls, and 50% higher than 








Figure 4.31 BRIC256-647 / Annexin-V FITC dual-labelled vesicles (events/µl) over time 
admitted (h). Studied cohorts where serial samples obtained only; Healthy controls and 
Crisis Cohort SCD patients 
 
Over the course of the study, levels of dual-labelled extracellular GPA-pos / 
PS pos RCDP, remained stable for the majority of the SCD crisis patients and 
healthy controls tested, which suggests following treatment no increase or 
decrease in PS positive RCDP occurs (see figure 4.31). For the two patients 
with the highest number of PS pos RCDP, patients 1 and 5 fell over the 
course of admission and treatment, however PS pos RCDP did not have any 
correlation with length of stay as they were discharged at 24h and 48h 
respectively, when compared to patient to 9 who had much lower PS positive 
RCDP present and a longer period of admission. Healthy control 3 had higher 
PS pos RCDP levels than most of the SCD crisis patients tested, but with no 





4.3 Microvesicle subpopulation comparison 
Of all of the subpopulations of MV detected, Annexin V PS positive MV were 
the most numerous in the plasma of the cohorts studied. With these 
microparticles being higher in number in both the SCD crisis patients 
(mean:13630 events/µl; SD +/- 7741 events/µl) and steady state patients 
(mean:13334 events/µl; SD +/- 9562 events/µl) than the healthy control cohort 
(median: 9939 events/µl; SD +/- 7025 events/µl). When comparing the numbers 
of these PS-pos MV with ones which were RBC in origin (BRIC256-647 / 
Annexin V dual-labelled), RCDMV which were extracellular GPA-positive as 
well as PS positive were the second most numerous particle detected, but were 
not as numerous as the PS positive, single stained MVs, suggesting a 
subpopulation of MVs that are not RBC-derived which were not excluded from 
analysis by pre-analytical processing and setup protocols established to reduce 
containation by other MVs. 
The majority of the subpopulations of MVs studied were elevated in SCD 
crisis and SCD steady state patients when compared to healthy controls, with 
the exception of Intracellular GPA (BRIC163) stained AVs, where AV number 
was higher in the healthy control and SCD steady state cohorts than the SCD 
crisis cohort. However, this difference in increase MV number was not 







Figure 4.32. Average microvesicle number categorised by flow cytometric labelling. 
Average (Mean average +/- 2 SD) MV numbers in each MV subpopulation were measured 
using single markers to both extracellular (BRIC256-647) and Intracellular (BRIC163-488) 
RBC-derived GPA, and Phosphatidylserine (Annexin V FITC), in addition to dual staining to 
detect RBC-derived fragments and RBC-derived right-side out and inside-out PS positive 
fragments. PS positive MV were the largest subpopulation detected. MVs were increased in 
all SCD crisis and steady state patients when compared with healthy controls with the 






4.4 Is there a significant threshold for MV number to predict VOC? 
 
To determine if there was any correlation for any of the MV subpopulations in 
plasma to predict VOC, statistical analysis, using univariate analyses and a 
Binomial Generalised Linear Model (GLM) was performed, examining the 
following 7 variables; 
 
(i) Antibody BRIC256 
(ii) Antibody BRIC163 
(iii) Antibody Annexin V 
(iv) Antibody BRIC256/163 
(v) Antibody BRIC256/Annexin V 
(vi) Sickle Cell Haemoglobin (HbS) percentage 
(vii) Reticulocyte count. 
 
 
The results from fitting a Binomial Generalised Linear Model with logit link for 
a patient experiencing VOCs at the time of admission are shown below, in 
Table 4.1. The only variable (at the 5% significance level) found to have a 
statistically significant explanatory value associated with VOCs in these sickle 
cell patients was the HbS percentage, with increased percentages being 
associated with greater likelihood of patients experiencing VOCs. The 
evidence however is weak, as the 95% confidence interval (CI) for the odds 
ratio includes 1.00, which denotes no change in the likelihood of patient’s 
crisis for increasing values of HbS. The results of the analysis showed no 
statistically significant correlation between any microvesicle subpopulation 
number studied and VOC. These results are limited by the small number of 












95% CI P 
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Other factors considered: 
Number of vesicles in the plasma of patient using antibody BRIC256 (p=0.76) 
Number of vesicles in the plasma of patient using antibody BRIC163 (p=0.88) 
Number of vesicles in the plasma of patient using antibody Annexin V (p=0.42) 
Number of vesicles in the plasma of patient using antibody BRIC256-163 (p=0.86) 
Number of vesicles in the plasma of patient using antibody BRIC256 Annexin V (p=0.35) 





Chapter 5: Discussion 
 
 
The pathological symptoms of SCD are caused by the repeated sickling and 
unsickling of the HbS erythrocyte leading to polymerisation of HbS, a 
reduction in membrane deformability, subsequent membrane damage and 
membrane loss via membrane blebbing, producing microvesicles, which 
express surface exposed PS (Westerman et al. 2008; van Tits et al. 2009; van 
Beers et al. 2009; Gerotziafas et al. 2012). This premature destruction of the 
HbS erythrocyte also results in an increase in the production of their 
progenitor, the reticulocyte (Bernard et al. 2006). Previous work by Griffiths et 
al. (2012) describes a third mechanism of microvesicle formation during the 
later stages of reticulocyte maturation, which results in the production of a 
subset of microvesicles termed the Autophagic Vesicle (AV). Later, studies by 
Mankelow et al. (2015) showed that AV’s had an inside-out orientation, 
resulting in discrete areas of surface-exposed PS and exposure of the 
cytoplasmic domains of red cell plasma membrane proteins. They further 
demonstrated that the numbers of red cells with AVs are elevated in steady- 
state SCD patients and patients who had been splenectomised. They 
postulated that ordinarily these AVs would be removed by splenic 
macrophages in the reticuloendothelial system, but in the absence of a spleen 
they would eventually be released directly into plasma where, due to the 
expression of PS on the AV surface they could contribute to the prothrombotic 
state that causes VOC. They suggested that by using apheresis it may be 
possible to remove PS-positive vesicles from circulating red cells ex vivo, and 
that this may provide a useful additional therapy for patients with SCD, 
potentially reducing the incidence of VOC. However, the numbers of AV in 
SCD patients in VOC was not known, and therefore the need and potential 
efficacy of this proposed intervention was unknown. 
 
In this feasibility study we describe the analysis of MV in samples obtained 
from three cohorts; healthy individuals, SCD patients in a steady state and 
SCD patients in VOC. We use a combination of confocal microscopy and flow 





respectively. MV subpopulations quantified include right-side out RCDPs, 
inside-out AVs, PS-positive MVs, RBC-derived membrane fragments and PS- 
pos RCDP. Subpopulations in these three cohorts were examined to see if 
there are any statistically significant differences between healthy individuals, 
steady state SCD patients and those SCD patients in VOC. 
 
5.1 Confocal Microscopy 
 
 
Using both live cell and fixed cell confocal microscopy experiments to 
examine the RBC, PS-positive vesicles and GPA-positive vesicles were 
labelled with monoclonal antibodies (Annexin V-FITC and R10-488), and 
subsequently quantified. In both live cell and fixed cell confocal microscopy 
studies, statistically significantly higher numbers of PS-positive and GPA- 
positive vesicles were seen when comparing healthy controls to steady state 
SCD patients and SCD patients in VOC. 
 
In live cell confocal microscopy experiments, which looked at PS-positive 
vesicles, the differences in PS-positive vesicle percentage were statistically 
significant when comparing healthy controls and crisis patients (p<0.0001) 
with the mean vesicle percentage being significantly larger in the latter than in 
the former group. 
 
In fixed cell confocal microscopy experiments, which looked at extracellular 
trypsin sensitive Glycophorin A (GPA) positive vesicles, using the mAb R10, 
statistically significant differences were observed between the healthy controls 
and crisis patients (p<0.0001), with the mean vesicle percentage being 
significantly larger in the latter than in the former group. There was however 
no significant difference in R10-positive vesicle expression between the 
steady state and SCD crisis cohorts. There were differences in amounts of PS 
and R10 labelling in both live cell and fixed cell confocal microscopy 
experiments, respectively. If these represent PS decorated AVs then this 
indicates that externalisation of PS had already taken place, but there were 





increasing the amount of procoagulant phospholipid at the RBC membrane 
surface. 
 
During the period of admission, both PS-positive and GPA-pos vesicle 
number on RBC declined in the SCD crisis patients when compared with the 
healthy control cohort. This may be due to the patients receiving either 
exchange or top-up transfusion during the course of their admission, reducing 
the MV number by reducing the circulating volume of HbS RBC by either 
replacement or dilution by way of addition of healthy donor-derived RBC. 
 
5.2 Flow Cytometry 
 
 
Flow cytometric analysis of the plasma showed that there were different 
subpopulations of RCDP as well as a large number of PS-pos 
microparticles/microvesicles. This suggests that the situation is not as 
straightforward as there just being a regular population of “red cell derived 
vesicles” present. Of all subpopulations of MV detected, PS-positive MV were 
the most numerous in the plasma of all the cohorts studied. This is in line with 
the confocal microscopy studies which showed that statistically significant 
numbers of PS-positive MV were seen in SCD patients in VOC and in steady 
state SCD patients when compared to healthy controls. 
 
However, unlike the confocal microscopy studies, levels of PS-pos MVs in the 
plasma were not elevated enough to achieve statistical significance and did 
not decrease during the period of the study but were variable from day to day. 
Day-to-day variation in MP in the blood of SCD patients will occur due to 
fluctuations in inflammatory intensity (van der Pol et al. 2016). It is unknown 
whether these detected PS-pos MV were all reticulocyte or erythrocyte- 
derived, or whether they were particles derived from either platelets or 
endothelial cells (van Beers et al. .2009; del Conde et al. 2005) but it is likely 
that from their larger number when compared to dual-labelled RBC-derived 





This would indicate that the although the sampling and processing mitigation 
measures taken to reduce cellular contamination appear effective, MV and 
MP contamination cannot be removed or reduced by the processing 
measures taken in this study. The finding that PS-positive MV were raised in 
all cohorts but were higher in both steady state and VOC SCD patient cohorts 
when compared to healthy controls, is in line with other published studies 
(Wood et al. 2006; Kennedy, 2015; Whelihan et al. 2016) and is indicative of 
the role that PS plays in VOC and thrombogenic states (Setty et al. 2016). 
 
When looking specifically at RCDPs, the largest subpopulation detected were 
the dual-labelled RCDP, which were PS-positive (BRIC256-647 / annexin V). 
Levels of these remained relatively stable throughout the course of the study 
in most patients and controls observed. Two of the VOC SCD patients 
(patients 1 ad 5) had increased numbers of BRIC256-647 / annexin-V dual- 
labelled vesicles at admission, but increased levels of these dual-labelled 
vesicles were not associated with increased length of admission, and in one 
healthy control, levels of these dual-labelled MV were higher than five of the 
VOC SCD patients but were not associated with any clinical symptoms or 
associated disease state. The presence of this subpopulation as the largest 
RCDMV population correlates with previous studies and the effects of RBC- 
exposed PS in the pathophysiology of SCD (Wood et al. 2006; Kennedy, 
2015; Whelihan et al. 2016) 
 
There was a difference in the overall number of single-labelled (annexin V 
labelled) PS-positive MV, described above and dual-labelled RCDP, which 
were PS-positive (BRIC256-647 / annexin V). This would also support the 
suggestion that there were large numbers of PS-positive MVs or small 
particulate matter that was not RBC-derived and may be microparticles from 
platelets or endothelial cells (van Beers et al. 2009; del Conde et al. 2005). 
Additionally, it may also be that the binding of BRIC256-647 / Annexin V mAbs 
was not effective due to steric hindrance. This occurs when the size of the 
antibody molecule (150,000 Daltons for IgG) interferes with the reaction of the 





antigenic determinants are closely spaced (Kent et al. 1978). If this is the case 
the two mAbs would not be able to bind to their respective sites due to the 
small size of the MV and the binding sites upon it. While annexin V has been 
the most commonly used label for the detection of externalized PS, the failure 
of the low scatter small particles to bind annexin V in addition to BRIC256-648 
may also be due to the curvature of these sub-cellular particles rather than an 
absence of PS. A study by Shi et al. (2004). suggested an alternative PS 
marker, lactadherin. Lactadherin may be a more specific and sensitive marker 
in studies such as these by virtue of its ability to bind to MP having smaller 
radii of curvature. 
 
Of the remaining RCDP detected by flow cytometry, small populations of right- 
side out (BRIC256-647 positive) RCDP and inside-out (BRIC163-488 positive) 
AV respectively were detected in the plasma. Of these two subpopulations, 
right side out MV were the most numerous, reflecting MV produced as part of 
HbS-positive erythrocytes undergoing cellular blebbing during repeated cycles 
of cellular sickling and recovery (Allen et al. 1982). A smaller subpopulation of 
inside-out MV, most likely AV, which are produced in the latter stages of 
reticulocyte maturation (Griffiths et al. 2012; Mankelow et al. 2015) were 
detected in the plasma. In both of these subpopulations of right-side out and 
inside-out RCDP, the RCDP were more numerous in steady state SCD 
patients than patients in VOC. 
 
The increased presence of RCDP, in particular AV in steady state SCD 
patients when compared to SCD in VOC is a novel finding, however the 
differences in MV number were not significant enough to achieve statistical 
significance and the small numbers of patients in each of the cohorts may 
have skewed the results. They did not decrease over time in either healthy 
controls or SCD patients, with numbers remaining relatively constant in most 
participants studied, which would indicate that they are being produced 





Quantification of dual stained extracellular / intracellular GPA-pos RCDP, 
(BRIC256-647 / BRIC163-488 labelled), which most likely represent unsealed 
RBC membrane fragments showed these were the smallest subpopulation of 
MV detected. Flow cytometric gating was set to capture small, lower scatter 
events, measuring <1µm, and more specifically RCDP, which have an 
average size of 0.15µm (Piccin et al. 2007). As some RBC membrane 
fragments will have been greater than this size it is likely that they were 
excluded from the endpoint analysis and are therefore not a significant 
subpopulation in this study. Despite their size range, these MVs would have 
expressed PS and could still be a significant factor in VOC. 
 
Finally, when looking at whether MV quantification enabled prediction of VOC, 
no statistical significance was found in any of the MV subpopulations studied, 
with the only significant predictor of VOC being HbS%, which is in agreement 
with current guidelines regarding the monitoring and management of SCD 





Limitations associated with the study included the small size of the cohorts, 
which affected the analysis of results where outliers were present in the flow 
cytometry experiments where single specificity mAb labelling was used. If 
more participants had been recruited to the study, it would have increased the 
confidence in the findings and significance of the statistical analysis. Factors 
affecting recruitment included a limited cohort at a single study site, 
consenting and total time allocated for the study. 
 
We encountered difficulty in serial monitoring of patients during admittance for 
VOC, as some patients were admitted for very short (<24h) time periods 
before discharge. This meant that with some patients only 1 sample was 
obtained for analysis from admission to discharge, which then made serial 
monitoring impossible. Day-to-day variation in MV in the blood of SCD 





steady state patients. By not having this information for the steady state 
cohort, as they were day case patients, and some of the SCD VOC cohort 
patients due to their recovery and discharge made longitudinal analysis and 
trending of results problematic. 
 
No association was found between length of admission and MV number, with 
some patients discharged at earlier points even when their vesicle number 
throughout the study was higher. The length of admission however may not 
be solely attributable to severity of crisis, as additional factors such as social 
and personal issues may have affected the ability to discharge the patient at 
an earlier stage. 
 
Fixed cell confocal microscopy experiments showed larger variation in results 
due to difficulties with fixation and staining. The impact of loss of cells during 
these experimental procedures, which have previously been optimised for 
healthy RBC populations, may have adversely affected the results, but they 
were still different enough to achieve statistical significance. In addition, 
expertise of the author with new techniques performed in the study may have 
introduced potential bias in the protocol. 
 
Challenges associated with the flow cytometric experimental protocol included 
agglutination of the samples if left for longer than 30 minutes before analysis. 
In the original protocol patient’s plasma was mixed with the respective mAb 
and then left to incubate on ice in the dark for 30 minutes. Next, 300µl of 
binding buffer was added to each tube and they were loaded onto the flow 
cytometer for analysis. The latter tubes in the flow cytometer run failed to 
acquire sufficient events to enable interpretation, and upon examination, 
agglutination was observed in the tubes which had been waiting for analysis. 
As the tubes contained citrated plasma and the annexin V binding buffer 
reagent contained Ca2+ in order to facilitate binding of Annexin V to PS it was 
thought that this could potentiate agglutination in the sample if left for 





To overcome this agglutination, tests were run as single tube assays, with 
annexin V binding buffer added to the test immediately before analysis on the 
flow cytometer. This prevented agglutination and enabled the analysis of the 
sample and acquisition by the flow cytometer (see figure 5.1). As mentioned 
earlier, annexin V has been the most commonly used label for the detection of 
externalized PS. The milk-derived protein, lactadherin may have been a more 
appropriate marker to use in this study, due to its increased specificity and 
sensitivity over annexin V, due to its ability to bind to MP having smaller radii 
of curvature. In addition, as its binding does not require re-calcification of 
citrated plasma samples which can lead to agglutination and an invalid test 
result, it may therefore be a more suitable reagent for PS pos MV analysis in 
future studies. 
 
Figure 5.1. Agglutination observed in flow cytometry testing. Agglutination observed in 
multiple tube tests (a) caused low event number in gated FS/SS and FL1/FL6 scatter graphs 
(b) and (c). No agglutination in single tube tests (c) or in the subsequent gated FS/SS and 
FL1/FL6 scatter graphs (d) and (e). Caused by activation of clotting factors in patient serum 





There remains an ongoing challenge to develop a method to accurately 
categorise and enumerate MV in plasma. In this study, despite attempts to 
identify and subsequently quantify small (<0.15µm) RCDP in plasma by 
including protocols to mitigate against contamination with microparticles and 
particulate matter from other cellular sources, it appears, from the levels of 
PS-positive microparticles, that this has not been wholly successful. There 
remains no consensus for flow-cytometry analysis of MPs (Hebbel and Key, 
2016), which has led to the creation of numerous protocols which then make 
the most accurate strategy unclear. Flow cytometric analysis has historically 
been the most commonly used methodology for MP detection (Shet et al. 
2003; van Beers et al. 2009; Piccin et al. 2015), but its ability to accurately 
detect and categorise the smallest particles is limited, which has led to varying 
reports of RCDP percentage, ranging from 3%-75% of total MV detected 
(Shet et al. 2003; van Beers et al. 2009; Piccin et al. 2015). The use of flow 
cytometry sizing beads may not be appropriate for calibration of modern flow 
cytometers to detect and define MV and MP of such small size. They have a 
different refractive index to RBC-derived vesicles and may therefore not be a 
true representative calibrating material. However, it should also be noted that 
all bead-based calibration strategies have been criticized for the fact that other 
standards with refractive indices closer to MP may be preferable for size 
calibration (van der Pol et al, 2014). 
 
Studies have described a limitation of flow cytometric analysis in its inability to 
detect ‘swarms’ of MVs (Harrison and Gardiner, 2012). As MV’s are small, it is 
highly likely that they will be in increased concentrations in the analyte as it 
passes through the flow cell. Consequently, multiple swarming MVs may be 
detected at once by the laser beam of the flow cytometer. These swarming 
MVs will have a greater forward scatter and may be excluded from analysis if 
incorrectly size gated as a single large particle or cell. Dilution of the sample 
should decrease MV concentration and mitigate against MV swarming, 
decreasing the probability that multiple MVs passing through the laser beam 





Until standardisation of collection, processing and analysis is achieved, then 
accurate enumeration and classification of MVs by flow cytometry is an 
ongoing challenge. Attempts at standardisation have been made in workshops 
run by the International Society of Thrombosis and Haemostasis (ISTH) with a 
new initiative to standardize EV measurements 
started in 2014. (van der Pol et al. 2014). Reference materials and samples 
were circulated to 33 laboratories worldwide for analysis by a specified 
technique. From this exercise, dedicated software has been developed which 
can automatically correct for differences in optical configurations of the flow 
cytometers used, and to correct for differences in light scattering between 
reference materials and EVs (van der Pol et al. 2014). 
 
Presently, the study of MV in SCD provides further opportunities for future 
research into the prevention of the pathophysiological symptoms of the 
disease. However, the complexity of symptoms experienced and subtle 
differences in the haemoglobinopathy genotypes may mean that monitoring 
approaches may be too varied and complex to be achievable by all but a very 
few specialised centres, which may inhibit their feasibility and application. 
Until the development of an effective technology and standardised process 
that allows an optimised approach to this monitoring is available, then the 
current multi-faceted approach to management of these patients with existing 
and emerging new drugs, such as selectin inhibitors or L-Glutamine is the 
best and only option for these patients. Whilst gene therapy offers promise, it 
is too far on the horizon for many patients in the western world and an 
unachievable dream for the vast majority of patients in the developing world. 
 
5.4 Further work 
 
A potential technological solution may come in the form of imaging flow 
cytometry. A recent study by Smith et al. (2020) examined the plasma of SCD 
patients in both steady state and crisis compared with healthy controls, to 
ascertain the role Red Cell Derived Particles (RCDP) in the pathology of SCD 
and whether their removal by apheresis would be of therapeutic benefit to 







The authors used imaging flow cytometry to quantify RCDP and AV in SCD 
plasma. The use of imaging flow cytometry allowed the authors to identify 
RCDP which varied in size, ranging from large macrovesicles (MaV) which are 
similar in size to erythrocyte ghosts, to microvesicles. The heterogeneity in 
size of RCDP was unsurprising given the destructive cellular haemolytic 
process and associated inflammation associated with SCD, particularly in 
those patients in crisis. 
 
Similar to this study, of the RCDP detected, the majority bound antibodies to 
extracellular epitopes on glycophorin A (GPA) and were right-side out in their 
orientation. A second, minor population of inside-out AVs was detected with 
antibodies to epitopes on the intracellular domain of GPA. This was confirmed 
by electron micrograph experiments using transmission electron microscopy 
and immunolabelling techniques. The large, right-side out GPA pos MaV 
exposed PS at the membrane surface. The subsequent removal of these right 
side-out MaV from SCD patient plasma samples using anti-GPA coated 
magnetic beads resulted in a seven-fold increase in the plasma clotting time. 
 
These results suggest that removing RCDP from plasma of SCD patients 
would be of therapeutic value by minimising the pathological effects of 
hypercoagulation. Potentially leading to a new therapeutic approach to 
managing VOC, avoiding the need for an intensive transfusion regime, with 








Figure 5.2 Cellular fluorescence “spot” analysis using Imaging flow cytometry to 
detect emerging AV. Annexin V FITC stained erythrocytes can be examined using an 
ImageStream®X Mark II imaging flow cytometer (Luminex, USA) and the data generated 
analysed using the “Spot Analysis” functionality of IDEAS 6.2 software (Luminex, USA) 
whereby fluorescent positive events (cells) can be sorted into negative, positive, and positive 
but only in a small region of the cell surface (a spot). This type of analysis is much faster and 
less subjective than live cell confocal imagining and because you can rapidly calculate the 
percentage of AV positive cells from 100,000 cells (c.f. manually counting approximately 2000 
cells by confocal), you would expect it to be more accurate. Preliminary data using 3 healthy 
samples gave a mean % of AV positive cells of 0.07%. Two steady state SCD samples have 
been analysed by both live cell confocal imaging and ImageStream spot analysis, one gave a 
figure of 2.3% of AV positive cells by confocal and 2.7% by ImageStream, the other 1.0% by 









The results show that a heterogeneous population of MV were present in the 
plasma of both healthy controls and SCD patients in steady state and in VOC. 
In confocal microscopy studies, statistically significantly elevated numbers of 
PS-positive MV, and GPA-pos MV were identified which is concordant with 
previous studies (Mankelow et al. 2015). In flow cytometry studies, RCDP of 
an inside out orientation, most likely AVs, are indeed present in the plasma of 
SCD patients in both steady state and VOC but were not significantly 
increased in either cohort when compared to healthy controls. Overall, no 
population of MV was found to be a statistically significant predictor of VOC in 
this study, which was limited by the small cohorts examined and limitations in 
the existing experimental methodology used. Future studies in this area 
should utilise newer, more accurate methodologies, such as the ImageStream 
imaging flow cytometer, to differentiate MVs from RBCs/ platelets and other 
cellular debris, and to examine their clinical significance as potentiators of the 
pathophysiological symptoms of SCD. As the population of the United 
Kingdom changes and the prevalence of SCD increases, the need for an 
effective prognostic test for SCD becomes more pressing. Current treatments 
are largely defensive in their nature, with bone marrow transplantation the 
only curative option available for very few patients. While gene therapy offers 
future promise of a cure, long-term outcomes are unknown, and the cost is 
currently prohibitive to most healthcare systems. As new reagents and 
technologies become available, they must be used to build a complete picture 
of the complex interactions in SCD patients and address the current relatively 
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Description of proposed research (500 words maximum) 
Please include: 
(a) Aims of the research 
 
Patients with homozygous (HbSS) SCD are at risk of painful Vaso-Occlusive crises 
(VOCs), and haemolysis, caused by deoxygenated, sickle shaped erythrocytes 
(red blood cells) occluding the microcirculation. Recent studies have indicated that 
VOCs may also be associated with the release of inside-out autophagic erythrocyte 
membrane vesicles into the bloodstream. The release of inside-out autophagic 






Ordinarily these vesicles would be removed from the circulation through the 
process of sequestration by splenic macrophages. However sickle cell patients 
have a non-functioning spleen, or have been splenectomised. This results in 
increased numbers (8-10 fold) of circulating vesicles in this group of patients. 
Unpublished work has shown that these inside-out vesicles express 
phosphatidylserine (PS), which acts as a substrate for the prothrombin/thrombin 
complex, potentially increasing the propensity of thrombosis and VOC. 
(b) Principal research question(s) 
 
To ascertain if there is a correlation between numbers of circulating autophagic 
erythrocyte membrane vesicles and the severity and likelihood of VOCs. 
(c) Proposed methods 
 
Monoclonal antibodies (BRIC256 and BRIC163) have been developed at the 
Bristol Institute of Transfusion Science (BITS). These monoclonal antibody 
clones are specific for the PS structures on the outside of the vesicles. There 
is potential for these monoclonal antibodies to be used in flow cytometry 
experiments to quantify the numbers of autophagic vesicles in the patient’s 
plasma. Confocal microscopy will also be used to quantify the numbers of 
vesicles located on the erythrocytes of the same patients. 
(d) Potential impact of research 
Quantification of autophagic vesicles may form the basis of a clinical 
diagnostic testing regimen, in order to predict, and therefore prevent VOC’s in 
this cohort of patients 
(e) A summary of patient and public involvement in the research 
 
Patients attending UCL will be consented to allow for an additional sample to be 
taken in order to perform the analysis. The sample will be taken when they are 
admitted in VOC, in addition to existing diagnostic sampling. It is envisaged that 
the innovation could lead to novel therapeutic interventions in the management of 
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PARTICIPANT STUDY NUMBER: 
 
Chief Investigator: Prof. John Porter 020 7380 9638 
PART 1; 
 
Why am I being asked to be in this Research Study? 
 
We are inviting you or your child to take part in a research study. 
Research is a way of attempting to gain new knowledge. A person who participates in 
research study is called a “subject”. Before you decide we would like you to understand 
why the research is being done and what it would involve for you. One of our team 
will go through the information sheet with you and answer any questions you 
have. We would suggest this should take at least 30 minutes. Talk to others about the 
study if you wish. 
Part 1 tells you about the purpose of the study and what will happen to you if you take 
part. Part 2 gives you more detailed information about the conduct of the study. Ask us 
if there is anything that is not clear. 
 
What is the purpose of this study? 
 
The purpose of the research study is to understand the role of microvesicles in Sickle 
Cell Anaemia. Microvesicles are broken bits of cells that circulate in the blood. 
Research done so far, shows that these microvesicles are sticky. This may be 
important in Sickle cell diseasewhere we know that many of the problems are caused 
by cells becoming sticky and blocking the blood vessels. We will measure the levels of 
the microvesicles and related aspects of blood stickiness in the blood and see if that 
helps identify people who have more problems with their Sickle Cell Anaemia. We hope 
in the future these measures may be used to predict who may get complications of 
their disease or to guide doctors when to start or stop treatments for the complications. 
We will publish the results of the study and present it at meetings. We will provide the 
study centres with a leaflet explaining the outcome of the study that they can distribute 
to participants. 
 
Why have I (my child) been invited? 
 
You (or your child) are being asked to take part in this study because you (or your 
child) have Sickle Cell Anaemia. This study will simply involve a blood test and does 
not involve any treatment changes. It is expected that a total of approximately 300 
patients will participate in this study from UCLH, The Whittington Hospital and Guys 





This research information sheet explains why this study is being done, what is involved 
in participating in the research study, the possible risks and benefits of the research 
study, and your rights as a research subject. The decision to participate or not is yours. 
Your participation in this research study is voluntary and you can stop being in this 
study at any time. Leaving the research study will not affect your medical care in any 
way. If you decide to participate, please sign and date at the end of the consent form. 
We will give you a copy so that you can refer to it while you are involved in this research 
study. 
 
Do I have to take part? 
 
It is up to you to decide to join the study. We will describe the study and go through the 
information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What is involved in the research study? 
The study doctors and nurses will make sure that you (or your child) meet the study 
requirements to take part in the study. After your study doctor determines that you (or 
your child) are eligible to participate in the study then you (or your child) will have an 
additional amount of blood taken at the time of a routine blood test. This will be in the 
form of an additional blood bottle that in small children takes about a teaspoon of blood 
and in a larger child or adult, five teaspoons of blood. If you are having an apheresis 
procedure, we will take the left over blood that is usually diSCDrded also. You (or your 
child) will not need an extra needle for the study. The samples will be taken to the 
laboratory and prepared for later analysis at University College London, University 
College Hospital London or the National Blood Service. We will also be comparing the 
results of this test with your other blood results and measurements taken in clinic. 
 
Will there be any cost or compensation for my participation? 
 
You (or your child) will not be paid for participating in this trial. Participation in the study 
will not involve any additional cost to you. 
 
What are the possible disadvantages and risks of taking part? 
 
There are no drugs involve in this study. The possible risks related to the study are 
listed below. 
 
Risks associated with blood tests: Risks include a possible bruise or infection at the 
needle site. Suitable precautions will be taken to minimize risk. Children will be offered 
local anaesthetic cream (EMLA / Ametop) or cold-spray to numb the skin prior to the 
blood test. The blood is being taken when other blood tests are being taken as a matter 
of normal care in any case. No extra needle will be needed. There will be one further 
sample taken at that time for the study (one teaspoon in a small child, five teaspoons 
in a larger child or adult). If you are having an apheresis procedure, we will take the 
left over blood that is usually diSCDrded also. 
 
What are the possible benefits of taking part? 
 
Taking part in this research study may or may not provide direct benefit to you (or your 
child). We hope the information learned from this research study will help the research 
doctors learn more about your (or your child’s) future treatment and that of other 






Will my participation in the study be stopped? 
 
Your (or your child’s) participation in the study may be stopped by your (or your child’s) 
doctor, even without your consent, for medical reasons. The sponsor of this study, UCL 
(University College London) can end the study at any time, for any reason. 
 
What if there is a problem? 
 
The risks of participation in an observational study are minimal. However, in the event 
of an injury resulting directly from your (or your child’s) participation in this research 
study, medical treatment will be provided. Provision of such medical care does not 
imply any negligence or other wrongdoing on the part of Hospital or any of the 
physicians or other personnel involved in the study. The NHS indemnity scheme will 
apply and the sponsor will provide insurance for negligent harm. 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and information about you will be handled 
in confidence. The details are included in Part 2. 
 







What if relevant new information becomes available? 
 
Sometimes we get new information about the investigation being studies. If this 
happens and it may affect your care, we will let you know. 
 
What are my rights as a study participant? 
 
You (or your child) are entitled to certain rights. These rights include, but are not limited 
to, your (or your child’s) right to have information about the purpose and nature of the 
research, the procedures and any treatment, any discomfort or other risks, any benefits 
to you (or your child) or to others and available medical care if complications occur. 
You (or your child) have the right to receive answers to all of your questions, as best 
as your doctors can explain them to you (or your child). 
 
If you decide that you want to withdraw/destroy any of your (or your child’s) blood 
samples during the study, please notify the Chief Investigator or study staff members 
at your facility in writing (their contact information is on the first page of this form). Since 
the blood samples stored in the repository (storage facility) and the clinical database 
will have all your identifying information removed at the end of the study, you (your 
child) will not be able to withdraw/destroy your (or your child’s) samples once the 
database has been sealed and all identifiers and means of linking your samples back 
to you have been removed at the end of the study. Blood tests completed before you 
request that the sample be withdrawn/destroyed will be kept by the study. 
 
What if I have more questions? What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your question. You can contact the 
Principle or Chief Investigators on the numbers above. 
For Complaints please contact the Patient advisory Liaison Service (PALS) on 
………….. or the complaints department at this site on …………. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for legal action 
for compensation against UCL or your hospital trust, but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
Will my study records be kept confidential? 
 
General Principles: All our procedure for handling, processing, storage and destruction 
of their data adhere to the Caldecott principles, the Data Protection Act (1998) and the 
NHS Data Protection Charter. If you join the study, some parts of your medical records 
and data collected for the study will be looked at by authorised persons form the 
sponsor (UCL). They may also be looked at by authorized people to check that the 
study is being carried out correctly. All will have a duty of confidentiality to you as a 
research participant and we will do our best to meet this duty. Data collected during 
this study may be sent to associated researchers to countries where the law’s don’t 
protect your privacy to the same extent as the law in the UK but all reasonable steps 





Medical Records: Medical information collected during this study will become part of 
your (or your child’s) hospital record only if it is determined to be pertinent to the care 
you (or your child) receive at University College London / The Whittington / Guy’s and 
St Thomas’ Hospitals. Medical records are considered permanent records; therefore, 
materials cannot be deleted from the record. Medical records are available to health 
care professionals at University College London / The Whittington / Guy’s and St 
Thomas’ Hospitals and may be reviewed by Hospital staff in their course of carrying 
out their responsibilities; however, they are required to maintain confidentiality in 
accordance with applicable laws and Hospital policies. 
 
Research Records: Information collected during the study that does not become part 
of your (or your child’s) medical record will be stored in separate research files 
maintained by the investigator and other research staff. The records will be stored on 
an encrypted memory stick and backed up on the encrypted component of a 
designated computer hard-drive. Any transfer of information will be encrypted, also. All 
data will be managed in accordance with the Data Protection Act. The data will be 
pseudoencrypted. That is, it will have most personal data removed, but the study team 
will be able to trace back whose sample was whose, if the need arose. Records are 
kept for 20 years at the first instance. This is standard procedure. 
 
Storage and use of study specimens 
 
Blood will be collected at the hospital and then tested at University College London 
(UCL). Some of the sample will be tested within the week, others at a later date. The 
sample will be stored at University College London (UCL). Samples will be kept for 5 
years at the first instance. The samples will be used for the purpose of the study. If you 
have chosen to “gift” your sample, then that will give us permission to use any left-over 
sample for a future study (please see consent form). 
 
Involvement of the General Practitioner / Family Doctor (G.P.) 
 
We will inform your G.P. that you have been involved in a research study. We will ask 
for your permission for this on the consent form. 
 
What will happen to the samples I give? 
 
Your sample will be taken to your NHS laboratory where it will be prepared and stored 
for later transfer to UCL for analysis. Those working the departments have access to 
the samples. Your (or your child’s) blood sample will not be labeled with your (or your 
child’s name) or other direct personal information. On the consent form you will be able 
to tell us whether we can use any sample left over at the end of the planned testing for 
other research or whether it must be destroyed. This is known as “gifting” your sample 
for future research. 
 
What will happen to the results of the research study? 
 
We hope to publish the research in peer reviewed journals and at national and 
international meetings. We will present the findings to the UK forum for 
Haemoglobinopathies, to the Sickle Cell Society and to the teams in the centres 
taking part in the study. 
 





The cost is being covered by the NHS and the Chief Investigator. UCL is the 
research Sponsor. 
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect your interest. This study has been reviewed 






Patient Consent form 
PATIENT CONSENT FORM V3 12.2.13 
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UCL PROJECT ID: 10/0270 
NHS REC REFERENCE: 10/H0715/61 





PARTICIPANT STUDY NUMBER: 
 
 
1. I confirm that I have read and understand the 
information sheet dated 12.2.13 
(Version 3), for the above study. I have had the 
opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
2. I confirm that I have had sufficient time to consider 
whether or not I want to be included in the study. 
 
3. I understand that my participation is voluntary and 
that I am free to withdraw my consent at any time, 
without giving any reason, without my medical care 
or legal rights being affected. 
 
4. I understand that relevant sections of any of my 
medical notes and data collected during the study, 
may be looked at by responsible individuals from 
regulatory authorities, from the NHS trust or 
representatives of the sponsor for purposes of 
monitoring or auditing, where it is relevant to my 
taking part in this research. I give permission for 
these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation 
in the study. 
 
6. I agree to take part in the above study and have been 
given a copy of this form. 
 
7. OPTIONAL: This is optional. Please indicate below if 
you (or your child) agree to the gift of a blood sample 
to the researchers. This blood sample will be stored 
and used for testing for indicators that may influence 
the course of Sickle Cell Anaemia. 
 
[ ] YES, I AGREE to have my (my child’s) blood 





sickle cell studies that are related to this research 
study. 
 
[ ] YES, I AGREE to have my (my child’s) blood 
gifted and stored for future 
sickle cell studies that are not related to this research 
study. 
 
[ ] YES, I AGREE to have my (my child’s) gifted 
blood sample to be shared for 
sickle cell research done by investigators who are 
related to this research study. 
 
[ ] YES, I AGREE to have my (my child’s) gifted 
blood sample to be shared for 
sickle cell research done by other investigators who 
are not related to this 
research study. 
 
[ ] NO, I do NOT AGREE to have my (my child’s) 
blood gifted and stored for 
future sickle cell research 
If subject is 18 years or older: 
  
 
Name of Adult participant Date Signature 
 
























Name of person taking consent Date 
Signature 
(if different from PI) 
 
 
When completed: 1 for participant; 1 for research site file; 1 (original) 






Healthy volunteer control Information Sheets 
 
GENERIC HEALTHY VOLUNTEER INFORMATION SHEET V3 12.2.13 
PROTOCOL V5 12.2.13 
UCL PROJECT ID: 10/0270 
NHS REC REFERENCE: 10/H0715/61 




PARTICIPANT STUDY NUMBER: 
PART 1; 
 
Why am I being asked to be in this Research Study? 
 
We are inviting you or your child to take part in a research study. 
Research is a way of attempting to gain new knowledge. A person who participates in 
research study is called a “subject”. Before you decide we would like you to understand 
why the research is being done and what it would involve for you. One of our team 
will go through the information sheet with you and answer any questions you 
have. We would suggest this should take at least 30 minutes. Talk to others about the 
study if you wish. 
Part 1 tells you about the purpose of the study and what will happen to you if you take 
part. Part 2 gives you more detailed information about the conduct of the study. Ask us 
if there is anything that is not clear. 
 
What is the purpose of this study? 
 
The purpose of the research study is to understand the role of microvesicles in Sickle 
Cell Anaemia. Sickle cell diseaseis an inherited blood disorder commoner in people 
who are of African ethnicity or from other countries where malaria is prevalent. 
Microvesicles are broken bits of cells that circulate in the blood. Research done so far, 
shows that these microvesicles are sticky and this may be important in Sickle cell 
diseasewhere we know that many of the problems are caused by cells becoming sticky 
and blocking the blood vessels. We will measure the levels of the microvesicles and 
related aspects of blood stickiness in the blood and see if that helps identify people 
who have more problems with their Sickle Cell Anaemia. We hope in the future these 
measures may be used to predict who may get complications of their disease or to 
guide doctors when to start or stop treatments for the complications. We will publish 
the results of the study and present it at meetings. We will provide the study centres 
with a leaflet explaining the outcome of the study that they can distribute to participants. 
 
Why have I (my child) been invited? 
 
You (or your child) are being asked to take part in this study because you (or your 
child) do(es) not have Sickle Cell Anaemia. This study will simply involve a blood test 
and does not involve any treatment changes. It is expected that a total of approximately 
60 non-sickle cell participants will participate in this study from UCLH, The Whittington 





This research information sheet explains why this study is being done, what is involved 
in participating in the research study, the possible risks and benefits of the research 
study, and your rights as a research subject. The decision to participate or not is yours. 
Your participation in this research study is voluntary and you can stop being in this 
study at any time. Leaving the research study will not affect your medical care in any 
way. If you decide to participate, please sign and date at the end of the consent form. 
We will give you a copy so that you can refer to it while you are involved in this research 
study. 
 
Do I have to take part? 
 
It is up to you to decide to join the study. We will describe the study and go through the 
information sheet. If you agree to take part, we will then ask you to sign a consent form. 
You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What is involved in the research study? 
 
The study doctors and nurses will make sure that you (or your child) meet the study 
requirements to take part in the study. After your study doctor determines that you (or 
your child) are eligible to participate in the study then you (or your child) will have a 
blood test. This will be in the form of an additional blood bottle that in small children 
takes about a teaspoon of blood and in a larger child or adult, five teaspoons of 
blood. If you are having an apheresis procedure, we will take the left over blood that 
is usually diSCDrded also. Children will not have an extra needle for their study, they 
will only take part if they are having a blood test in any case. Healthy adult volunteers 
may participate even if they are not due a blood test other than for the study. If the 
adult does not know their sickle cell status we will need to check that also. That will 
involve an extra sample. We will tell you the results of your sickle cell test (see 
consent form). The samples will be taken to the laboratory and prepared for later 
analysis at University College London, University College Hospital London or the 
National Blood Service (NHSBT). We will also be comparing the results of this test 
with your other blood results and measurements taken in clinic. 
 
Will there be any cost or compensation for my participation? 
 
You (or your child) will not be paid for participating in this trial. Participation in the study 
will not involve any additional cost to you. 
 
What are the possible disadvantages and risks of taking part? 
 
There are no drugs involve in this study. The possible risks related to the study are 
listed below. 
 
Risks associated with blood tests: Risks include a possible bruise or infection at the 
needle site. Suitable precautions will be taken to minimize risk. Children will be offered 
local anaesthetic cream (EMLA / Ametop) or cold-spray to numb the skin prior to the 
blood test. The blood is being taken when other blood tests are being taken as a matter 
of normal care in any case. No extra needle will be needed. There will be one further 
sample taken at that time for the study (one teaspoon in a small child, five teaspoons 
in a larger child or adult). 
 





Taking part in this research study may or may not provide direct benefit to you (or your 
child). We hope the information learned from this research study will help the research 
doctors learn more about your (or your child’s) future treatment and that of other 
patients with Sickle Cell Anaemia. 
 
Will my participation in the study be stopped? 
 
Your (or your child’s) participation in the study may be stopped by your (or your child’s) 
doctor, even without your consent, for medical reasons. The sponsor of this study, UCL 
(University College London) can end the study at any time, for any reason. 
 
What if there is a problem? 
 
The risks of participation in an observational study are minimal. However, in the event 
of an injury resulting directly from your (or your child’s) participation in this research 
study, medical treatment will be provided. Provision of such medical care does not 
imply any negligence or other wrongdoing on the part of Hospital or any of the 
physicians or other personnel involved in the study. The NHS indemnity scheme will 
apply and the sponsor will provide insurance for negligent harm. 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and information about you will be handled 
in confidence. The details are included in Part 2. 
 







What if relevant new information becomes available? 
 
Sometimes we get new information about the investigation being studies. If this 
happens and it may affect your care, we will let you know. 
 
What are my rights as a study participant? 
 
You (or your child) are entitled to certain rights. These rights include, but are not limited 
to, your (or your child’s) right to have information about the purpose and nature of the 
research, the procedures and any treatment, any discomfort or other risks, any benefits 
to you (or your child) or to others and available medical care if complications occur. 
You (or your child) have the right to receive answers to all of your questions, as best 
as your doctors can explain them to you (or your child). 
 
If you decide that you want to withdraw/destroy any of your (or your child’s) blood 
samples during the study, please notify the Chief Investigator or study staff members 
at your facility in writing (their contact information is on the first page of this form). Since 
the blood samples stored in the repository (storage facility) and the clinical database 
will have all your identifying information removed at the end of the study, you (your 
child) will not be able to withdraw/destroy your (or your child’s) samples once the 
database has been sealed and all identifiers and means of linking your samples back 
to you have been removed at the end of the study. Blood tests completed before you 
request that the sample be withdrawn/destroyed will be kept by the study. 
 
What if I have more questions? What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your question. You can contact the 
Principle or Chief Investigators on the numbers above. 
For Complaints please contact the Patient advisory Liaison Service (PALS) on 
………….. or the complaints department at this site on …………. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for legal action 
for compensation against UCL or your hospital trust, but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
Will my study records be kept confidential? 
 
General Principles: All our procedure for handling, processing, storage and destruction 
of their data adhere to the Caldecott principles, the Data Protection Act (1998) and the 
NHS Data Protection Charter. If you join the study, some parts of your medical records 
and data collected for the study will be looked at by authorised persons form the 
sponsor (UCL). They may also be looked at by authorized people to check that the 
study is being carried out correctly. All will have a duty of confidentiality to you as a 
research participant and we will do our best to meet this duty. Data collected during 
this study may be sent to associated researchers to countries where the law’s don’t 
protect your privacy to the same extent as the law in the UK but all reasonable steps 





Medical Records: Medical information collected during this study will become part of 
your (or your child’s) hospital record only if it is determined to be pertinent to the care 
you (or your child) receive at University College London / The Whittington / Guy’s and 
St Thomas’ Hospitals. Medical records are considered permanent records; therefore, 
materials cannot be deleted from the record. Medical records are available to health 
care professionals at University College London / The Whittington / Guy’s and St 
Thomas’ Hospitals and may be reviewed by Hospital staff in their course of carrying 
out their responsibilities; however, they are required to maintain confidentiality in 
accordance with applicable laws and Hospital policies. 
 
Research Records: Information collected during the study that does not become part 
of your (or your child’s) medical record will be stored in separate research files 
maintained by the investigator and other research staff. The records will be stored on 
an encrypted memory stick and backed up on the encrypted component of a 
designated computer hard-drive. Any transfer of information will be encrypted, also. All 
data will be managed in accordance with the Data Protection Act. The data will be 
pseudoencrypted. That is, it will have most personal data removed, but the study team 
will be able to trace back whose sample was whose, if the need arose. Records are 
kept for 20 years at the first instance. This is standard procedure. 
 
Storage and use of study specimens 
 
Blood will be collected at the hospital and then tested at University College London 
(UCL). Some of the sample will be tested within the week, others at a later date. The 
sample will be stored at University College London (UCL). Samples will be kept for 5 
years at the first instance. The samples will be used for the purpose of the study. If you 
have chosen to “gift” your sample, then that will give us permission to use any left-over 
sample for a future study (please see consent form). 
 
Involvement of the General Practitioner / Family Doctor (G.P.) 
 
We will inform your G.P. that you have been involved in a research study. We will ask 
for your permission for this on the consent form. 
 
What will happen to the samples I give? 
 
Your sample will be taken to your NHS laboratory where it will be prepared and stored 
for later transfer to UCL for analysis. Those working the departments have access to 
the samples. Your (or your child’s) blood sample will not be labeled with your (or your 
child’s name) or other direct personal information. On the consent form you will be able 
to tell us whether we can use any sample left over at the end of the planned testing for 
other research or whether it must be destroyed. This is known as “gifting” your sample 
for future research. 
 
What will happen to the results of the research study? 
 
We hope to publish the research in peer reviewed journals and at national and 
international meetings. We will present the findings to the UK forum for Haemoglobin 
Disorders, to the Sickle Cell Society and to the teams in the centres taking part in the 
study. 
 





The cost is being covered by the NHS and the Chief Investigator. UCL is the 
research Sponsor. 
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect your interest. This study has been reviewed 






Healthy volunteer control Consent form 
HEALTHY VOLUNTEER CONSENT FORM V4 12.2.13 
PROTOCOL V5 12.2.13 
UCL PROJECT ID: 10/0270 
NHS REC REFERENCE: 10/H0715/61 
TITLE OF PROJECT: 





PARTICIPANT STUDY NUMBER: 
 
 
Please initial box: 
 
1. I confirm that I have read and understand the information sheet dated 12.2.13 
(version 5) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I confirm that I have had sufficient time to consider whether or not I want to be 
included in the study. 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
my consent at any time, without giving any reason, without my medical care or 
legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data 
collected 
during the study, may be looked at by responsible individuals from regulatory 
authorities, from the NHS trust or representatives of the sponsor for purposes 
of monitoring or auditing, where it is relevant to my taking part in this research. 
I give permission for these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation in the study. 
 
6. I agree to take part in the above study and have been given a copy of this form. 
 
7. I understand that if I do not know my sickle cell status, then I shall be tested 
and the results given to me via (please mark preference and give contact 
details). 
[ ] address 
[ ] telephone number 
 
8. OPTIONAL: This is optional. Please indicate below if you (or your child) agree 
to the gift of a blood sample to the researchers. This blood sample will be 
stored and used for testing for indicators that may influence the course of 







[ ] YES, I AGREE to have my (my child’s) blood gifted and stored for 
sickle cell studies that are related to this research study. 
[ ] YES, I AGREE to have my (my child’s) blood gifted and stored for 
 






[ ] YES, I AGREE to have my (my child’s) gifted blood sample to be 
shared for 
sickle cell research done by investigators who are related to this research 
study. 
 
[ ] YES, I AGREE to have my (my child’s) gifted blood sample to be 
shared for 





[ ] NO, I do NOT AGREE to have my (my child’s) blood gifted and stored 
future sickle cell research 
 




Name of Adult participant 
 
If subject is less than 18 years old: 
 Date Signature 
 
   
Relationship to child 
parent/guardian 













Name of person taking consent Date Signature 
(if different from PI) 
 
 
When completed: 1 for participant; 1 for research 
C2 16501855 
223 
 
 
 
